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ABSTRACT 
Beta cell dysfunction and loss play central roles in the pathogenesis of type 2 
diabetes. Strategies to overcome the detrimental effects of cellular stress 
factors is fundamental for the protection of beta cell mass and function. In this 
study two hormones, somatostatin (SST) and ghrelin, were assessed for their 
roles in regulating 1) beta cell and/or islet survival in response to cellular 
stressors typical of type 2 diabetes and 2) acute insulin release. In addition, 
the mechanisms underlying their actions were explored and it was tested 
whether any effects of ghrelin on beta cells was mediated via somatostatin 
receptor 3 (SSTR3) to identify a potential interaction between ghrelin and SST 
in islet function. 
The rodent pancreatic beta cell lines MIN6 and INS-1 and primary pancreatic 
mouse islets were used as research models in this study. Cell viability was 
assessed by detecting metabolic activity of viable cells and apoptosis by 
measurement of caspase 3/7 activity. Static incubation experiments and 
radioimmunoassays were performed to detect hormone secretion. mRNA 
expression of genes of interest was detected by quantitative PCR (qPCR) and 
protein expression by Western blot. 
Treatment with SST reduced apoptosis in MIN6 cells in response to 
lipotoxicity. SSTR3 was detected in beta cells and the receptor partly mediated 
an inhibitory effect of SST on insulin secretion, but not the observed protective 
effect of SST on MIN6 cell survival. Incubation with ghrelin did not modify the 
clonal beta cell response to apoptosis, despite the ghrelin receptor (GHSR1a) 
being expressed in these cells. In contrast, treatment with ghrelin reduced 
apoptosis in islets from female mice in a sex-dependent manner, but this effect 
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did not appear to be mediated by the ghrelin receptor, GHSR1a. Antagonising 
GHSR1a by liver-expressed antimicrobial peptide 2 resulted in a sex-specific 
increase in insulin secretion in islets from male mice. Finally, SSTR3 did not 
appear to mediate any potential effects of ghrelin on islet insulin secretion.  
In conclusion, the results presented in this thesis suggest that both SST and 
ghrelin play important roles in protecting the pancreatic beta cells and/or 
islets against cellular stresses leading to cell death. The underlying 
mechanisms are complex and may rely on direct interaction between SST and 
ghrelin. In addition, a novel, sex-dimorphic role for ghrelin in islet function 
was identified, that highlights a potential need to develop sex-specific 
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1.1 Pancreatic islets of Langerhans 
1.1.1 The structure and function of islets  
Pancreatic islets, initially described by Paul Langerhans in 1869, are small 
spherical organs that constitute the endocrine section of the pancreas (Arrojo 
e Drigo et al., 2015; Lefèbvre, 2011) (Fig. 1.1). They correspond to 2% of the 
entire pancreatic tissue with the remainder being exocrine tissue. The number 
of islets in a healthy human pancreas has been estimated to be approximately 
1-14.8 million (Dolenšek et al., 2015; Lefèbvre, 2011) whereas about 1000-
5000 are found in a rodent pancreas (Dolenšek et al., 2015; Lefebvre et al., 
2010) indicating that islet number is proportional to the size of the organism 
and metabolic requirements (Steiner et al., 2010). However in all species islet 
diameter varies between 100-700 µm (Dolenšek et al., 2015; Ionescu-
Tirgoviste et al., 2015).  
Figure 1.1 Pancreatic islets of Langerhans. Islets of Langerhans are spherical 
organs found within the pancreas that are clusters of alpha, beta, delta, epsilon and 
pancreatic-polypeptide (PP) cells. Comprised of about 1000-2000 cells, their tight 
coordination is important for correct function to maintain glucose homeostasis 
(Biocrine  2012; Lefèbvre, 2011). 
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Islets are composed of five endocrine cell types: alpha, beta, delta, epsilon and 
pancreatic polypeptide releasing cells (PP cells) as well as immune cells, 
vasculature and innervations (Arrojo e Drigo et al., 2015) (Fig. 1.1). Alpha 
cells are the glucagon producing cells of the pancreas and constitute about 15-
20% of rodent islet cells (Steiner et al., 2010). They are found in close 
proximity to beta cells and capillaries (Brereton et al., 2015). Beta cells 
produce insulin and correspond to about 60-80% of the rodent islet cells 
(Steiner et al., 2010). Delta cells are neurone-like elongated cells that secrete 
somatostatin (SST) and are found towards the outer layer of islets in rodents 
(Cabrera et al., 2006). They constitute approximately 5-10% of the rodent islet 
cell population. Their dendrite-like protrusions extend towards the centre of 
the islet and allow paracrine communication with other islet cell types 
(Brereton et al., 2015). The remaining epsilon cells and PP cells correspond to 
less than 1% of rodent islet cells. Epsilon cells are a more recently identified 
cell type that produce ghrelin (Wierup et al., 2002). Despite the presence of 
the same types of cells, human islets contain slightly different proportions of 
the three main cells types: ~50% beta cells, ~40% alpha cells and ~10% delta 
cells (Steiner et al., 2010). In addition, numerous studies have highlighted the 
differences in islet architecture between species. In rodents, beta cells form the 
central core of islets and non-beta cells form the periphery (Cabrera et al., 
2006). In islets of larger species, non-human primates and human islets, the 
different cell types are more scattered throughout the islet (Fig. 1.2) (Cabrera 
et al., 2006). Even in these islets beta cells have been shown to form small 
clusters highlighting the importance of cell-to-cell contact for their function 
(Bonner-Weir et al., 2015). 
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Islets are highly vascularised organs (Fig. 1.3) which is important for adequate 
supply of oxygen and other stimuli including nutrients (In’t Veld and Smeets, 
2014). They consist of large and fenestrated capillaries that develop during 
embryogenesis stimulated by vascular endothelial growth factor A (VEGF-A) 
(Arrojo e Drigo et al., 2015). Despite only constituting about 2% of pancreatic 
mass, islets receive approximately 10% of pancreatic blood flow that is further 
elevated to 15% with hyperglycaemia (Janssons and Hellerström, 1983).  
 
 
Figure 1.2 Species-specific differences in pancreatic islet structure. 
Pancreatic sections labelled by immunofluorescence for insulin (red), glucagon 
(green) and somatostatin (blue). Beta cells are randomly distributed in the islets of 
human (A) monkey (B) and pig (D) pancreata whereas in mice (A) beta cells constitute 
the central core. Scale bar 50 µm. (Cabrera et al., 2008:2235). 
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Three patterns of blood flow have been described in mouse islets: outer to 
inner, inner to outer and top to bottom (i.e. a polarised pattern). The outer to 
inner model suggests that blood flows from outer cells into the inner cells 
therefore suggesting that peripheral alpha and delta cell secretions influence 
beta cell activity (Fujita and Murakami, 1973). In the inner to outer model beta 
cells are first perfused followed by non-beta cells suggesting that insulin 
secreted by beta cells affect the alpha and delta cell function (Bonner-Weir and 
Orci, 1982; Samols et al., 1988). Finally, the top to bottom pattern implies that 
islet blood flows from one pole to the other of the islet regardless of the cell 
types (Liu et al., 1993). More recent in vivo imaging showed 60% of blood flow 
Figure 1.3 Mouse islet vasculature. Mouse pancreatic islet immunolabelled for 
insulin (green), glucagon (blue) and endothelial cell marker, CD31 (red) (A). Mouse 
islet from an animal infused with fluorescein isothiocyanate‐conjugated tomato lectin 
(green) to label the functional vasculature (B). Islet capillaries (within dashed line) 
are thicker, denser and more tortuous than vessels in the surrounding exocrine tissue 
(Aamodt and Powers, 2017:127). 
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to be inner to outer and 35% being polarised (Nyman et al., 2008). In contrast, 
blood flow directionality in human islets remains largely unknown (Jansson et 
al., 2016). Some have reported that in human islets cellular interactions may 
not depend on islet blood flow, since different islet cell types are randomly 
associated with blood vessels (Cabrera et al. 2006). This suggestion was 
confirmed by Cohrs et al. (2017) who reported that alpha and beta cell 
paracrine signalling was not influenced by islet blood flow or size in their 
study. However, neither of these studies employed direct measurement of 
blood flow, instead relied on the distribution patterns of islet cells. Others, 
using non-human primate islets have found that islet blood flow is dynamic 
and results in rapid changes in directionality due to metabolic demands (Diez 
et al., 2017). Taken together these studies indicate that rodent islets display 
distinctive directionality in islet blood flow that is yet to be confirmed in 
human islets. However, the differences in cytoarchitecture between rodent and 
human islets imply that the islet blood flow pattern in human islets may differ 
from that in rodents. 
In addition to interactions via microcirculation, islets cells communicate via 
interstitial space by autocrine and paracrine secretions, as well as through 
direct cell-to-cell contact, for example via gap junctions. These interactions 
occur between the same types of cells as well as between different cell types in 
the islets (reviewed by Arrojo e Drigo et al., 2015; reviewed by Koh et al., 2012; 
reviewed by Meda, 2013) (Fig. 1.4). 
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Paracrine and autocrine signalling between islet cells 
As mentioned above paracrine and autocrine interactions can modulate the 
function of different islet cell types. These interactions occur via secreted 
hormones, neurotransmitters and ions.  
 Insulin receptors (IRs) are present on alpha, beta and delta cell membranes 
(Hauge-Evans et al., 2012; reviewed by Koh et al., 2012). Insulin secreted by 
beta cells suppress glucagon secretion from isolated rat alpha cells and intact 
Figure 1.4 Paracrine and direct cell-cell interactions in mammalian islets 
of Langerhans. The primary islet hormones and their paracrine signalling (A). Islets 
cells also communicate via direct cell-cell contact, e.g.: via gap junction proteins such 
as connexin 36 (Cx36) and pannexin 1 (Pnx1) (B) (modified from Meda, 2013:7). The 
tight coordination between pancreatic islet cells is fundamental for their correct 
function in order to maintain normoglycaemia. Cadherins and N-CAM are cell 
adhesion molecules, integrins allow adhesion to extracellular matrix and occludin and 
claudins form tight junctions. 
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islets (Franklin et al., 2005). It was suggested that activation of voltage-gated 
potassium ion (KATP) channels by insulin, and consequent membrane 
hyperpolarisation resulted in inhibition of vesicle exocytosis (Franklin et al., 
2005). Others have shown that alpha-cell specific IR knockout mice exhibited 
increased glucagon secretion under both normal and low glucose conditions, 
confirming the negative regulation of glucagon secretion by insulin (Kawamori 
et al., 2010). Furthermore, it has been found that in type 1 diabetes patients 
elevations in plasma insulin inhibited glucagon secretion (Cooperberg and 
Cryer, 2010), confirming the inhibitory effect of insulin on glucagon in 
humans. In addition to insulin, beta cells secrete the neurotransmitter gamma 
aminobutyric acid (GABA). It has been shown that binding of GABA to its 
receptor subtype GABAA present on alpha cells resulted in inhibition of 
glucagon secretion in mouse alpha cell lines  (Xu et al., 2006). Similarly, in rat 
pancreatic islets antagonising GABA receptors specific to alpha cells resulted 
in increased glucagon secretion (Wendt et al., 2004).  Furthermore, 
contrasting evidence exists on the role of Zn2+ ions, released during insulin 
exocytosis, on glucagon secretion. Some reported that only glucose or insulin 
are responsible for inhibition of glucagon secretion from clonal or isolated 
primary mouse alpha cells, but not Zn2+ (Ravier and Rutter, 2005), whereas 
others have shown that Zn2+ enhanced glucagon secretion in streptozotocin-
induced diabetic rats (Zhou et al., 2007), therefore suggesting a role for Zn2+ 
in islet paracrine regulations. 
The effect of beta cell secretions on delta cells, however, remains disputed. 
Previously, it has been suggested that insulin does not mediate the release of 
somatostatin from delta cells in the presence of insulin secretagogues (Hauge-
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Evans et al., 2012). Although insulin receptor mRNA expression was detected 
in clonal delta cell line TGP52, treatment with exogenous insulin did not affect 
SST secretion. In the same study, insulin receptor blockade either 
pharmacologically or with an antibody reportedly did not alter glucose-
induced SST secretion in TGP52 cells (Hauge-Evans et al., 2012). More 
recently however, it has been reported that insulin stimulates SST secretion in 
a glucose-dependent manner in mouse islets (Vergari et al., 2019). Here 
antagonism of the insulin receptor was found to significantly reduce SST 
secretion (Vergari et al., 2019).  
Two isoforms of insulin receptor (IR) A and B are present in the beta cell 
membrane and insulin acting via these can influence beta cell function in an 
autocrine manner. Some have shown that insulin mRNA synthesis is 
upregulated by the action of insulin on beta cells (Muller et al., 2006; Leibiger 
et al., 2001). Others, however, have reported that insulin’s autocrine action via 
the phosphoinositide-3 kinase (PI3K)-dependent pathway causes 
downregulation of insulin secretion in human islets (Persaud et al., 2002).  
Glucagon receptors are expressed in both alpha and beta cells (Kieffer et al., 
1996). Binding of glucagon to its receptor activates adenylate cyclase, and 
increases 3',5'-cyclic adenosine monophosphate (cAMP). This enhances Ca2+-
dependent exocytosis of both glucagon and insulin respectively (reviewed by 
Gromada et al., 2007; Ma et al., 2005). Glutamate is a neurotransmitter that 
is secreted simultaneously with glucagon. It has been found to modulate islet 
cell secretory responses by binding to ionotropic glutamate receptors (iGluRs) 
that are expressed on alpha and delta cells, although its expression in beta cells 
remains contested (reviewed by Koh et al., 2012).  
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However, in islets from humans, monkeys and mice activation of iGluR 
subtypes enhanced glucagon release (Cabrera et al., 2008). This was suggested 
to be related to an increase in intracellular Ca2+ concentration that promoted 
Ca2+-dependent exocytosis, hence resulting in autocrine regulation of 
glucagon secretion (Cabrera et al., 2008). Furthermore, delta cells were found 
to express a splice variant of an iGluR subtype that reportedly promoted SST 
release from delta cells in rat islets (Muroyama et al., 2004). 
Somatostatin receptors are present in all islet cell types in rodents (Ludvigsen 
et al., 2004) and humans (Kumar et al., 1999) as described in 1.3.1.2. In 
humans, administration of SST inhibits glucose-induced insulin release 
(Efendic et al., 1978). The same effect was observed when stimulated with 
insulinogogues glucagon and arginine (Efendic et al., 1978). Somatostatin 
secreted by delta cells inhibits both insulin and glucagon secretion in mice 
(Hauge-Evans et al., 2009). Here mice lacking Sst globally had enhanced 
insulin and glucagon secretion. Furthermore, neonatal mice lacking delta cells 
displayed hyperinsulinaemia resulting in hypoglycaemia (Li et al., 2018), 
highlighting the importance of delta cell paracrine regulation in the 
maintenance of normoglycaemia. 
As mentioned before, delta cells are elongated and contain filopodia-like 
structures and these have been shown to form the structural basis for 
communication with other islet cells (Arrojo e Drigo et al., 2019). It was found 
that under conditions of pre-diabetes delta cell filopodia undergo structural 
remodelling as a potential adaptation to changes in islet secretions (Arrojo e 
Drigo et al., 2019). A recent study found that beta cell activity on delta cells via 
gap-junctions resulted in enhanced delta cell activity and suppressed alpha cell 
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activity. It was suggested that the modulation of delta cells by beta cells caused 
SST release and therefore suppression of glucagon secretion from alpha cells 
(Briant et al., 2017). Others have also reported similar findings that glucose-
induced secretion of both insulin and SST were necessary to inhibit alpha cell 
glucagon secretion in human and mouse alpha cells (Elliott et al., 2015). 
In addition to the primary islet hormones insulin, glucagon and somatostatin, 
ghrelin has been found to modulate islet cell secretions (reviewed by Koh et 
al., 2012). However, the paracrine actions of islet-specific ghrelin are not well 
understood, and the role of ghrelin on islet function is further elaborated in 
section 1.3.2 of this thesis. 
Taken together the above reports indicate that the tight coordination among 
islet cells is important for islet cell secretory responses to changes in 
circulating blood glucose levels. 
1.1.2 Glucose metabolism 
Glucose is the main type of fuel in mammalian cells (Nelson and Cox, 2008) 
and the maintenance of normoglycaemia is fundamental for maintenance of 
biological function of an organism (In’t Veld and Smeets, 2014). The 
pancreatic hormones insulin and glucagon play central roles in maintaining 
blood glucose levels between 4-6 mM via their actions on the liver, central 
nervous system, muscle, gut and adipose tissue (Röder et al., 2016, Fig. 1.5). 
The liver plays an integral role in glucose homeostasis by promoting storage 
(glycogen synthesis) or release (gluconeogenesis and glycogenolysis) of 
glucose via signalling from either insulin or glucagon, respectively (Meshkani 
and Adeli, 2009).  
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Cell membranes of hepatocytes express glucose transporter GLUT2 that 
facilitates movement of glucose both inwards and outwards of the cell 
depending on blood glucose levels (Leturque et al., 2005). 
In muscles and adipocytes insulin promotes glucose uptake via the glucose 
transporter GLUT4 which is stored in the internalised vesicles in the 
cytoplasm (reviewed by Navale and Paranjape, 2016). Binding of insulin to its 
receptor activates receptor tyrosine kinase that phosphorylates insulin 
receptor substrate 1 (IRS-1). IRS-1 activates the PI3K pathway that promotes 
Figure 1.5 The regulation of glucose homeostasis. Combined action of 
insulin and glucagon contribute to maintenance of normoglycaemia by either 
storage or release of glucose (reviewed by Röder et al., 2016:3). 
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glucose transport, protein synthesis and glycogen synthesis (reviewed by 
Olson, 2012). Upon activation of PI3 kinase and protein kinase B (Akt), 
vesicles containing GLUT4 are translocated to the cell membrane. Their fusion 
with the plasma membrane increases GLUT4 expression. Glucose internalised 
by active transport is either utilised by myocytes to generate adenosine 
triphosphate (ATP) or stored as glycogen (reviewed by Huang and Czech, 
2007; reviewed by Olson, 2012).  
 
1.1.3 Insulin biosynthesis and secretion 
1.1.3.1 Insulin biosynthesis 
Insulin secreted by pancreatic beta cells is a 51-amino acid hormone 
consisting of two chains (A and B) connected by two disulphide bridges (Nicol 
and Smith, 1960). The insulin gene that contains 1563 base pairs encodes the 
inactive protein preproinsulin that includes proinsulin and a signal peptide of 
24 amino acids (Chan et al., 1976). The signal peptide is indicative of the 
molecule being a secretory hormone (Patzelt et al., 1978). Preproinsulin is 
processed in the rough endoplasmic reticulum (RER) where the signal peptide 
is cleaved in the lumen by a signal peptidase. The resulting peptide proinsulin 
is folded, and disulphide bonds are created to produce the tertiary structure 
consisting of chains A, B and connecting peptide (C peptide) (Huang and 
Arvan, 1995). Proinsulin is rapidly transported via the Golgi apparatus into 
immature secretory granules where it is converted to mature insulin and C-
peptide (Steiner, 2008). Two types of enzymes are responsible for the 
processing of proinsulin: trypsin-like endoproteases and an exopeptide. The 
former peptides have been identified to be prohormone convertases PC2 and 
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PC 1/3 that cleave the ends of the C domain. First, PC 1/3 cleaves at the B 
chain-C peptide junction. The resulting intermediate product is then cleaved 
by PC2 (Davidson et al., 1988; Smeekens and Steiner, 1990; Smeekens et al., 
1992). The exopeptidase carboxypeptidase E (also known as H) is responsible 
for the removal of the basic residues remaining following the activity of 
endoproteases (Davidson and Hutton, 1987; Steiner, 2008). 
Secretory granules mature in the cytosol of beta cells. Within the acidic 
environment of granules (pH 5.0-5.5) (Orci et al., 1986) insulin molecules 
form crystals with Zn+ to stabilise the structure. The insulin-zinc complexes 
are stored within the dense core of the granules with the C peptide residing in 
the periphery (Dodson and Steiner, 1988; Frank and Veros, 1970).  
1.1.3.2 Insulin secretion 
Upon stimulation by a number of factors such as glucose, nutrients as well as 
other hormones, beta cells secrete insulin (reviewed by Fu et al., 2014). This 
process involves fusion of mature secretory granules with the plasma 
membrane resulting in the release of insulin and C peptide (reviewed by 
Steiner, 2008). Glucose remains the main stimulus of insulin secretion. In 
response to elevations in plasma glucose beta cells secrete insulin to achieve 
normoglycaemia (4-6 mM). Islet vasculature plays an important role in this 
process by allowing rapid exchange of molecules via fenestrated blood vessels 
that are abundant within the islets (reviewed by Fu et al., 2014). Insulin 
secretion follows a biphasic pattern consisting of a short term first phase 
followed by a more prolonged second phase (reviewed by Röder et al., 2016). 
Insulin granules are stored in the cytoplasm of the beta cell, however only <5% 
of these are ready to be released immediately called the readily releasable pool 
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(RRP). The remaining >95% called the reserve pool need to undergo 
modifications and translocation towards the plasma membrane. It is reported 
that the first phase of insulin secretion primarily results in the release of RRP 
and second phase of the reserve pool (Eliasson et al., 1997; Rorsman et al., 
2000; Rorsman and Renström, 2003).  
1.1.3.3 Glucose-induced insulin secretion 
Glucose transporters (GLUTs) are constitutively expressed on beta cells, with 
GLUT2 being expressed in rodents, and GLUT1 and 3 being the primarily 
expressed types in human islets (Pingitore et al., 2017). These transporters act 
as glucose sensors and allow facilitated diffusion of glucose into the cytoplasm 
(Fig. 1.6, reviewed by Fu et al., 2014; reviewed by Navale and Paranjape, 
2016). The main glucose sensor found within the cytoplasm is glucokinase, a 
subtype of hexokinase that displays lower binding affinity for glucose than 
hexokinase and is not negatively regulated by increases in glucose 
concentration (Fu et al., 2014; Nelson and Cox, 2008). Upon entering the cell 
glucose is phosphorylated by glucokinase to produce glucose-6-phophate that 
undergoes glycolysis resulting in the production of pyruvate. In the 
mitochondria pyruvate is further oxidised via the tricarboxylic acid cycle (TCA 
cycle) to generate ATP molecules (Nelson and Cox, 2008). Increases in the 
cytoplasmic ATP to adenine diphosphate (ADP) ratio causes closure of 
voltage-gated ATP-sensitive potassium channels (KATP) resulting in cell 
membrane depolarisation. At low glucose KATP channels are open and K+ ions 
flow outwardly maintaining a membrane potential of -70 mV (MacDonald and 
Rorsman, 2006). As a consequence of KATP channel closure, voltage-gated 
calcium channels are opened causing influx of Ca2+ ions into the cytoplasm 
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(Komatsu et al., 2013). Exocytosis is a Ca2+-dependent process that is 
regulated by several proteins as described below. 
 
Figure 1.6 Illustration of glucose-stimulated insulin secretion. Glucose is 
transported into beta cells via GLUT2 and undergoes glycolysis to generate ATP. The 
resulting closure of KATP channels causes opening of voltage-gated calcium channels and 
influx of Ca2+ ions. Alternatively, during glycolysis glucose-6-phosphate can be 
metabolised into dihydroxyacetone phosphate (DHAP) resulting in the production of 
diacylglycerol (DAG) or acyl-Coenzyme A (acyl-CoA). Both pathways lead to insulin 
exocytosis via fusion of insulin containing granules with the plasma membrane (Fu et 
al., 2014). ATP= adenosine triphosphate; ADP= adenosine diphosphate; Gly-3P= 
glycerol-3-phosphate; FFA= free fatty acids; NAD+= nicotinamide adenine 
dinucleotide; PKC= protein kinase C; TCA= tricarboxylic acid cycle; alpha-KG= alpha-
Ketoglutaric acid. 
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In addition, in the mitochondria anaplerotic reactions occur to replenish 
components of the TCA cycle such as glutamate that can also signal insulin 
secretion by amplifying KATP channel-dependent insulin secretion (Maechler 
and Wollheim, 1999). 
Alternatively, glucose-6-phosphate can be metabolised into dihydroxyacetone 
phosphate (DHAP) that produces glycerol-3-phosphate (Gly3P) (Bender et al, 
2006). Acyl-Coenzyme A (acyl-coA) and diacylglycerol (DAG) are generated by 
Gly3P and can also result in increased insulin secretion (reviewed by Fu et al., 
2014). 
Insulin secretion is regulated by a number of proteins such as the soluble N-
ethylmaleimide-sensitive factor attachment protein (SNAP) receptor 
(SNARE) that facilitates fusion of vesicles with the plasma membrane (Wang 
and Thurmond, 2009). Upon docking of insulin containing vesicles three 
SNARE proteins form a complex that simultaneously binds to the membrane 
of the granule, the beta cell membrane and the membrane associated protein 
SNAP-25 to promote vesicle fusion and exocytosis of insulin (Wang and 
Thurmond, 2009). Membrane fusion requires the calcium sensor 
synaptotagmin, which is found on the membranes of the vesicles (Martens et 
al., 2007). Binding of synaptotagmin to Ca2+ triggers membrane fusion of 
vesicles via mechanisms that are not clearly understood (Jahn and Fasshauer, 
2015; Trexler and Tarasaka, 2017). 
Other stimuli such as nutrients and incretins can activate cAMP, cyclic guanine 
monophosphate (cGMP), inositol 1,4,5 triphosphate (IP3) and DAG that 
result in the initiation of cell signalling cascades to promote exocytosis, with 
cAMP playing a key role (reviewed by Fu et al., 2014; Henquin, 1985). cAMP 
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activates protein kinase A (PKA) that potentiates stimulus-induced insulin 
secretion from beta cells (Thams et al., 2005). cAMP-mediated potentiation of 
insulin secretion can also occur via a PKA-independent pathway by activation 
of exchange protein directly activated by cAMP (Epac) (Seino and Shibasaki, 
2005). Both pathways result in an increase in cytosolic Ca2+ ions and 
exocytosis of insulin granules (Henquin and Nenquin, 2014). 
 
1.2 Diabetes mellitus 
1.2.1 Diagnosis and classification of diabetes mellitus  
According to the International Diabetes Federation (IDF) there are currently 
463 million people affected by diabetes mellitus and this number is predicted 
to reach 700 million by 2045 (IDF, 2019). Diabetes mellitus is a chronic 
condition characterised by hyperglycaemia that over extended periods results 
in damage to various organs including heart, eyes, nerves, kidneys and blood 
vessels. The condition is diagnosed if one or more of the criteria indicated 
below are met: fasting plasma glucose of ≥ 7.0 mmol/L, glycated haemoglobin 
A1c (HbA1c) ≥ 48 mmol/mol (equivalent to 6.5%) and plasma glucose ≥ 11.1 
mmol/L two hours following 75 g oral glucose load or taken at random (IDF, 
2019). The most common types of diabetes are type 1, type 2 and gestational 
(pregnancy related) diabetes (Kharroubi and Darwish, 2015), although other 
forms have been reported (Schwitzgebel, 2014).  
Type 1 diabetes 
Type 1 diabetes accounts for about 5-10% of patients with diabetes and 
generally manifests between 0-14 years of age with increasing incidence 
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between 5-7 years and at puberty. However, this condition can also arise at a 
later stage (Atkinson et al., 2014; Bluestone et al., 2010).  Type 1 diabetes 
develops due to immune cell-mediated destruction of islet beta cells or 
insulitis resulting in reduced or no production of insulin. This is caused by beta 
cells being infiltrated by T cells (CD8+ and CD4+), macrophages (CD68+) and 
CD20+ B cells (Atkinson et al., 2014). Two distinct disease phenotypes have 
been identified based on the rate of B cell infiltration namely hyper-immune 
CD20Hi and pauci-immune CD20Lo (Arif et al., 2014). The former was found 
to be characterised by high level of autoantibodies and interferon gamma and 
identified in patients at age of five or less, whereas the latter was characterised 
by none or few autoantibodies and a higher level of interleukin-10, and 
observed in older patients (Arif et al., 2014). More recently, it has been 
reported that patients diagnosed before the age of seven displayed CD20Hi 
insulitic profile with impaired insulin processing (endotype 1), whereas those 
diagnosed later than 12-13 years of age are always of CD20Lo profile with 
better insulin processing than the former (endotype 2) (Leete et al., 2016; 
Leete et al., 2020).   
The causes of the immune response are not fully understood, however genetic 
factors and environmental factors such as viral infections have been found to 
trigger the immune response in type 1 diabetes (reviewed by Richardson and 
Morgan, 2018; reviewed by Robertson and Rich, 2018). For example, genome-
wide association studies and meta-analyses have found about 40 loci 
contributing to type 1 diabetes risk, including human leukocyte antigen (HLA) 
(Barrett et al., 2009). A number of HLA class II haplotypes were found to be 
associated with autoantibody formation, such as HLA-DR4-DQ8 associated 
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with insulin autoantibodies (Krischer et al., 2015). Beta cells are highly 
susceptible to human enteroviral infections and these viruses can activate 
chronic low-level infection in some cases (reviewed by Richardson and 
Morgan, 2018). One such virus is Coxsackie B that was detected in pancreatic 
tissues from patients with type 1 diabetes (Busse et al., 2017). Type 1 diabetes 
is managed by daily insulin injections where regular monitoring of blood 
glucose levels is imperative. In a small number of cases pancreas or islet 
transplantation can be an option (reviewed by Atkinson et al., 2014). 
Type 2 diabetes 
Type 2 diabetes is a chronic condition associated with metabolism of 
carbohydrates, lipids and proteins. It constitutes about 90-95% of cases of 
patients with diabetes and is generally diagnosed later in life (40-59 years). 
Recently, younger people in their 30s have been diagnosed (reviewed by Wu et 
al., 2014). Type 2 diabetes is characterised by insulin resistance in target 
tissues in conjunction with relative insulin insufficiency, resulting from beta 
cell dysfunction and loss that may arise due to oxidative stress and 
endoplasmic reticulum stress as further described in the next section 
(reviewed by Kharroubi and Darwish, 2015; Wu et al., 2014). 
The risks of developing type 2 diabetes are associated with genetics and 
environmental factors. The condition is considered polygenic, therefore 
influenced by polymorphisms at multiple loci associated with reduction in 
peripheral insulin sensitivity and impaired beta cell function (reviewed by Ali, 
2013). For example, polymorphisms at peroxisome proliferator-activated 
receptor-gamma (PPARγ) locus, that are involved in adipose tissue 
differentiation and insulin sensitivity, are associated with type 2 diabetes risk 
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(Ruchat et al. 2009). Similarly, polymorphisms at loci involved in beta cell 
function such as potassium channel inwardly rectifying subfamily J member 
11 (KCNJ11), that encodes KATP channels found in beta cells have been 
identified as risk factors of the condition (reviewed by Ali, 2013; Hani et al., 
1998). Genetic polymorphisms can not only directly influence beta cell 
function and peripheral insulin sensitivity, but also alter physiological 
responses to environmental risk factors (reviewed by Ali, 2013). Numerous 
environmental factors are considered as mediators of type 2 diabetes risk 
including inadequate physical activity, pollution, unhealthy diets and stress 
(reviewed by Dendup et al., 2018). These life-style changes result in high 
cholesterol, obesity, increased blood pressure and prediabetes that in the long 
term can develop into type 2 diabetes (reviewed by Dendup et al., 2018). 
The management of type 2 diabetes can be achieved by healthy diet, physical 
activity and pharmacological agents that lower blood glucose levels (Reusch 
and Manson, 2017). Some of these compounds include biguanides 
(metformin), which act by increasing insulin sensitivity in peripheral tissues 
and suppressing hepatic gluconeogenesis (reviewed by Rena et al., 2017); and 
more recently developed sodium-glucose co-transporter-2 (SGLT2) inhibitors 
such as empagliflozin, which prevent glucose reabsorption in kidneys and 
promote renal glucose excretion (Ndefo et al., 2015). In patients with poorly 
controlled blood glucose levels, i.e.: displaying frequent fluctuations in 
glycaemic levels, administration of subcutaneous insulin is recommended 
(Inzucchi et al., 2015; reviewed by Wu et al., 2014).  
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1.2.2 Factors affecting beta cell dysfunction and loss in type 2 
diabetes  
1.2.2.1 Insulin resistance in target tissues 
Insulin resistance refers to the inefficiency of insulin to increase glucose 
uptake and utilisation in target tissues compared to the extent in a healthy 
individual (reviewed by Lebovitz, 2001). It therefore develops in liver, skeletal 
muscle and adipose tissue. Many mechanisms of insulin resistance exist due 
to multiple pathways activated by insulin upon binding to its receptor as 
described in section 1.1.2. Potential causes of insulin resistance are suggested 
to be, but not limited to genetic mutations in the signalling pathways and 
adiposity (reviewed by Lebovitz, 2001). Obesity constitutes a risk factor in 
developing insulin resistance due to incidence of chronic systemic 
inflammation (reviewed by Kwon and Pessin, 2013; reviewed by Stinkens et 
al., 2015). Adipose tissue is involved in the regulation of feeding behaviours 
and inflammation. It is suggested that increased subcutaneous adipocyte size 
results in impaired glycaemic control and insulin responses (Hoffstetd et al., 
2010). In addition, adipocyte hypertrophy can cause oxidative and 
endoplasmic reticulum (ER) stress, described below, resulting in adipocyte 
dysfunction. This causes excessive secretion of pro-inflammatory cytokines 
that triggers local and systemic inflammation (reviewed by Kwon and Pessin, 
2013). Furthermore, adipocyte dysfunction increases circulating free fatty 
acids (FFAs) that infiltrate other tissues such as skeletal muscle and cause 
muscle insulin resistance (reviewed by Boden, 2011).  As mentioned in 1.1.2, 
skeletal muscle is a main target of glucose where it is taken up, stored and 
utilised. It has been shown that elevated circulating FFAs cause intramuscular 
lipid accumulation and insulin resistance in healthy humans (Boden et al., 
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2001). This has been suggested to be associated with lipid metabolite 
production and subsequent interference with insulin signalling via impaired 
translocation of GLUT4 (Boden, 1997; Cline et al., 1997; Garvey et al., 1998). 
FFAs can cause muscle cell insulin resistance in a number of ways including 
triggering of ER stress, and via secretion of pro-inflammatory cytokines 
(reviewed by Rachek et al , 2014).  
Mitochondrial dysfunction due to oxidative stress can also impair FFA 
oxidisation resulting in accumulation of FFAs in the cells, which is a feature of 
high-fat diet induced insulin resistance (Bonnard et al., 2008). Similarly, in 
the liver, chronic inflammation by FFAs interfere with insulin signalling 
resulting in impaired glycogen synthesis and increased hyperglycaemia 
(Meshkani and Adeli, 2009). 
Insulin resistance can lead to type 2 diabetes in some individuals, but not all 
due to compensatory mechanisms maintaining normoglycaemia. However, 
over long-term hypersecretion of insulin can result in beta cell dysfunction 
that progresses the condition to type 2 diabetes mellitus (reviewed by Fu et al., 
2014). 
 
1.2.2.2 Beta cell dysfunction and loss 
The secretory dysfunction of beta cells and the consequent beta cell loss are 
causative factors in developing diabetes. Analysis of pancreata from patients 
with type 2 diabetes showed a marked depletion in beta cell mass compared to 
patients without diabetes (Cho et al., 2011; Matveyenko and Butler, 2008). 
Although it is known that in type 1 diabetes beta cell loss occurs as a result of 
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an autoimmune response, in type 2 diabetes the mechanism is not very well 
understood. 
Beta cell dysfunction is a determining factor in developing type 2 diabetes 
(reviewed by Kahn, 2000). In order to manage hyperglycaemia due to insulin 
resistance beta cells hypersecrete insulin. To compensate for this beta cells 
undergo hypertrophy (Ackermann and Ganon, 2006). The two phases of 
insulin secretion (pg. 14) are altered in type 2 diabetes. In people with 
impaired glucose tolerance the first phase of insulin secretion was reported to 
be absent (Gerich, 2002).  In another study investigating the effects of acute 
hyperglycaemia it was found that short-term modest hyperglycemia inhibited 
first phase of insulin secretion, whereas second phase was found to increase 
linearly with hyperglycaemia (Toschi et al., 2002). Over time, however, 
sustained severe hyperglycaemia results in complete inefficiency in glucose-
stimulated insulin secretion (GSIS) including second phase of insulin 
secretion. At this stage beta cells display morphological changes such as 
degranulation of the cell indicating lack of insulin production including 
downregulation of insulin mRNA expression (Weir et al., 2001).  
As described in 1.1.1 islets are highly vascularised and in type 2 diabetes islet 
vasculature has been found to adapt to high metabolic activity due to 
hyperglycaemia (Dai et al., 2013). In addition, it has been found that the islet 
architecture is altered in animal models of type 2 diabetes and that beta cells 
can differentiate into alpha cells (Talchai et al., 2012). These changes therefore 
result not only in islet cell secretory dysfunctions but also in the disruption of 
intra-islet regulation in people affected by diabetes (Brereton et al., 2015). 
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The drivers of beta cell dysfunction are described as cellular stress signals 
generated from prolonged exposure to high glucose (glucotoxicity), high fat 
(lipotoxicity), a combination of both (glucolipotoxicity) as well as pro-
inflammatory cytokines resulting is inflammation (reviewed by Hasnain et al., 
2016). These factors cause beta cell oxidative stress and endoplasmic 
reticulum (ER) stress that are characteristic of beta cells in patients with type 
2 diabetes (reviewed by Hasnain et al., 2016). High metabolic activity of beta 
cells leads to excessive production of reactive oxygen (ROS) and reactive 
nitrogen (RNS) species. These include nitric oxide (NO), superoxide, hydrogen 
peroxide and peroxynitrite (Nelson and Cox, 2008). Usually, beta cells are 
capable of coping with their production, however due to high demand for 
oxygen during insulin resistant hyperglycaemia, the overproduction of ROS 
and RNS result in beta cell oxidative stress (Meares et al., 2013). The RNS and 
ROS species can also react and form more potent stress factors that can induce 
ER stress. One such example is peroxynitrite that is generated by nitric oxide 
reacting with superoxide (Nelson and Cox, 2008). In addition, prolonged 
exposure to elevated concentrations of fatty acids causes downregulation of 
insulin gene expression, impaired glucose-stimulated insulin secretion and 
apoptosis (Hagman et al., 2005; Johnston et al., 2018). For example, rat 
pancreatic islets cultured in medium containing a high concentration of fatty 
acids for 7 days displayed a number of apoptotic features including DNA 
fragmentation and ceramide formation (Shimabukuro et al., 1998).  The 
presence of FFAs has been found to increase production of ROS and RNS via 
mitochondrial metabolism that upregulates expression of nitric oxide synthase 
(iNOS) resulting in the generation of NO (Rachek et al., 2006). 
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Oxidative stress and ER stress are interconnected, and the detrimental effects 
of each process are difficult to distinguish. Instead this indicates that beta cell 
dysfunction is connected to beta cell apoptosis. Protein misfolding is an 
inevitable occurrence in the ER, however exceeding the threshold that cannot 
be counter regulated triggers the unfolded protein response (UPR), leading to 
ER stress (reviewed by Hasnain et al., 2016). Prolonged ER stress can cause 
inflammation, autophagy and apoptosis. UPR is activated by heat shock 
protein binding immunoglobulin protein (Bip). Dissociation of Bip from UPR 
initiating molecules inositol-requiring enzyme-1 (IRE1α), protein kinase-R-
like ER kinase (PERK) and activating factor 6 (ATF6) triggers their activation 
and consequently UPR. The primary function of these molecules is to reduce 
ER workload and recovery of ER function which is achieved by reducing 
protein translation, restoration of correct protein folding and ER associated 
degradation of misfolded proteins (reviewed by Bravo et al., 2013). However, 
in this process downstream molecules of PERK and IRE1α can trigger 
apoptosis. PERK phosphorylates transcription factors activating factor 4 
(ATF4) and CCAAT-enhancer-binding protein homologous protein (CHOP) 
that can trigger ER stress induced apoptosis in beta cells and other cell types 
(Marciniak et al., 2004). IRE1α is mainly involved in degradation of misfolded 
proteins, however it can also activate c-Jun N-terminal kinase (JNK) signalling 
resulting in cell death (Urano et al., 2000). 
Oxidative stress and ER stress due to lipotoxicity can also activate nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFκB) that is a 
regulator of inflammation. NFκB can trigger release of cytokines such as 
interleukin-1 β (IL-1β) from resident leukocytes of the pancreatic islets 
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(Igoillo-Esteve et al., 2010). Pro-inflammatory cytokines in turn exacerbate 
oxidative stress and ER stress and production of detrimental nitric oxide 
(Kacheva et al., 2011).  
Since early stages of type 2 diabetes is characterised by beta cell dysfunction 
rather than loss, the former can be considered the main driver of this 
condition. This process is potentially reversible and therefore identifying 
target candidates modifying the progression is of utmost relevance (reviewed 
by Hasnain et al., 2016).  
 
1.3 The roles of somatostatin and ghrelin in maintenance 
of glucose homeostasis and type 2 diabetes.  
1.3.1 Somatostatin 
1.3.1.1 The structure and function of somatostatin 
Somatostatin (SST), also known as somatotropin-releasing factor (SRIF), is 
primarily an inhibitory peptide that acts on several tissues including brain, 
gut, retina and pancreas (reviewed by Günther et al., 2018). 
There are two main forms of the hormone: a 14 amino acid peptide (SST-14) 
that was initially identified in the sheep’s hypothalamus (Brazeau et al., 1973) 
and a 28 amino acid peptide isolated later (Pradayrol et al., 1980). Both forms 
of SST have a cyclic structure with a disulphide bridge (Fig. 1.7).  
The precursor of both peptides is preprosomatostatin. It is encoded by the 
gene SST1 and consists of 116 amino acids that includes a signal peptide at the 
N terminus (Goodman et al., 1983). Preprosomatostatin undergoes rapid 
cleavage into prosomatostatin consisting of 92 amino acids which is then 
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processed by specific protein convertases such as PC2 to generate the mature 
forms (Goodman et al., 1983; Marcinkiewicz et al., 1994). Somatostatin is 
widely expressed in the body. For example, in rats 65% of total SST is found in 
the gut, 25% in the brain, 5% in pancreas and 5% in other tissues such as 
thyroid, liver, kidney, heart, muscle and blood vessels (Kumar and Grant, 
2009; reviewed by Martinez, 2013). SST-14 is mainly found in the central 
nervous system and pancreatic islets, whereas SST-28 is produced in the 
gastro-intestinal (GI) tract and corresponds to the majority of circulating SST 
(Kumar and Grant, 2009; Mani and Zigman, 2015).  
 
As mentioned before SST mainly acts as an inhibitor of hormone secretion 
(Fig. 1.8). Indeed, SST-14 has been well characterised as an inhibitor of growth 
hormone (GH) secretion in the brain. Rats injected with somatostatin had 
reduced GH concentration compared to saline injected controls (Brazeau et 
al., 1973). 
Figure 1.7 The structure of the two somatostatin isoforms in humans. 
Somatostatin (SST) is a cyclical peptide of 14 (SST-14) or 28 (SST-28) amino acids 
linked together by a disulphide bridge (Cuevas-Ramos and Fleseriu, 2016:229). 
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 GH release is stimulated by growth hormone releasing hormone (GHRH) and 
SST-14 was found to inhibit GHRH (Barinaga et al., 1983).  Others have 
shown that SST-14 acts directly on the pituitary to inhibit GH secretion and 
indirectly suppresses GHRH (Katakami et al., 1988). These results were 
further confirmed in Sst null mice where basal GH levels were higher 
compared to wild type controls (Low et al., 2001). In addition, the action of 
SST-14 on the anterior pituitary reduced secretion of thyroid stimulating 
hormone (TSH) (Ridgway et al., 1983). As a result of reduced TSH levels the 
production of calcitonin from parafollicular cells in the thyroid is hindered 
(Kumar and Grant, 2009). Furthermore, in patients with hypothyroidism SST-
14 directly suppresses the TSH-induced release of thyroxine (T4) and 
Figure 1.8 The hormonal targets of somatostatin. Somatostatin mainly 
acts as an inhibitory hormone in central nervous system, gut and pancreatic islets. 
(Kumar and Grant, 2010:142). 
 Chapter 1 - General introduction 
 30   
 
triiodothyronine (T3), and therefore is considered to be a causative factor of 
hypothyroidism (Loos et al., 1978).  
In the GI tract SST-28 suppresses gastric acid secretion, release of gut 
hormones such as gastrin and motilin, bile and digestive enzymes. It also 
impairs gallbladder contractility, gastric emptying and intestinal peristalsis 
(reviewed by Günther et al., 2018). For example SST infusion into the 
duodenum of dogs prevented motilin-induced contractility and therefore 
digestive process (Ormsbee et al., 1978).  
SST-14 is produced by pancreatic islet delta cells (Orci and Unger, 1975) and 
influences both insulin and glucagon secretion. For example, in healthy 
humans administration of SST decreased plasma insulin levels (Alberti et al., 
1973). In the same study, infusion of SST into perfused canine pancreata 
resulted in impaired glucose-mediated insulin secretion that was recovered 
following termination of SST infusion (Alberti et al., 1973). Indeed, it has been 
shown that SST-14 inhibits insulin and glucagon secretion in a paracrine 
manner (Hauge-Evans et al., 2009). This finding was confirmed by the 
discovery that the haematopoietically expressed homeobox  (Hhex) gene, a 
gene important for developmental regulation of several organs, is primarily 
expressed on pancreatic delta cells, but not alpha and beta cells. Its islet-
specific knockout resulted in ~75% reduction in delta cell area. Consequently, 
decreased SST release and concomitant paracrine regulation of beta and alpha 
cells’ secretory responses were observed (Zhang et al., 2014).  As described in 
1.3.1.2, somatostatin acts via five receptor subtypes (SSTRs), with SSTR2 
being primarily expressed in alpha cells. Targeting of this receptor by a SSTR2 
agonist caused increase in arginine-induced glucagon secretion in wildtype 
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mice, but not in Sst-/- mice (Strowski et al., 2006). Similarly, in a recent study 
tolbutamide-induced glucagon secretion was elevated in islets from Sst-/-mice 
(Cheng-Xue et al., 2013). Taken together these studies further confirm the role 
of SST as paracrine regulator of islet secretions.  
In addition to its role as a regulator of secretory functions, SST has been 
studied in the context of cell survival and apoptosis as further described in 
section 3.1. Briefly, a number of studies exploring the role of somatostatin in 
various tissues have found that it exerts an anti-proliferative effect in some 
cancers including pancreatic, breast, small-cell lung and colorectal (reviewed 
by Pyronnet et al., 2008; Schally et al., 1988). In primary pancreatic 
neuroendocrine tumour cells treatment with somatostatin analogues 
octreotide and pasireotide reduced cell viability and induced apoptosis 
(Mohamed et al., 2014). In contrast, in other tissues such as the retina and 
nerve fibres incubation with SST has been reported to prevent cell apoptosis 
and reduce inflammation (Hernandez et al., 2013; Pintér et al. 2006). In 
accordance with the latter studies, work conducted in our lab showed that SST-
14 protects beta cells and islet cells from apoptosis induced by palmitate 
and/or a combination of pro-inflammatory cytokines (Damsteegt et al., 2019). 
However, the receptor subtype mediating the pro-survival effect of SST in beta 
cells and islets remains to be elucidated. 
1.3.1.2 Somatostatin receptors 
Somatostatin receptors are classified as G-protein coupled receptors (GPCR) 
that consist of seven transmembrane spanning alpha helices, an extracellular 
C terminal and an intracellular N terminal (reviewed by Günther et al., 2018; 
reviewed by Martinez, 2013). There are five SST receptor subtypes identified: 
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SSTR1-5. These receptors are coupled to G proteins Gαi/G0 and Gq and 
adenylate cyclase. Therefore, the activation of SSTR and the second messenger 
systems can trigger numerous downstream signalling events leading to 
regulation of hormone secretions, vesicle exocytosis, and cell survival and 
proliferation (reviewed by Ferjoux et al., 2000; reviewed by Kumar and Grant, 
2009). 
Similar to somatostatin its receptor subtypes are also widely expressed in the 
body including in the brain, kidneys, thyroid, pancreas and GI tract (reviewed 
by Günther et al., 2018). SSTR2 was preferentially expressed in the stomach 
both at mRNA and protein level confirmed by immunohistochemistry 
(reviewed by Martinez, 2013). In the small intestine and colon all five receptor 
subtypes were detected with SSTR2 being expressed at the highest level 
(reviewed by Martinez, 2013).  All five SST receptors are present in the brain 
(Bruno et al., 1993) and SSTR1 predominates particularly in the arcuate 
nucleus together with SSTR2 (Tannenbaum et al., 1998). 
In the pancreatic islets of both rodents and humans all five SSTR subtypes 
have been detected. Using fluorescence immunohistochemistry Kumar et al. 
(1999) have found that human islet beta cells expressed SSTR1, SSTR5 and to 
a lesser extent SSTR2. They have also reported that SSTR2 was the dominant 
subtype in alpha cells and SSTR5 in delta cells. In accordance with these 
findings SST was found to inhibit glucagon secretion via SSTR2 and insulin 
secretion via SSTR5 in rodents (Strowski et al., 2000). However, in human 
islets SSTR2 activation exerted the most potent inhibition of insulin and 
glucagon secretion (Singh et al., 2007). The expression patterns of SSTRs in 
the rodent islets was elucidated in a number of studies (Adriaenssens et al., 
 Chapter 1 - General introduction 
 33   
 
2016; Ludvigsen et al. 2004; Somvanshi et al., 2018) Ludvigsen et al. (2004) 
showed that mouse beta cells express SSTR1,2 and 5 at the highest level (85-
95%) and SSTR3 and 4 at lower level. In rats no difference in the levels of 
SSTRs was detected in beta cells in this study. SSTR2 and 5 were detected in 
80% of alpha cells with the remaining subtypes detected at much lower level 
in islets of mice and rats. Finally, similar levels of SSTR1-4 were detected in 
delta cells with SSTR5 being the lowest. This pattern was observed in both 
mice and rats (Ludvigsen et al., 2004). These findings were mostly confirmed 
in a recent study by Somvanshi et al. (2018). Here beta cells were found to 
mainly express SSTR1 and 5 with lower expression of SSTR3 and 4, alpha cell 
expressed SSTR2, 3 and 5, and delta cells expressed SSTR3 at a low level 
(Somvanshi et al., 2018). Despite many studies reporting the detection of 
SSTR1, 2 and 5 in beta cells, recent single-cell transcriptomic analyses have 
reported only Sstr3 to be present in beta cells and Sstr2 and 3 in alpha cells of 
mouse islets (Adriaenssens et al., 2016; DiGruccio et al., 2016) as described in 
section 3.1 of this thesis.  
 A number of SSTR antagonists have been developed including the pan 
antagonist PRL2915 (Hocart et al., 1999) and SSTR5 antagonist PRL3195 
(Rajeswaran et al., 2001). However commercially available SSTR3-selective 
antagonists are limited. MK4256 is a recently identified SSTR3 competitive 
antagonist (He et al., 2012) (Fig. 1.9). In oral glucose tolerance tests (OGTT) 
performed in mice, increasing doses of MK4256 resulted in reduced blood 
glucose levels. This was confirmed in Sstr3-/- mice where the reduction in 
blood glucose following administration of MK4256 was not significant (He et 
al., 2012). 
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Furthermore, the compound showed synergistic effects on glucose levels when 
given in adjunct with sitagliptin which is an antidiabetic medication that 
prevents degradation of incretins resulting in increased insulin secretion and 
reduced glucagon secretion (Thornberry and Gallwitz, 2009). Therefore, 
MK4256 was used in the present study to assess the role of SSTR3 in 
modulating clonal beta cell and mouse islet function.  
 
1.3.1.3 The role of Somatostatin in diabetes 
Being a paracrine regulator of insulin and glucagon secretion, somatostatin is 
inevitably associated with diabetes mellitus. By inhibiting glucagon secretion, 
it has been suggested that SST-14 may help to prevent hyperglycaemia in 
patients with both type 1 and 2 diabetes (reviewed by Rutter, 2009; reviewed 
by Strowski and Blake, 2007). In type 1 diabetes, adjunct therapy of SST with 
insulin helped to reduce the amount of exogenous insulin required to obtain 
normoglycaemia. It was thought that suppression in glucagon release 
Figure 1.9 The structure of MK4256 (He et al., 2012). 
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following administration of SST may have contributed to this effect, although 
other effects of SST on GI tract and islet exocrine secretions could not be 
dismissed (Gerich et al., 1977). Similarly, in patients with type 2 diabetes co-
administration of SST analogue octreotide with insulin resulted in reduced 
postprandial blood glucose (Giustina et al., 1991).  Some have reported that 
the number of somatostatin producing delta cells is increased in both type 1 
and 2 diabetes as reviewed by Strowski and Blake (2007) whereas Lawlor et al. 
have reported this to be lower using transcriptomic analysis (Lawlor et al., 
2017). Furthermore, the expression patterns of SSTRs have been shown to be 
altered in the islet cells of patients with diabetes (Portela-Gomes et al., 2010). 
Beta cell SSTR3 level was significantly higher in isolated mouse islets cultured 
in 28.8 mM glucose, but not in alpha cells (Ludvigsen et al., 2011). In another 
study, expression of SSTR1 and 4 was reduced in alpha cells whereas SSTR1, 
3 and 4 expression was reduced in delta cells (Portela-Gomes et al., 2010).  
Taken together these studies indicate that somatostatin plays a role in the 
management of diabetes mellitus.  
In summary, these studies highlight that islet cell type specific SST receptor 
expression patterns are disputed and require further elucidation to 
understand the mechanism of action of SST in these islets. 
 
1.3.2 Ghrelin 
1.3.2.1 The structure and function of ghrelin 
Ghrelin is a 28-amino acid orexigenic hormone that is mainly produced in 
X/A-like cells in the oxyntic glands of the stomach, but also found to be 
expressed in pancreatic islets, brain, heart and upper intestines (Gnanapavan, 
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2002; Sato et al., 2011; Wierup et al., 2002; Wierup et al., 2014). The ghrelin 
gene encodes a precursor molecule of 117 amino acids called preproghrelin 
that is cleaved into ghrelin and a 23-amino acid peptide named obestatin of 
unclear physiological function (Granata et al., 2010). Ghrelin exists in two 
forms: the acylated form (acyl-ghrelin) and the unacylated form (des-acyl-
ghrelin). The acylation is catalysed by the enzyme ghrelin-O-acyltransferase 
(GOAT) that transfers an octanoate group on to the third serine residue of the 
peptide. This modification is essential for the binding of the peptide to its 
known receptor. Ghrelin is highly conserved between species where rat and 
mouse ghrelin only differ from human ghrelin by two amino acids (Fig.1.10; 
Castañeda et al., 2010; Sivertsen et al., 2013).  The term ghrelin will be used 
to refer to the acylated form of the peptide in the subsequent sections unless 
otherwise specified. 
Numerous studies have found that both in humans and rodents ghrelin plays 
a role in regulating appetite, food intake, energy metabolism, weight gain and 
fat mass via its activity on the hypothalamus, where it signals via the arcuate 
nucleus (reviewed by Delporte, 2013; Kojima et al., 1999; reviewed by 
Pradhan et al., 2013). 
In both obese and lean participants, infusion of ghrelin resulted in increased 
food intake (Druce et al., 2005). Similarly, it was stimulated by administration 
of ghrelin in rats (Wren et al., 2001). Chronic administration of ghrelin causes 
adiposity in rodents (Tschöp et al, 2000).  In particular, treatment lasting one-
week increased food intake in satiated rats, resulting in hyperphagia and 
higher body weights. These rats had elevated levels of white adipose tissue 
deposits (Wren et al., 2001). It is known that ghrelin regulates body weight in 
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the long term and that ghrelin levels are lower with weight gain, whereas 
caloric restriction can increase ghrelin levels (reviewed by Delporte, 2013). 
Ghrelin is also known to act via the pituitary and promote growth hormone 
secretion (Kojima et al., 1999). In addition to its orexigenic effects a number 
of studies have reported that ghrelin modulates cardiac functions, muscle 
atrophy, bone metabolism and cancer (Fig 1.11; reviewed by Delporte, 2013; 
reviewed by Pradhan et al., 2013).  
 
Figure 1.10 The structures of human unacylated (des-acyl) ghrelin 
and acylated (acyl) ghrelin. Octanoate group O=C-(CH2)4/6/8-CH3 is 
transferred by GOAT to des-acyl ghrelin to generate acyl-ghrelin.  
Cleaved amino acid 
Amino acids differing between human and rodent ghrelin. 
Arginine11 – valine12 are found in human ghrelin whereas 
lysine11 – alanine12 are present in rodents. (Modified 
from Castañeda et al., 2010:45). 
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The functions of ghrelin in the cardiovascular system vary from decreasing 
mean arterial pressure to improving chronic heart failure. For example, 
administration of ghrelin improved cardiac output, left ventricular function, 
increased muscle strength and decreased systemic vascular resistance (Nagaya 
et al., 2004). In rats with myocardial infarction, frequency of arrhythmias was 
reduced by acute ghrelin treatment thereby improving survival (Schwenke et 
Figure 1.11 Image representing well-known functions of ghrelin. Ghrelin 
has been shown to have multiple physiological functions in brain, gut, cardiovascular 
system, pancreas, liver and bone. (Sivertsen et al., 2013:1350). VTA = Ventral 
tegmental area. 
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al., 2008) Ghrelin has also been shown to activate extracellular signal-
regulated kinases (ERK 1/2) and Akt in cardiomyocytes and endothelial cells 
resulting in inhibition of apoptosis (Baldanzi et al., 2002).  
In the gastrointestinal tract peripheral administration of ghrelin increased 
gastric acid secretion (reviewed by Delporte, 2013). Similarly, it was reported 
that the central administration of ghrelin induced gastric acid secretion in 
fasted rats (Date et al. 2001), in contrast gastric acid secretion was found to be 
reduced in fasted mice in another study (Sibilia et al. 2002).  
Some studies have indicated an anti-inflammatory function of ghrelin in a 
number of conditions including inflammatory bowel disease, sepsis, 
pancreatitis and arthritis (reviewed by Delporte, 2013). For example, pre-
treatment with ghrelin prior to establishing experimental pancreatitis, showed 
improved blood flow to the pancreas, reduced IL-1β levels and stimulation of 
pancreatic cell proliferation (Warzecha et al., 2010). Furthermore, ghrelin 
mRNA was detected in a number of pituitary tumours such as prolactinomas 
suggesting a role for ghrelin in cancer growth and progression as reviewed by 
Pradhan et al. (2013). In the context of bone metabolism, ghrelin was found 
to increase proliferation and differentiation of osteoblasts in vitro and bone 
mineral density in vivo (reviewed by Delhanty et al., 2013). 
Furthermore, ghrelin also regulates glucose homeostasis (reviewed by Alamri 
et al., 2016). For example, administration of ghrelin resulted in increased 
plasma glucose and reduced insulin levels in healthy humans (Broglio et al., 
2001). Acute administration of ghrelin alone and in combination with arginine 
caused elevated glycaemia in young males with concomitant reduction in 
insulin secretion (Broglio et al., 2003). Similarly, in healthy humans, infusion 
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of ghrelin caused decreased acute insulin response to glucose suggesting that 
ghrelin modulates glucose tolerance in humans (Tong et al., 2010). In a study 
conducted in mice, inhibition of GOAT, enzyme responsible for acylation of 
ghrelin resulted in elevated plasma insulin and reduced blood glucose levels 
compared to control treated mice (Barnett et al., 2010). Here inhibition of 
GOAT in isolated pancreatic islets caused increased glucose-induced insulin 
secretion compared to control, suggesting a direct role for ghrelin in islet 
insulin secretion and therefore glucose homeostasis (Barnett et al., 2010). 
In the pancreas ghrelin has been found to be produced in pancreatic epsilon 
cells by Wierup et al., (2002). However, Volante et al., (2002), showed that 
ghrelin is also expressed in beta cells by double insulin and ghrelin staining. 
Others reported ghrelin to be expressed in both alpha and beta cells 
(Kageyama et al., 2005) and in alpha cells only (Date et al., 2002). The role of 
ghrelin in the pancreas has been mainly focused on the regulation of insulin 
secretion from beta cells. In the clonal beta cell line INS-1 (832/13) glucose-
induced insulin secretion was suppressed by ghrelin in a dose-dependent 
manner (Wierup et al., 2004). Simultaneous injection of ghrelin and glucose 
in oral glucose tolerance tests (OGTT) resulted in reduced insulin response 
and increased glucose responses in mice compared to controls without ghrelin. 
Here the use of a ghrelin receptor (GHSR1a) antagonist reversed the effects of 
ghrelin (Dezaki et al., 2004). Others however have found that 100 nM ghrelin 
enhanced insulin secretion in response to 20 mM glucose in isolated mouse 
islets (Salehi et al., 2004) suggesting that the function of ghrelin in the islets 
remains controversial.  
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As mentioned above, ghrelin has been reported to promote cell survival, 
proliferation and angiogenesis in a number of organs as well as in regulating 
insulin secretion in the pancreas, however its function in promoting beta cell 
and islet survival is not as well understood. Some studies have shown that 
ghrelin promoted survival in the INS-1E and HIT-T15 beta cell lines (Diaz-
Ganete et al., 2015; Zhang et al., 2007). It has also been shown that ghrelin 
promoted beta cell and human islet proliferation and inhibited apoptosis in 
HIT-T15 cells and isolated human islets (Granata et al., 2007) as further 
described in section 4.1.  
Unacylated ghrelin (UAG) does not bind the known ghrelin receptor named 
growth hormone secretagogue receptor type 1A (GHSR1a), therefore initially 
it was considered to be inactive. However, subsequent studies have found that 
UAG prevents doxorubicin-induced apoptosis in cardiomyocytes (Baldanzi et 
al., 2002) and to influences food intake signalling. In the hypothalamus UAG 
was found to induce food intake via a mechanism independent of GHSR1a/ 
neuropeptide Y (NPY) related signalling (Toshinai et al., 2006). When 
administered peripherally, however, UAG decreased food intake in rats (Chen 
et al., 2005). Others have found that co-administration of UAG with acyl-
ghrelin opposed the increase in blood glucose seen when treated with acyl-
ghrelin in humans (Broglio et al., 2004). These studies suggest that unacylated 
ghrelin exerts effects that are common, opposite or independent of acyl-
ghrelin. Since UAG does not bind GHSR1a, it is believed that its effects are 
mediated by an as-yet-unknown receptor (reviewed by Granata et al., 2010). 
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1.3.2.2 Ghrelin receptor 
Ghrelin is known to act via the GPCR GHSR1a (Fig. 1.12). Initially thought to 
be important for growth hormone release, GHSR1a is mainly known and 
characterised for promoting orexigenic effects via NPY/agouti-related peptide 
neurons in arcuate nucleus of hypothalamus (Sivertsen et al., 2013). 
Alternative splicing of the Ghsr gene produces GHSR1b, a truncated receptor 
that shows opposing actions to GHSR1a (reviewed by Albarrán-Zeckler and 
Smith, 2013). 
Figure 1.12 GHSR1a activates multiple signalling pathways. GHSR1a 
has been shown to signal via G-protein subunits: Gαq, Gαi and Gα12/13 as well as via 
arrestin coupling. Gαq activates phospholipase C (PLC) and leads to increased 
inositol triphosphate (IP3) and diacylglycerol (DAG) thereby increasing Ca2+ 
signalling. This pathway can also activate ERK. Gα12/13 acts via RhoA leading to 
Serum response element (SRE) transcription. Gαi activation inhibits adenylate 
cyclase thereby reducing cAMP activation and reduction in Ca2+ signalling. 
(Sivertsen et al., 2013:1352; Dezaki, 2013). 
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With the use of human embryonic kidney 293 (HEK293) cells over-expressing 
both receptor subtypes, it was found that GHSR1b dimerises with GHSR1a at 
the endoplasmic reticulum to regulate GHSR1a expression on the cell 
membrane (Chow et al., 2012).  
GHSR1a belongs to a small group of GPCRs that present constitutive activity 
including melanocortin receptor (MC4, Holst et al., 2007) and the ghrelin 
receptor has been shown to present about 50% intrinsic constitutive activity 
(Damian et al., 2011; Veldhuis and Bowers, 2010). 
 GHSR1a has been reported to be expressed in stomach, brain, pancreas, blood 
vessels, reproductive organs (testis and ovaries), intestines and heart 
(Gnanapavan et al., 2002; Katugampola et al., 2001; Ueberberg et al., 2009). 
However, the localisation of GHSR1a within specific islet cell types remains 
disputed with some indicating that it is exclusively expressed on delta cells 
(Adriaenssens et al., 2016; DiGruccio et al., 2016) and others reporting its 
detection in alpha (Chuang et al., 2011) and beta cells (Kageyama et al., 2005) 
as further described in section 5.1 of this thesis. 
There are a number of GHSR1a antagonists that can be used to investigate if 
the functional effects of ghrelin are mediated by the known ghrelin receptor, 
These include the synthetic compounds YIL781, JMV2959, GSK1614343 and 
a more recently identified endogenous compound named liver-expressed 
antimicrobial peptide 2 (LEAP2).  
YIL781 or 6-[(4-fluorophenyl) oxy]-2-methyl-3-{[(3S)-1-(1-methylethyl)-3-
piperidinyl]methyl}-4(3H)-quinazolinone was synthesised by Esler et al. 
(2007) and was reported to be a competitive antagonist of GHSR1a (Fig. 1.13). 
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In addition, the compound was selective to GHSR1a as it did not bind the 
closest homolog of GHSR1a – the motilin receptor.  In the same study further 
analysis conducted using dispersed rat islets found that inhibition of insulin 
secretion by ghrelin was completely reversed by this compound. In vivo 
analysis showed that pre-administration of YIL781 to fasted rats caused a 23% 
decrease in blood glucose levels immediately after administration of glucose 
via stimulation of insulin secretion. This effect was similar to an incretin 
mimetic used as control (Esler et al., 2007).  
In a study testing the efficacy of a newly synthesized GHSR1a antagonist, 
YIL781 was used as a control and similar to observations by Esler et al., 
YIL781 was shown to bind GHSR1a (Perdonà et al., 2011). Others 
investigating the effect of a peptide encoded by the ghrelin gene known as 
obestatin on insulin secretion, found that obestatin increased insulin secretion 
in INS-1 cells that was reversed in the presence of YIL781 suggesting that 
obestatin acts via GHSR1a (Pradhan et al., 2017).  
A recent publication (Ge et al., 2018) identified the peptide LEAP2 to be an 
endogenous irreversible antagonist of GHSR1a. LEAP2 is a 40-amino acid 
Figure 1.13 The structure of YIL781. A piperidine-substituted 
quinazolinone derivative, YIL781, was identified as a novel GHSR1a antagonist 
(Esler et al., 2007). 
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peptide containing two disulphide bridges (Henriques et al., 2010). The 
mature form of the peptide is identical in humans and mice. In vivo testing 
showed that LEAP2 antagonised the ghrelin-induced increase in growth 
hormone release and food intake (Ge et al., 2018).  
When LEAP2 was expressed in a mouse model of caloric restriction, mice lost 
approximately 28% of their body weight and their blood glucose levels dropped 
to below 30 mg/dL, suggesting hypoglycaemia, however, the effect on insulin 
secretion and regulation of beta cell mass was not investigated (Ge et al., 
2018). Being an endogenous compound, and as the number of commercially 
available GHSR1a antagonists is limited this discovery was of great interest for 
the current project as it was found to bind GHSR1a in an irreversible manner. 
Therefore, the GHSR1a antagonists YIL781 and LEAP2 were used in this 
study to identify the role of GHSR1a in mediating the effects of ghrelin on 
function and survival of clonal beta cells and primary mouse islets. 
1.3.2.3 The role of ghrelin in diabetes 
Due its association with insulin secretion and glucose homeostasis ghrelin has 
been reported to play a role in type 2 diabetes, however its role in obesity and 
beta cell function remain contested. A study looking at Ghsr null mice found 
that the mice showed resistance to diet induced obesity (Zigman et al., 2005). 
In another study, however, ablation of ghrelin gene expression in leptin-
deficient ob/ob mice did not revert their obese phenotype. Despite a lack of 
effect on obese phenotype, Ghrelin-/- mice displayed improved insulin 
secretion and peripheral insulin sensitivity resulting in reduced 
hyperglycaemia (Sun et al., 2006). Others have shown that antagonising the 
action of ghrelin improved glycaemic control and prevented weight gain in rats 
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(reviewed by Poher et al., 2018). Furthermore, transgenic mice overexpressing 
Ghrelin exhibited increased food intake, reduced glucose-stimulated insulin 
secretion and increased insulin tolerance (Bewick et al., 2009). In contrast, in 
streptozotocin-induced diabetic rats treatment with ghrelin significantly 
elevated basal insulin secretion in isolated pancreatic fragments (Adeghate 
and Ponery, 2002). These studies confirm that alteration of ghrelin expression 
in mouse models of obesity and diabetes impacts parameters, which are 
important in diabetes, such as insulin secretion, insulin sensitivity and 
hyperglycaemia, however, findings are at times conflicting. 
 Some have reported that ghrelin inhibited apoptosis in beta cell lines and 
human islets in the presence of pro-inflammatory cytokines typical of type 1 
diabetes (Diaz-Ganete et al., 2015; Granata et al., 2007).  Since some pro-
inflammatory cytokines are also causative factors of beta cell dysfunction and 
death in type 2 diabetes as described in 1.2.2, it is therefore possible that 
ghrelin could be employed to prevent this. 
1.3.3 Interaction between somatostatin and ghrelin 
As mentioned in 1.1.1 somatostatin inhibits both insulin and glucagon release 
in a paracrine manner in pancreatic islets, and ghrelin has also been shown to 
influence beta cell secretory function. Both ghrelin and somatostatin act on 
several common target tissues including the central nervous system and 
pancreatic islets (Barkan et al., 2003), and a number of studies have pointed 
towards an interaction between the two hormones both centrally and in 
peripheral physiological functions. It has been reported that SST-14 and its 
analogue octreotide reduced plasma ghrelin levels in humans (Norrelund et 
al., 2002). In another study continuous infusion of octreotide decreased 
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plasma ghrelin level in healthy men compared to saline infusion (Barkan et al., 
2003). Furthermore, in rats subcutaneous injection of octreotide decreased 
fasting plasma ghrelin levels, and in a dose-dependent manner in ad libitum 
fed rats (Silva et al., 2005). In the same study treatment with octreotide for 
two weeks caused weight loss compared to saline treated controls. Shimada et 
al. (2003) also reported reduction in plasma ghrelin by SST. Here treatment 
with octreotide dose-dependently reduced ghrelin secretion in perfused rat 
stomach further suggesting the regulatory action of SST on ghrelin secretion 
in the stomach. These studies suggest that SST negatively regulates plasma 
ghrelin levels and stomach ghrelin secretion. 
As described in 1.3.1 and 1.3.2 both SST and ghrelin regulate pancreatic islet 
function, however the role of ghrelin on SST secretion remains controversial. 
It has been reported that ghrelin suppressed SST secretion in perfused rat 
pancreata (Egido et al., 2002). In contrast, findings by recent single-cell 
transcriptomic analyses showed that ghrelin stimulated SST release in islets, 
suggesting that the action of ghrelin is mediated by SST released by pancreatic 
delta cells (Adriaenssens et al., 2016; DiGruccio et al., 2016). In both studies 
treatment with ghrelin stimulated SST secretion from delta cells, resulting in 
consequent reduction in insulin secretion in either perfused mouse pancreata 
(Adriaenssens et al., 2016) or in isolated mouse and human islets (DiGruccio 
et al., 2016). It is, therefore, possible that ghrelin and somatostatin may 
interact in promoting pancreatic islet survival. Having already identified a pro-
survival role for somatostatin in pancreatic beta cells and islets under 
conditions typical of type 2 diabetes (Damsteegt et al., 2019), the next step is 
to assess whether ghrelin may also modulate islet function under those 
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conditions, prior to addressing a potential interaction between the two 
hormones. 
 
1.4 Cell models for the study of beta cell and islet function 
Many factors limit the utilisation of primary pancreatic beta cells in biological 
research. These include the reduced availability of pancreatic tissue as well as 
technically challenging islet isolation and purification procedures and 
maintenance. In addition, conforming to the principles of the 3Rs 
(replacement, reduction and refinement) as set out by Russell and Burch 
(1959) is fundamental for ethical research. This has led to the development of 
cell lines derived from primary explants or dispersed cell suspensions (Skelin 
et al., 2010). Others have developed pseudoislet models to study cell-cell 
interactions (Persaud et al., 2010). Nonetheless primary islets still remain the 
gold standard for the study of their function (Balboa et al., 2019) and are 
highly used in the study of diabetes mellitus. Some clonal beta cell lines and 
pseudoislet models are described below including the experimental model 
used in the current study. 
1.4.1 Clonal beta cell lines 
1.4.1.1 Mouse insulinoma-6 (MIN6 cells) 
Mouse insulinoma 6 or MIN6 cell line was derived from transgenic mice 
expressing simian virus 40 (SV40)-T antigen/insulin promoter construct 
where primary beta cells were transformed into immortalised insulinomas 
(Miyazaki et al., 1990). MIN6 cells express glucokinase and GLUT2 and 
respond to glucose at physiological levels similar to primary islets (Ishihara et 
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al., 1993). It has however been reported that their glucose responsiveness is 
reduced in later subculture passages (35-40) (Kayo et al., 1996). 
1.4.1.2 Insulinoma -1 (INS-1 cells) 
The Insulinoma 1 or INS-1 cell line was developed by X-ray irradiation-
induced formation of rat insulinomas. INS-1 cells express GLUT2 and 
glucokinase, have high insulin content (about 20% of primary beta cells) and 
have high insulin responsiveness to glucose at physiological levels (2.8-20 
mM) (Asfari et al., 1992). The main disadvantage of these cells is the use of 2-
mercaptoethanol for culture that can result in protein denaturation, however 
it is important for INS-1 cell proliferation and function (Skelin et al., 2010). 
In addition, similar to MIN6 cells, glucose responsiveness of INS-1 cells has 
been reported to be decreased in later passages (Hohmeier et al., 2000).  
1.4.1.3 Hamster islet transformed-tioguanine resistant clone-15 (HIT-T15) 
HIT-T15 cells were produced by lentiviral expression of SV40-T antigen in 
vitro in isolated hamster pancreatic beta cells (Santerre et al., 1981). These 
cells have membrane bound insulin granules that is a feature of native hamster 
beta cells. However, they contain 2.5-20 times less insulin content than native 
cells. HIT-T15 cells secrete insulin in response to numerous stimuli including 
glucose, glucagon and pharmacological agents. With increase in passage 
number from 41 to 88 insulin secretion decreased by 30% (Santerre et al., 
1981). 
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1.4.1.4 EndoC-βH1 cells 
EndoC-βH1 cells are a transformed human beta cell line derived from 
transduction of human pancreata and islets with a lentiviral expressing SV40 
large T antigen (SV40LT) (Ravassard et al., 2011). The transduced tissues 
were transplanted under the kidney capsule of severe combined 
immunodeficient (SCID) mice to allow differentiation of islet tissue. The 
resulting highly vascularised and differentiated tissue was isolated and 
following dissociation into clusters, were re-transduced with a lentiviral vector 
expressing human telomerase reverse transcriptase (hTERT) to achieve 
immortalisation of cells. After a second round of transplantation for further 
tissue expansion secondary insulinomas were isolated (Ravassard et al., 
2011). The expression of insulin mRNA is about 40% and insulin content is 
less than 10% in EndoC-βH1 cells compared to native islets. These cells are 
responsive to glucose and other insulin secretagogues such as sulfonylurea 
drugs and exendin-4 (Ravassard et al., 2011; Weir and Bonner-Weir, 2011). 
Although other human pancreatic beta cell lines have been developed before, 
namely CM, TRM1 and βlox5, these cells were either non-responsive to 
glucose or had low insulin content (Skelin et al., 2010). 
1.4.2 Pseudoislets 
Pseudoislets are aggregates of one or more types of islet cells that constitute 
islet-like structures in culture (Kelly et al., 2011). They were first reported in 
1980 when culture of single islet cells obtained following digestion of a dog 
pancreas resulted in the formation of cell aggregates after 4-8 days (Scharp et 
al., 1980). Usually pseudoislets are used to study structure-function 
relationships between islet cells.  Using a pseudoislet model consisting of 
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clusters of beta cells only, it has for example been shown that beta to beta cell 
interaction resulted in enhanced secretory responses to nutrient stimuli 
compared to a model using a single layer of beta cells (Hauge-Evans et al., 
1999). Similarly, heterotypic pseudoislets comprised of three islet cell types 
(beta, delta and alpha) have been found to display a better secretory response 
to glucose and other insulin secretagogues compared to monolayer cells (Kelly 
et al., 2011). In addition, pseudoislets constitute an especially attractive 
approach to increase islet availability for transplantation in patients with type 
1 diabetes mellitus since this process is greatly hindered by the lack of 
adequate donor islets (Kojima et al., 2014). However, their use has clear 
limitations in this context. 
The research model adopted in the current investigation is based on the 
experimental use of rodent pancreatic beta cell lines and primary pancreatic 
mouse islets and aimed to assess pancreatic islet function and potential targets 
to promote beta cell and islet survival.  
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1.5 Aims of the thesis 
This study aims to explore the roles and the molecular mechanisms 
underlying the action of somatostatin and ghrelin in clonal beta cell and 
pancreatic islet function, with particular focus on apoptosis induced by 
stressors typical of type 2 diabetes. Therefore, the following aims were 
investigated as part of this thesis. 
 
1. To investigate the role of somatostatin and SST receptor 3 in the 
modulation of clonal beta cell function in response to cellular stressors 
typical of type 2 diabetes. 
2. To explore the role of ghrelin in clonal beta cell and primary mouse islet 
function in the presence of cellular stressors typical of type 2 diabetes. 
3. To evaluate the role of GHSR1a in mediating the functional effects of 
ghrelin in clonal beta cells and mouse islets. 
4. To assess the roles of GHSR1a-independent factors in mediating the 
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The research model used in this study aimed to investigate pancreatic islet 
function and survival to identify and assess potential targets to promote beta 
cell and islet survival. It was based on the experimental usage of rodent 
pancreatic beta cell lines and primary pancreatic mouse islets. Cell lines were 
maintained in culture at facilities available at the University of Roehampton, 
whereas the primary mouse islets were obtained through collaboration with 
Dr Aileen King, King’s College London (KCL). Laboratory mice of the CD-1® 
strain were supplied by Charles River Laboratories International Inc, UK and 
were housed at the animal facilities of KCL.  
2.1. Cell culture of pancreatic beta cell lines 
As mentioned in 1.4 due to limitations in usage of primary pancreatic islets in 
biological research, cell lines have been developed as models. Cell lines 
constitute a model with numerous advantages such as the ready availability of 
cells, reduced cost, no requirement of an animal house, tissue consisting of one 
cell type only which can be easily manipulated genetically (Kaur and Dufour, 
2012; Skelin et al., 2010; Ulrich et al., 2002). Most importantly, in this study 
cell lines were used for screening and optimisation purposes to reduce animal 
usage. However, cell lines have the disadvantage of loss of phenotype/function 
over time and one cell type does not constitute an ideal physiological model 
for pancreatic islets. Therefore, it was imperative to repeat the results of cell 
line work using primary islets (Kaur and Dufour, 2012; Skelin et al., 2010; 
Ulrich et al., 2002).  
2.1.1 MIN6 cell culture 
The MIN6 cells used in this study were kindly provided by Prof. J-I Miyazaki 
(University of Tokyo, Japan). Cells were maintained in Dulbecco’s modified 
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eagle’s medium (DMEM) containing 4500mg/L glucose and 4 mM L-
glutamine, additionally supplemented with 10% v/v foetal bovine serum 
(FBS), 2 mM L-glutamine and penicillin (100 U/ml)/ streptomycin (0.1 
mg/ml). The cells were maintained in culture in T75 flasks in a humidified 
incubator at 37 ºC and 5% CO2, and when 70-80% confluent were spilt using 
0.05% w/v trypsin- ethylenediaminetetraacetic acid (EDTA) and re-cultured 
every week up to passage number 40 or cryopreserved. 
2.1.2 INS-1 cell culture 
The INS-1 cell line used in this study was kindly provided by Dr Natasha Hill 
(Kingston University London, UK). The cells were grown in Roswell Park 
Memorial Institute (RPMI) 1640 medium containing 11.1 mM D-glucose and 
2.1 mM L-glutamine. The medium was additionally supplemented with 10% 
v/v FBS, 2 mM L-glutamine, 10 mM HEPES buffer (pH 7.2-7.5), 1 mM sodium 
pyruvate, penicillin (100 U/ml)/ streptomycin (0.1 mg/ml) and 0.05 mM 2-
mercaptoethanol (2-ME). The cells were grown in T75 flasks in a humidified 
incubator at 37 °C and 5% CO2. Cell were passaged at about 80% confluency 
using 0.05% w/v trypsin-EDTA for a maximum of 10-12 passages or 
cryopreserved. 
2.1.3 Splitting clonal beta cells and counting 
Following removal of old media, cells were washed in 1x phosphate buffered 
saline (PBS, pH 7.4) not containing CaCl2 and MgCl2 and incubated with 0.05% 
w/v trypsin-EDTA for 3 min to dislodge the cells from the flask. Trypsin was 
neutralised by adding media containing serum and the cells were sub-cultured 
as necessary.  
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When plating for experiments, cells were counted prior to adding to the plates 
or dishes. For this the cell suspension was centrifuged at 1500 rpm (MIN6) 
and 1000 rpm (INS-1) for 3-4 min respectively once trypsin was neutralised. 
The pellet was re-suspended in 1 ml of media and 10 µl of cell suspension was 
added to 190 µl of PBS in a 1.5 ml tube at 1:20 dilution. Cells were counted 
manually using a Neubauer haemocytometer (Hawksley, UK) where only live 
cells that appeared bright and intact were included in the count. The total cell 





= 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 × 104  ×  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
 
2.1.4 Cryopreservation and thawing of beta cell lines 
Long-term storage of cells was obtained by preservation of cells in liquid 
nitrogen (LN2) at -196 °C. Cells were trypsinised at ~80% confluency, 
resuspended in respective fully supplemented media and pelleted at 1000 rpm 
for 3 min. Cell pellets were re-suspended in media with dimethyl sulfoxide 
(DMSO) added as cryoprotectant (MIN6: 95% complete DMEM and 5% 
DMSO and INS-1: 90% complete RPMI and 10% DMSO) at a seeding density 
of approximately 3 x106 cells/ml. 1.5ml of cell suspension was added to 2 ml 
cryovials and placed in a Mr Frosty freezing container (Nalgene, ThermoFisher 
Scientific, UK) containing 250 ml 98-99% isopropyl-alcohol for 24 h at -80 °C. 
The presence of DMSO prevents formation of ice crystals whereas isopropyl 
alcohol in Mr Frosty ensures that the cells are frozen down gradually at a rate 
of 1 °C/min to maintain cell viability. 
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Cryopreserved cells were defrosted by quickly thawing in a water bath at 37 °C 
and transferring gradually to a 15 ml tube containing 5 ml of complete media. 
The cells were then pelleted at 1000 rpm for 3 min, re-suspended in fresh fully 
supplemented media and transferred to a T75 flask. Cells were allowed to grow 
for 10 days with media refreshed every three days prior to splitting. 
 
2.2 Islet isolation from mice 
The islet isolation procedure followed in this study was granted approval by 
the University of Roehampton ethics committee (Ref: LSC 17/ 195). Male or 
female CD-1® mice aged 6-10 weeks supplied by Charles River, UK, were 
humanely killed by cervical dislocation in accordance with UK Home Office 
regulations (Schedule 1, section 6 of Guidance on the Operation of the Animals 
Act, 1986). The Schedule 1 killing and islet isolation procedures were 
conducted at a designated licenced animal facility at King’s College London. 
Isolated islets were transported to Whitelands College, University of 
Roehampton, in a tightly sealed container. The transportation process was 
assessed as non-hazardous to the general public (Risk Assessment no. 
RISK_LSC_00365).  
2.2.1 Surgical procedure 
Prior to commencing surgery collagenase from Clostridium histolyticum was 
prepared at 1 mg/ml in Eagle minimal essential medium (MEM) and placed 
on ice. Mice were sacrificed by cervical dislocation and the abdominal cavity 
was surgically exposed. The sternum was clipped, liver was flipped over and 
covered with a delicate task wipe to expose the common bile duct and the 
mouse was placed under a dissecting microscope. Vater’s ampulla was 
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clamped (Fig. 2.2.1) and 2.5 ml of 1 mg/ml collagenase was injected at a steady 
pace into the common bile duct. The pancreas was removed surgically and 
placed in a 50 ml tube on ice. Up to three pancreata were added per tube. 
  
Figure 2.2.1 Clamping of Vater’s ampulla during islet isolation. Prior to 
injection of collagenase the pancreatic duct is clamped at Vater’s ampulla to prevent 
the collagenase from leaking into the duodenum and to ensure maximum distension 
of the pancreas. (Modified from Hundt and Young, 2019). 
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2.2.2 Pancreas digestion and purification of islets 
Tubes containing isolated pancreata were incubated for 10 min at 37 °C in a 
water bath to allow digestion of exocrine tissue by collagenase. During 
incubation MEM media was supplemented with 10% v/v new-born calf serum 
(NCS), penicillin (100 units/ml) and streptomycin (100 µg/ml). Upon 
completion of incubation, tubes containing digested pancreata were 
transferred onto ice and 25 ml of supplemented MEM was added to stop any 
further digestion. Then the tubes were vigorously shaken by hand to separate 
digested pancreatic tissue and centrifuged at 1400 rpm for 1.15 min at 10 °C. 
Following careful removal of supernatant each pellet was re-suspended in 25 
ml of supplemented MEM, tubes were vortexed to disrupt the pellet and were 
centrifuged. This step was repeated two more times. Following final wash, the 
newly re-suspended pellets were sieved through a 425 mm sieve and a funnel 
into new 50 ml tubes. The tubes were centrifuged for 1.5 min at 1500 rpm at 
10 °C. Next the supernatant was removed, tubes were kept inverted and any 
medium left on the wall of the tubes was removed with a delicate task wipe 
without disturbing the pellet. Then the pellet was re-suspended in Histopaque-
1077 by vortexing and 10 ml of fresh supplemented MEM was added very 
gently using the G setting of the auto-pipettor in order to allow formation of 
density gradient interface between cell suspension in histopaque and media. 
The tubes were centrifuged at 3510 rpm for 24 min and without breaking at 
10 °C.  Following centrifugation islets were removed from the interface and 
placed in a new 50 ml tube and topped up with MEM up to 50 ml mark and 
centrifuged at 1500 rpm for 1.5 min at 10 °C. The centrifuged tubes were 
placed on ice for 4-5 min to allow sedimentation of islets, 25 ml media was 
removed from the top, fresh media was added up to 50 ml mark and 
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centrifuged. This step was repeated a further three times and pelleted islets in 
20 ml of media were transferred to a non-tissue culture treated 90 mm petri 
dish. Islets were handpicked into a new petri dish and washed 3-4 times with 
10 ml fresh RPMI supplemented with 10% v/v FBS, penicillin (100 U/ml) and 
streptomycin (0.1 mg/ml). Following purification, isolated tissue was 
transported in supplemented RPMI in 50 ml tubes placed in a wet ice box and 
upon arrival at the University of Roehampton, cultured in RPMI (Gibco, UK) 
containing 11 mM glucose and 2.1 mM L-glutamine, additionally 
supplemented with 10% v/v FBS, 2 mM L-glutamine and penicillin (100 
U/ml) and streptomycin (0.1 mg/ml). Mouse islets were maintained in culture 
at 37 ºC and 5% CO2 in a designated humidified incubator. 
2.3 Haematoxylin and Eosin staining  
Haematoxylin and eosin staining of vaginal smears were performed to 
determine the oestrus cycle stage of the female mice used in the current study. 
This was conducted in collaboration with Drs Natasha Hill and Amanda 
Dandagama at Kingston University London.  
Prior to islet isolation procedures female mice were housed for two weeks to 
allow synchronisation of their oestrus cycle.  Following removal of the 
pancreas a vaginal smear was taken from female mice and placed on a glass 
slide. The smears were fixed in 3.7% formaldehyde in PBS for 15 min then 
washed twice with PBS and left to dry. The fixed smears were first hydrated in 
a series of industrial methylated spirit (IMS) washes (2x 100% IMS and 2x 
70% IMS) each for 3 min. The hydrated slides were washed three times in 
dH2O for two minutes each and stained with haematoxylin, Gill no 2 (Sigma 
cat no. GHS232) for 8 min. The slides were washed three times in running 
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dH2O and stained with eosin (Sigma cat no. HT110116) for 2-3 min and 
washed again three times in running dH2O. The stained slides were 
dehydrated in a series of IMS washes (2x 70% IMS and 2x 100% IMS) each for 
3 min. Coverslips were added on the stained samples using one drop of 
mountant (Vectamount H5000, Vector Labs) and secured with nail varnish. 
The slides were imaged using a Nikon Eclipse NI-E microscope (Nikon, Japan; 
model no. 920529) and NIS-Elements imaging software. 
The Oestrus cycle stages were determined according to (Caligioni, 2009) as 
follows: 
➢ Pro-oestrus: predominantly consists of single or clustered nucleated 
epithelial cells. Occasionally, cornified epithelial cells can also be 
detected. Here the mice are at pre-ovulatory stage. 
➢ Oestrus: This stage is identified by the presence of distinctive clusters 
of cornified epithelial cells. The irregular cytoplasm is granular with no 
apparent nucleus. Oestrogen (E2) levels are elevated during the 
morning and then decrease to basal levels. 
➢ Metestrus: This stage is characterised by a mixture of leukocytes and a 
small number of epithelial cells that can be either nucleated or 
cornified. E2 concentration in plasma is low. 
➢ Dioestrus: Leukocytes are predominant in dioestrus stage where E2 
levels begin to increase. 
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2.4 Measurement of hormone secretion 
Insulin secretion from beta cell lines and islets and ghrelin secretion from 
islets was determined by static incubation experiments. For this clonal beta 
cells or islets were continuously incubated in a set volume of buffer containing 
treatments as indicated in the respective results chapters for a set period of 
time during which the buffer was neither removed nor replaced.  
2.4.1 Static incubation experiments using MIN6 cells 
During static incubation experiments, clonal beta cells were incubated in 1x 
Gey and Gey (G&G) buffer, pH 7.4, with either 2 mM or 20 mM glucose with 
or without any insulin secretagogues and/or compounds of interest. G&G 
buffer was prepared as a 2x solution, pH 8.4 (Table 2.4.5.1) and stored at 4 °C. 
For static secretion experiments 1x G&G buffer was first prepared by diluting 
2x buffer 1:1 with distilled water and pH was adjusted to pH 7.4 with CO2. The 
buffer was then supplemented with 2 mM CaCl2 and 0.5 mg/ml bovine serum 
albumin (BSA).  
MIN6 cells were plated at 20,000 cells/wells in clear 96 well plates in complete 
DMEM and incubated in a humidified incubator at 37 °C and 5% CO2 for 48 h 
to allow the cells to adhere. Following incubation the cells were washed twice 
with 200 µl of 2 mM glucose G&G buffer per well and incubated with 2 mM 
glucose G&G for 2 h at 37 °C to lower the insulin secretion to basal levels. At 
the end of the incubation G&G buffer was aspirated and treatments were 
added at 200 µl/well and the plates were incubated for 1 h at 37 °C. Finally, 
160 µl of supernatant from each well was transferred to a new 96 well plate 
and stored at -20 °C or diluted for determination of insulin content by 
radioimmunoassay.  
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2.4.2 Static incubation experiments using mouse islets 
2.4.2.1 Insulin secretion 
Isolated mouse islets cultured for two days in fully supplemented RPMI were 
washed three times with 2 mM glucose G&G buffer and incubated for 1 h at 37 
°C in a humidified incubator with 5% CO2. Following incubation 3-5 islets were 
picked and transferred into 1.5 ml tubes placed on ice containing 400 µlof 
agents of interest prepared in G&G buffer containing either 2 or 20 mM 
glucose. Islets were then incubated in a water bath at 37 °C for 1 h after which 
the tubes were transferred on to ice and centrifuged at 4°C for 1 min at 2000 
rpm. Up to 350 µl of supernatant was transferred to new 1.5 ml tubes and 
either stored at -20 °C or diluted as required for assessment of insulin content 
by radioimmunoassay. 
2.4.2.2 Ghrelin secretion 
Isolated mouse islets cultured for two days in fully supplemented RPMI were 
washed three times with 11 mM glucose G&G buffer and incubated for 1 h at 
37 °C. Following incubation 25-30 islets were picked into 1.5 ml tubes placed 
on ice containing 300 µl of treatment prepared in G&G buffer containing either 
2 or 11 mM glucose. Islets were then incubated in a water bath as described 
above. Following centrifugation up to 260 µl of supernatant was transferred to 
new 1.5 ml tubes and either stored at -80 °C or diluted as required for 
assessment of ghrelin content by radioimmunoassay. 
2.4.3 Extraction of, MIN6 cell, islet and stomach tissue contents for 
measurement of ghrelin  
Following static incubation and removal of supernatants, islets were pelleted 
and washed three times in ice cold PBS. Islet pellets were frozen at -80 °C until 
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extraction of hormone contents. For MIN6 cells, 5x106 cells were transferred 
into a 1.5 ml tube following trypsinisation and counting. The cells were 
pelleted by centrifugation at 1500 rpm for 3 min, the supernatant removed 
and the cells were re-suspended in ice cold PBS. This step was repeated a 
further two times to wash the cells, and pellets were frozen at -80 °C until 
content extraction. 
Following isolation of the pancreas, stomach was removed and cut around the 
area delineated by a dashed line indicating the fundus (Fig. 2.4.1). The tissue 
was cleaned by removing any solid contents, washed with ice cold PBS and 
kept frozen at -80 °C. Approximately 3-4 mg of fundus was cut on the day of 
content extraction. 
 
Since the cell/tissue contents were tested for the presence of ghrelin, 0.5 M 
acetic acid was used for hormone extraction. Briefly, 0.5 M acetic acid in dH2O 
was warmed for 5 min at 100 °C and added to cell/tissue pellets. Samples were 
Figure 2.4.1 Diagram of mouse stomach with fundus delineated. Stomach 
was cut around the area indicated by the dashed line to isolate the fundus (modified 
from Rolig et al., 2012: 3714). 
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boiled at 100 °C for 15 min and transferred onto ice for further 10 min. 
Samples were centrifuged for 5 min at 5000 rpm at 4 °C and the supernatants 
were transferred into new 1.5 ml tubes. Samples were kept frozen at -80 °C 
until assessment of hormone content by radioimmunoassay. 
2.4.4 Radioimmunoassay 
Radioimmunoassay (RIA) is a competitive binding assay that relies on the 
binding of radiolabelled (Ag*) and unlabelled (Ag) antigen to an antibody (Ab) 
and allows the detection of low concentrations of antigen in a sample 
(Goldsmith, 1975). The assay is performed by incubating fixed amounts of Ag* 
and Ab with samples containing Ag (standards or unknown samples). These 
complexes are allowed to reach equilibrium for 48-72 h at 4 °C. 
Ab + Ag + Ag*            Ab:Ag + Ab:Ag* + Ag + Ag* 
 
2.4.4.1 Insulin radioimmunoassay  
Insulin content of the supernatants was assayed using an in-house 
radioimmunoassay (Jones et al., 1988). Insulin was radiolabelled with 
radioactive iodine (125I) to make Ag* by Dr Astrid Hauge Evans as previously 
reported (Salacinski et al., 1981). Insulin antibody (Guinea pig polyclonal to 
insulin) was kindly provided by Prof. Peter Jones (King’s College London). 
Insulin from bovine pancreas (Sigma, UK) was prepared as a 10 ng/ml stock. 
Borate buffer, pH 8.0 (Table 2.4.5.2) was used in this procedure.  
Static insulin secretion samples were diluted in borate buffer as needed to 
obtain concentrations within the range of the standard curve and a series of 
doubling dilutions of insulin stock was prepared (0.0-10 ng/ml) to construct a 
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standard curve. Tracer only (T), non-specific binding (NSB) and maximum 
binding (MB) were defined as reference samples. The Insulin antibody stock 
was further diluted to obtain a final dilution of 1/200,000. Insulin tracer was 
diluted to obtain 10,000 cpm per 100 ul/tube. Insulin standard was diluted in 
LP3 tubes with a final volume of 100 µl in triplicates and 100 µl of diluted 
samples were added in duplicates to LP3 tubes. Diluted antibody (100 µl) was 
added to all tubes except for T and NSB whereas tracer (100 µl) was added to 
all tubes with a final volume of 300 µl in all tubes except T that contained 100 
µl of tracer only (Table 2.4.1). The tubes were incubated at 4 °C for 48-72 h to 
allow formation of antigen-antibody complexes. Polyethylene glycol (PEG) 
was prepared as a 30% w/v solution (Table 2.4.5.3) and 1 ml of precipitation 
solution (Table 2.4.5.4) was added per tube at a final concentration of 12 % 
v/v PEG to precipitate the insulin and antibody complexes formed during 
incubation. The tubes were centrifuged at 2700 rpm for 15 min at 4 ºC. 
Supernatants were aspirated and radioactive counts per minute of the 
precipitate were detected using a Perkin Elmer Gamma Counter (2470-0020). 
The machine is equipped with WorkOut plus® (My Assays) software that 
generated a standard curve (Fig. 2.4.2) and calculated the concentration in 
each sample by interpolating from the standard curve according to a pre-set 
protocol. 
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Antibody Tracer Standard Sample 
Non-specific 
binding 
200 µl  100 µl   
Maximum 
binding 
100 µl 100 µl 100 µl   
Totals   100 µl   
Standards  100 µl 100 µl 100 µl  
Samples  100 µl 100 µl  100 µl 
Figure 2.4.2 Example standard curve of insulin RIA. 
Concentration of insulin (ng/ml) 
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2.4.4.2 Radioimmunoassay for ghrelin 
The ghrelin radioimmunoassay used in this study was developed in-house 
using the existing protocol for insulin RIA and the method previously used by 
Dr Michael Patterson with the same antibodies against ghrelin (Patterson et 
al., 2005). Although others have reported the employment of RIA for detection 
of ghrelin this was conducted mainly for tissues such as stomach and whole 
pancreas but not beta cells alone. Only one group reported the detection of 
islet ghrelin utilising an in-house RIA (Dezaki et al., 2004). However, the 
method of islet sample preparation was not provided, and the RIA method was 
based on the use of anti-sera against ghrelin and employed an alternative assay 
set up and incubation times (Hosoda et al., 2000) to the ones used by us. 
Acyl-ghrelin (Tocris) was iodinated by Dr Michael Patterson using the same 
procedure as for the insulin iodination, but with 0.06 M phosphate buffer, pH 
7.2 (0.0001% v/v Tween®20, Table 2.4.5.5). Ghrelin standard was prepared at 
a concentration of 100 pmol/ml and diluted to a final concentration of 0.0-5.0 
pmol/ml for acyl-ghrelin and 0.0-2.5 pmol/ml for total ghrelin. Dilutions of 
Gey and Gey buffer and acetic acid were added as assay controls to check for 
non-specific binding. Antibody to acyl-ghrelin rabbit polyclonal (G0-1) was 
kindly provided by Prof M. Ghatei (Imperial College, London) and antibody to 
total ghrelin goat polyclonal was obtained from Santacruz (C-18, cat no SC-
10368). 
As with the insulin RIA, a standard curve was prepared in triplicate and with 
diluted samples in duplicates. The radiolabelled tracer was diluted to a final 
radioactivity of 3500-4000 cpm/tube and the antibodies diluted 1:5000 (G-
01) and 1:1500 (C-18), respectively.  
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 The tubes were incubated for at least 72 h at 4 °C prior to precipitation as 
described in 2.4.4.1. Supernatants were aspirated and the radioactivity of 
samples determined on the Perkin Elmer Gamma Counter with a pre-set 
protocol generating a standard curve (Fig. 2.4.3) and calculating 










Concentration of ghrelin (pmol/ml) 
Figure 2.4.3 Example radioimmunoassay standard curves for acyl-
ghrelin (A) and total ghrelin (B). 
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2.4.5 Reagents 
Static incubation experiments 
Static insulin and ghrelin secretion experiments were conducted in Gey and 
Gey buffer (Table 2.4.5.1). The indicated reagents were dissolved in dH2O and 
pH was adjusted to 8.4 and the buffer stored at 4 °C. 
 





Insulin secretion experiment samples were diluted and radioimmunoassay 
was set up utilising borate buffer (Table 2.4.5.2). First boric acid, NaOH and 
EDTA were dissolved in dH2O and the pH of the solution was adjusted to 8.0. 
Finally, BSA was added to the solution and the buffer subsequently stored at 4 
°C. 
Reagent Mass (g) for 2 L 
Final concentration 
(mM) 
NaCl 26 111.23 
KCl 1.48 4.96 
NaHCO3 9.08 27.02 
MgCl2.6H2O 0.84 1.03 
KH2PO4 0.12 0.22 
MgSO4.7H2O 0.28 0.28 
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30% PEG solution  
A 30% PEG solution was prepared by gradually dissolving PEG in 1 L of 
distilled water and then topping up with dH2O up to 2 L (Table 2.4.5.3). The 
solution was stored at 4 °C. 
Table 2.4.5.3 30% PEG solution 
 
 
RIA precipitation solution 
To prepare a 12% PEG RIA precipitation solution, gamma globulins were fully 
dissolved in PBS at 1mg/ml and an equal volume of 30% PEG was added. 
Finally, Tween 20 was added at 0.5 µl/ml (Table 2.4.5.4). The solution was 
kept at constant agitating until use. 
Reagent Mass (g) for 2 L Final concentration 
Boric acid 16.5 133 mM 
NaOH 5.4 67.5 mM 
EDTA 7.4 10 mM 
BSA 2.0 1 g/L 
Reagent Amount 
PEG (MW 6000) 600 g 
Distilled water 2 L 
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Table 2.4.5.4 RIA precipitation solution 
 
 
0.06 M Phosphate buffer 
 Ghrelin secretion experiment samples and extracted hormone contents were 
diluted and radioimmunoassay was set up in phosphate buffer (Table 2.4.5.5). 
The reagents were dissolved in dH2O and the pH of the solution was adjusted 
to 7.2 and stored at 4 °C. 
 
 




Reagent Amount for 200 ml 
30% PEG 100 ml 
1x PBS 100 ml 
Gamma globulins 200 mg 
Tween 20® 100 µl 
Reagent Mass (g) for 1 L Final concentration 
Na2HPO4 9.0  63.4 mM 
KH2PO4 0.826 6.1 mM 
C10H14H2O8N2•2H2O 3.722 11.34 mM 
BSA 3 3 g/L 
 Chapter 2 - Methods 
 73   
 
2.5 Measurement of cell viability 
The MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
assay was utilised in this study for assessment of cell viability. This type of 
colourimetric assay is based on the colour change caused by reduction of 
tetrazolium salts to formazan by viable cells with active metabolism (Riss et 
al., 2004). It is a cost-effective assay which has been widely used for testing of 
cell viability and cytotoxicity for many years (Mosmann, 1983) including 
studies investigating beta cell and islet survival (Diaz-Ganete et al., 2015; 
Granata et al., 2007; Inberg and Linial, 2010). In this study the cells were 
plated in clear 96-well plates, pre-incubated as indicated in chapter 4 and  
exposed to 0.5 mM palmitate for 20 h. Media was aspirated and MTT prepared 
in a physiologically balanced solution of 0.5 mg/ml in 1x PBS was added to 
cells and plates were incubated for 3 h at 37 °C. Formazan crystal formation 
was confirmed under the microscope and crystals were dissolved using DMSO. 
Absorbance was recorded at 570 nm using a Multiscan EX plate reader 
(Thermo Scientific, UK). 
The MTT assay does not, however, assess the underlying cause of changes in 
cell viability (i.e. proliferation and/or programmed and un-programmed cell 
death). Therefore, CaspaseGlo assay (Promega, UK) that detects changes in 
the enzymatic activity of caspases 3 and 7 was used as a measurement of 
apoptosis as described in 2.6. 
 
2.6 Measurement of Apoptosis 
Apoptosis is a form of programmed cell death that occurs in response to a 
number of stimuli such as DNA damage, exposure to irradiation and cytotoxic 
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drugs. It is an energy-dependent process that is orderly executed via a pathway 
conserved among species (Elmore, 2007) and predominantly relies on the 
activation of cysteine aspartic acid-specific protease (caspase) members that 
are divided into initiators and effectors (Shi, 2004). 
Promega Caspase-Glo® 3/7 assay was used to determine cell apoptosis in this 
study. It measures the activity of caspase -3 and -7 that are key effectors of 
mammalian cell apoptosis (Shi, 2004). The assay reagent contains a 
luminogenic tetrapeptide sequence (DEVD-aminoluciferin), a proprietary 
thermostable luciferase and a lysis agent. Following cell lysis the released 
caspases -3 and -7 cleave DEVD-aminoluciferin substrate to free 
aminoluciferin that in the presence of ATP and O2 reacts with luciferase 
generating light (Fig. 2.6.1).  
The luminescent signal is measured on a luminometer (Promega GloMax 
Navigator) and is directly proportional to the activity of caspase -3 and -7. 
 
Figure 2.6.1 Caspase-3/7 cleavage of luminogenic substrate 
containing the DEVD sequence. Following cleavage by caspase, a substrate 
for luciferase (aminoluciferin) is released. This results in the luciferase reaction 
and the production of light that is measured using a luminometer (Promega, 
2019:2). 
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2.6.1 Measurement of apoptosis in beta cells 
Beta cells were trypsinised and seeded into white-walled 96 well plates. 
Following treatment, the cells were exposed to cellular stressors as indicated 
(100 µl medium/well) for 20 h at 37 ° C and 5% CO2. On the day of the assay, 
75 µl of medium was removed and 25 µl of re-constituted assay buffer was 
added to each well to provide a 1:1 ratio of medium and buffer. The plate was 
covered with foil, shaken for 5 min at 300 rpm and subsequently incubated for 
10 min at room temperature (RT) prior to reading. 
2.6.2 Measurement of apoptosis in islets 
Islets were pre-treated with agents of interest in 6 cm dishes and picked into a 
white-walled 96 well plate (5 islets/well) in 40 µl of medium with or without 
1000 U/ml tumour necrosis factor alpha (TNF-α) and 50 U/ml IL-1β. The 
islets were incubated for 20 h at 37° C and 5% CO2 after which 40 µl of assay 
reagent was added to each well after which the experimental protocol 
proceeded as described in 2.6.1.  
 
2.7 Determination of gene expression  
2.7.1 Total RNA extraction 
2.7.1.1 Cell line and tissue lysis 
• MIN6 cells were trypsinised, washed in ice-cold PBS and pelleted. The cell 
pellets were lysed with 350 µl RLT® buffer containing 10 µl/ml 2-ME.   
• Mouse islets (130-150/tube) were picked and washed in ice-cold PBS. 
Following centrifugation the islet pellets were lysed as indicated for MIN6 
cells. 
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• Hypothalamic tissue was isolated following the removal of pancreas. First 
the whole brain was removed from the skull and placed on a petri dish with 
ventral side up. Then it was dissected around the area marked by a dashed 
square (Fig. 2.7.1) to obtain a piece of tissue of approximately 0.4 cm3 
corresponding to the hypothalamic area. The tissue was kept frozen at -80 
°C. 
Ice-cold PBS washed hypothalamus was cut (25-30 mg) and kept frozen in 
liquid nitrogen. Immediately prior to lysing, 600 µl RLT® buffer containing 
10 µl/ml 2-ME was added and the tissue was lysed at 5 A for 5-10 s until 
completely lysed using a cell disruptor (MicrosonTM ultrasonic cell 
disruptor XL, Misonix). 
 
• Stomach fundus washed in ice-cold PBS was cut, 30 mg of tissue 
transferred to a cold 1.5 ml tube and snap frozen in liquid nitrogen. The 
frozen tissue was then moved to a mortar with a small volume of LN2 added 
on top and disrupted using the pestle. Once a powder-like consistency was 
Figure 2.7.1 Diagram showing sagittal and ventral views of mouse 
brain. Hypothalamus was isolated by cutting around the area delineated by the 
dashed square. (Modified from Hummel et al., 1966; Zha and Xu, 2015:630). 
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obtained the tissue was transferred into a cold 1.5 ml tube. 600 µl of RLT® 
buffer containing 10 µl/ml 2-ME was added to lyse the tissue. 
A Qiagen RNeasy Mini kit (Qiagen) and spin technology were utilised to 
extract RNA. The lysed samples of cells and tissues were homogenised using 
QIAshredders by centrifugation at 15,000 rpm for 2 min. 70% ethanol was 
added to the eluted lysates at a 1:1 ratio and mixed by pipetting. The lysates 
were transferred to an RNeasy mini spin column placed in a 2 ml collection 
tube and centrifuged at 12,000 rpm for 30 s at room temperature (RT). The 
flow through was discarded and the step was repeated if necessary, until the 
full amount of lysate was processed. Next, wash buffer RW1 (350 µl) was 
added to each column and tubes were centrifuged at 12,000 rpm for 30 s at RT 
after which the flow through was discarded. At this stage on-column DNase 
digestion was performed to remove any DNA contamination using an RNase 
free DNase set (Qiagen). DNase I was mixed with RDD buffer (10 µl DNase I/ 
70 µl RDD) and 80 µl of the mix was added directly onto the membrane in each 
column and incubated for 15 min at RT. Wash buffer RW1 (350 µl) was added 
to each column and tubes were centrifuged at 12,000 rpm for 30 s at RT and 
the flow through discarded. Next RPE wash buffer (500 µl) was added to each 
column and centrifuged at 12,000 rpm for 30 s at RT to wash the membrane 
and prevent carry over of salt traces. This step was repeated however the 
columns were centrifuged for 2 min. The collection tube was discarded with 
the flow through, the columns transferred to new 2 ml collection tubes and 
centrifuged at 15,000 rpm for 1 min to avoid ethanol carry over. The columns 
were transferred again to new 1.5 ml collection tubes and 20-25 µl of RNase-
free water was added directly to the membranes followed by centrifugation at 
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12,000 rpm for 1 min at RT. To concentrate the final RNA, the elute was 
pipetted directly onto the membranes of the respective columns and 
centrifuged again using the same 1.5 ml collection tubes. 
2.7.1.1 Determination of RNA concentration and purity 
The concentration of RNA was quantified on a NanoVue Plus 
spectrophotometer (GE Healthcare) which can detect the concentration and 
purity of RNA in a 2 µl sample. RNA purity was determined from two 
absorbance ratios, 260/230 and 260/280. The first ratio indicates phenol and 
salt contamination and the sample was considered pure if the ratio was <2.2. 
The latter (260/280) was used to determine protein contamination and the 
sample was considered pure at 1.9-2.2. The RNA concentration was quantified 
according to the absorbance at 260 nm since nucleic acids absorb at 260 nm. 
Following quantification the RNA samples were stored at -80 °C. 
2.7.2 cDNA reverse transcription 
Reverse transcription by a DNA polymerase (reverse transcriptase) allows 
DNA synthesis from an RNA template resulting in production of 
complementary DNA or cDNA. RNA was reverse transcribed using a High 
capacity cDNA reverse transcription kit (Applied Biosystems™, UK) as 
follows. A 2x reverse transcription master mix was prepared as indicated in 
Table 2.7.4.1 and placed on ice.   
RNA was diluted as required in RNase-free water in a maximum volume of 10 
µl and a 10 µl master mix added to each tube containing the RNA samples. 
Tubes were briefly centrifuged and loaded onto a thermal cycler (BIO-RAD 
T100TM Thermal cycler). Reverse transcription was performed using the 
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settings indicated in table 2.7.1. Following completion of reverse transcription 
the cDNA samples were stored at -20 °C. 





2.7.3 Quantitative polymerase chain reaction (qPCR) 
The mRNA expression of target genes was determined by quantitative real-
time PCR. Here the mRNA of a specific target is quantified by a fluorescent 
probe that can bind to double-stranded DNA in a non-specific (SYBR green) 
or sequence specific (TaqMan) manner. A house-keeping gene is also included 
in the assay and the mRNA expression of the genes of interest is calculated 
relative to the mRNA expression of the house-keeping gene. In this study gene 
expression was determined using a QuantiFast SYBR green PCR reagent kit 
(Qiagen) and a real-time PCR machine (StepOne Plus, Applied Biosystems™, 
UK) as follows. All reagents and tubes were kept on ice. SYBR® green master 
mix was made as indicated in table 2.7.4.2. Working primer stocks were 
prepared at 10 µM in molecular biology grade water. Master mix (18 µl) was 
added to 0.2 ml reaction tubes and 2 µl of cDNA or RNase-free water (no 
template control) were added to respective tubes which were vortexed and 
centrifuged briefly prior to adding 9.8 µl of each reaction mix per well in a 
MicroAmp™ Fast Optical 96-Well Reaction Plate (Applied Biosystems™, UK). 
The plate was covered with a film, centrifuged at 2000 rpm for 1 min and 
Settings Step 1 Step 2 Step 3 Step 4 
Temperature 
(°C) 
25 37 85 4 
Time (min) 10 120 5 Infinite hold 
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loaded onto a StepOnePlus™ Real-Time PCR System (Applied Biosystems™). 
A 2-step cycling protocol with the parameters indicated in table 2.7.2 was used 
to perform the assay. 
 Table 2.7.2 Parameters for 2-Step qPCR 
 
 Data was analysed using the ΔΔCT method where genes of interest were 
expressed relative to house-keeping genes Ppia and Hprt (Table 2.7.3) (Pfaffl 
et al., 2002) or using primer efficiency values as described by Amisten et al. 
(2011). 
 







1. Pre-incubation 5 min 95 °C denaturation 
2. PCR (40 cycles) 10 s 95 °C  
30 s 60 °C   
annealing/extension 





Ppia FW:  TACAGGTCCTGGCATCTTGTC 
   RV:  CTCCATGGCTTCCACAATG 
154 60 
Hprt    FW: AGTCCCAGCGTCGTGATTAG 
   RV: ACAGAGGGCCACAATGTGAT 
186 60 
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2.7.4 Reagents 
 cDNA reverse transcription 
A 2x master mix was prepared by adding the reagents indicated in Table 
2.7.4.1 except for the transcriptase enzyme into an RNase-free tube and it was 
vortexed and centrifuged. The enzyme was added last and mixed with pipette 
only.  
Table 2.7.4.1 Master mix for cDNA reverse transcription 
 
qPCR 
To make up 1x qPCR master mix SYBR® green was mixed with RNase-free 
water as indicated in Table 2.7.4.2. Forward and reverse primers were mixed 
separately and added to the master mix. 





Reagent Volume (µl) 
10X RT Buffer 2.0 
25X dNTP Mix (100 mM) 0.8 
10X RT Random Primers 2.0 
Nuclease-free H2O 4.2 
MultiScribe™ Reverse Transcriptase 1.0 
Reagent Volume (µl) 
2X SYBR® green 10 
RNase-free water 6 
Primers (10 µM) 2 
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2.8 Determination of protein expression 
2.8.1 Preparation of clonal cell and islet lysates 
2.8.1.1 Preparation of beta cell lysates 
MIN6 cell were trypsinised, washed in ice cold PBS and lysed with 200-500 µl 
1x radioimmunoassay precipitation (RIPA) + 1x Halt cocktail (stock 100x, 
ThermoFisher Scientific, UK). Tubes were kept on ice for 20 min with the cell 
suspension being vortexed every 5 min to ensure cell lysis. After 20 min cell 
lysates were centrifuged for 15 min at 12,000 rpm at 4 °C. Supernatants were 
stored at -80 °C.  
2.8.1.2 Preparation of islet lysates 
Islets of mixed sizes (120-150) were handpicked into 1.5 ml tubes and washed 
three times with ice cold PBS. Islet pellets were lysed by adding 40-60 µl 1x 
RIPA+ 1x Halt cocktail buffer and lysing for 5-10 s at 2 A until completely 
lysed using a cell disruptor (MicrosonTM ultrasonic cell disruptor XL, Misonix 
Inc, USA).  
2.8.1.3 Preparation of tissue lysates 
Stomach and hypothalamus isolated following removal of pancreas for islet 
isolation were kept frozen at -80 °C. To prepare lysates, 2-3 mg of each tissue 
was cut, quickly rinsed in ice cold PBS and transferred to 1.5 ml tubes kept on 
ice. 250-300 µl 1x RIPA+ 1x Halt buffer was added to each tube and the 
content lysed 5-10 s at 5 A utilizing a cell disruptor. Lysates were left on an 
orbital shaker for 2 h at 4 °C to ensure complete lysis. Lysates were centrifuged 
at 4 °C for 15 min at 12,000 rpm and supernatants were stored at -80 °C.  
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2.8.2 Protein quantification 
Lysates of beta cell lines, islets and tissues were quantified for protein content 
using Bio-Rad DCTM protein assay (BIO-RAD, UK cat no. 500-0116). The 
DCTM (detergent compatible) assay is a colourimetric assay based on the Lowry 
protein assay that has been modified to reduce procedure time (Bio-Rad DCTM 
protein assay manual LIT448). The assay kit consists of a reagent A (alkaline 
tartrate solution), reagent B (a diluted Folin reagent) and a proprietary reagent 
S. Where a lysis buffer containing detergents were used, a solution to 
neutralise them (solution AS) was made by adding 20 µl of solution S to each 
1 ml of reagent A.  
A serial doubling dilution of 10 mg/ml BSA ranging from 0.0-1.4 mg/ml in 
dH2O was prepared and 5 µl of each standard and sample was added in 
duplicates to a clear 96-well plate. 25 µl of solution AS was added to each well 
followed by 200 µl of reagent B. The plate was shaken using a plate shaker for 
1 min at 300 rpm and incubated for 15 min at room temperature. Absorbance 
was read at 750 nm using a Multiscan plate reader (ThermoFisher Scientific, 
UK). A representative standard curve is shown in figure 2.8.1. Following 
determination of protein concentration in the lysates 20 µg of protein of each 
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2.8.3 Sodium dodecyl sulfate- polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Poly-acrylamide gel electrophoresis is employed to separate proteins by 
molecular weight by exploiting the migration of charged proteins in an electric 
field. SDS binds to proteins and confers a negative charge and partially unfolds 
proteins. In addition, 2-mercaptoethanol further denature the proteins by 
breaking disulfide bonds. The overall negatively charged proteins then migrate 
from cathode to anode in an electric field where the polyacrylamide gel acts as 
a molecular sieve by separating the proteins by molecular weight. A molecular 
weight ladder is used as a reference to identify the molecular weight of protein 
of interest. 
 
Figure 2.8.1 Example standard curve of BSA protein standards. A 
standard curve was plotted using average absorbance values against protein 
concentrations. A line of best fit was drawn, and its equation was used to calculate 
the protein concentrations in unknown samples. 
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In-house made 12 or 15% polyacrylamide gels (resolving gels Table 2.8.5.2 
and stacking gel 2.8.5.3) were used in this study. Lysates diluted in sample 
buffer were boiled at 100 °C for 5 min and allowed to cool on ice. Samples were 
briefly centrifuged, mixed and loaded into wells at 20 µg/well.  4 µl of protein 
ladder (PageRuler™ Plus Prestained Protein Ladder, 10 to 250 kDa, 
ThermoFisher Scientific, UK) was added to designated wells. Any empty wells 
were filled with 6 µl of sample buffer. Gels were loaded onto a BIO-RAD Mini 
PROTEAN® Tetra Cell tank and run for 1.5-2 h at 120 V until proteins were 
completely separated according to molecular weight in 1x Tris-glycine-SDS 
buffer (BIO-RAD).  
2.8.4 Western blot 
Western blot consists of the transfer of proteins separated by SDS-PAGE on to 
a membrane for visualization. This process is performed in an electric field 
that is perpendicular to the surface of the gel. The transfer of proteins takes 
place from cathode to anode within a sandwich of filter papers, membrane and 
gel as shown in figure 2.8.2 and is known as an electrophoretic transfer that 
takes place in semi-dry or wet conditions (Mahmood and Yang, 2012). 
Western blotting was performed using a Trans-Blot Turbo semi-dry transfer 
machine (BIO-RAD, UK) onto a Nitrocellulose (GE Healthcare, UK) 
membrane at 25 V/gel for 7 min using ice-cold transfer buffer (Table 2.8.5.4). 
Successful transfer was visually determined using ponceau S stain. Following 
a quick wash with dH2O to remove the excess ponceau S the membrane was 
blocked with 5% non-fat milk for 45 min and incubated overnight with 
primary antibodies. Mouse anti-beta actin (Abcam cat no. ab8224) was used 
as loading control. 
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The next day, the membrane was washed for 3 x 20 min using 1x Tris Buffered 
Saline (TBS, Table 2.8.5.5) containing 0.001% Tween 20 (TTBS) then 
incubated with fluorescent secondary antibodies for 1.5 h at RT (Li-Cor 
IRdye® donkey anti-rabbit 680RD and donkey anti-mouse 800CW). This was 
followed by 3 x 15 min washes using TTBS. The membrane was imaged and 
the band intensity was quantified using a Licor Odyssey FC imaging system 
with Image Studio software version 5.2. The expression of proteins of interest 






Figure 2.8.2 Western blot sandwich. The SDS-PAGE gel is placed on top of 
the blotting membrane in between two sets of filter paper. The proteins are 
transferred from cathode to anode. (Modified from BIO-RAD, no date:12). 
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To prepare sample buffer or loading buffer first a 312 mM Tris-HCl solution 
was prepared by dissolving 3.8 g of tris in 100 ml of distilled water and pH was 
adjusted to 6.8 using HCl. Then the reagents in Table 2.8.5.1 were gradually 
mixed in the given order to obtain a 5x solution. Aliquots of 1 ml were stored 
at -20 °C. 





Resolving gels of 1.5 mm thickness were prepared using the reagents indicated 
in Table 2.8.5.2. First Tris, acrylamide solution, SDS and water were added to 
a 50 ml tube. Just prior to adding APS, TEMED was pipetted in and quickly 
mixed. Once APS was added the solution was quickly transferred between the 
casting plates using a 10 ml pipette ensuring that ~1 cm space was left at the 
top for the stacking gel. 
During polymerisation of the resolving gel, the reagents for stacking gels were 
mixed with the exception of TEMED and APS that were incorporated just 
before adding on top of the polymerised resolving gels (Table 2.8.5.3).  
Reagent Amount (for 20 ml) Final 
concentration 
312 mM Tris-HCl, pH 6.8 13 ml 202 mM 
SDS 2 g 10% w/v 
glycerol 5 ml 25% v/v 
2-mercaptoethanol 2 ml 10% v/v 
bromophenol blue 0.003 g 0.015% w/v 
 Chapter 2 - Methods 
 88   
 
Immediately a comb was inserted to make the wells. Once polymerised the gels 
were either used immediately or stored overnight in running buffer at 4 °C. 
Prior to loading the samples, the combs were removed ensuring the wells were 
intact. 
Table 2.8.5.2 12% and 15% polyacrylamide resolving gels  
 
 




Reagent Volume Final concentration 
 12% gel 15% 
gel 
12% gel 15% 
gel 
1 M Tris (pH 8.8) 3.75 ml 3.75 ml 0.4 M 0.4 M 
30% v/v acrylamide 
(protogel) 
3.6 ml  5 ml 12% 15% 
20% w/v SDS 50 µl 50 µl 0.1% 0.1% 





12.5 µl 12.5 µl 0.1% 0.1% 
10% w/v ammonium 
persulfate (APS) 
300 µl 300 µl 0.3%  0.3%  
Reagent Volume Final 
concentration 
1 M Tris (pH 6.8) 625 µl 0.1 M 
30% v/v acrylamide (protogel) 900 µl (5%) 5% 
20% w/v SDS 25 µl 0.1% 
Distilled water 3.3 ml - 
TEMED 12.5 µl 0.25% 
10% w/v APS 150 µl 0.3% 
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Transfer buffer 
In order to perform semi-dry transfer of proteins transfer buffer was prepared 
by mixing Tris, glycine, methanol and topping up with distilled water up to 1L 
(Table 2.8.5.4). The solution was stored at 4 °C.  




A 10x tris-buffered saline solution was prepared by dissolving tris and glycine 
in distilled water (Table 2.8.5.5). The pH of the solution was adjusted to pH 
8.0 and stored at RT. For experimental use the buffer was diluted 1:10 in dH2O 
and 0.001% Tween®20 was added. 






Reagent Amount (for 1 L) Final concentration 
Tris 3 g 25 mM 
Glycine 15 g 200 mM 
Methanol 200 ml 20% v/v 
dH2O Up to 1 L - 
Reagent Amount (for 1 L) Final concentration 
Tris 18.2 g 150 mM 
NaCl 87 g 1.5 M 
dH2O Up to 1 L - 
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2.9. Statistical analysis 
Raw data was processed and analysed using Microsoft Office 365 ProPlus 
Excel (version 1902). Statistical analysis was carried out using GraphPad 
Prism software version 8.3 and using the following statistical tests:  
For two sets of data paired and/or unpaired Student’s T-tests, and for three or 
more One-way analysis of variance (ANOVA) with post-hoc multiple 
comparison test Bonferroni were applied as indicated in the figure legends. 
Differences were considered significant at p<0.05. 
 
 












CHAPTER 3 - The role of somatostatin and SSTR3 
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3.1 Introduction 
Somatostatin (SST) is produced in the brain, retina, immune system, 
gastrointestinal tract and in the delta cells of pancreatic islets (reviewed by 
Martinez, 2013). The neuropeptide and hormone mainly acts as an inhibitor 
of secretion of hormones, and in particular pancreatic SST has been shown to 
act in a paracrine manner to inhibit insulin secretion from beta cells and 
glucagon secretion from alpha cells (Hauge-Evans et al., 2009). Although the 
function of SST in islet hormone secretion is well characterised there is little 
evidence about its role in beta cell survival. It has been found that SST 
promotes apoptosis in certain cancer cell lines including lung, gastric, 
colorectal and brain (reviewed by Ferjoux et al., 2000; Pyronnet et al., 2008). 
However, there are other studies indicating a protective role for SST in 
conditions such as retinal neurodegeneration that can lead to diabetes 
retinopathy (Carrasco et al., 2007), attenuation of liver damage when 
administered with prostaglandin E1 as well as suppression of inflammation in 
nerves (e.g. sciatica) (Jia et al., 2013; reviewed by Pintér et al., 2006).  
Findings in somatostatin knockout mice indicated that beta cell volume was 
reduced in one-year old mice lacking the somatostatin gene, and that the lack 
of Sst in early development resulted in increased apoptosis and decreased 
proliferation in pancreatic cells (Richardson et al., 2015).  Recent studies 
conducted in our lab showed that pre-treatment of MIN6 cells and mouse 
islets with SST resulted in protection against fatty acid-induced endoplasmic 
reticulum stress or cytokine-induced apoptosis (Damsteegt et al., 2019). It is 
therefore evident that SST protects beta cells and islets from detrimental 
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effects of stressors typical of type 2 diabetes. However the somatostatin 
receptor subtypes conveying this effect are yet to be identified. 
SST acts via five G-protein coupled receptors (SSTR 1-5). In rodents it has 
been found that SSTR2 and 5 are primarily expressed in beta cells, whereas 
alpha cells express mainly SSTR2 (reviewed by Strowski and Blake, 2007). The 
gene expression of Sstr3 in beta cells and Sstr2 and 3 in alpha cells only was 
recently detected in single-cell transcriptomic analyses utilising cells sorted 
from mouse islets (Adriaenssens et al., 2016; DiGruccio et al., 2016). 
Similarly, we have found that mRNA expression level of Sstr3 was significantly 
greater in MIN6 beta cells compared to that of other somatostatin receptors 
(Damsteegt et al., 2019). A study by Pasternak et al. (2012) reported that 
SSTR3 contributed to the insulinostatic effect of SST on mouse islets using a 
SSTR3 selective antagonist and the SST analogue, octreotide. It was also 
revealed that in the presence of the antagonist a reduction in glucose excursion 
was observed in wild-type mice following intraperitoneal dextrose injection. 
This effect was not observed in global Sstr3-/- mice suggesting that SSTR3 is 
involved in mediating the insulinostatic effect of SST (Pasternak et al., 2012). 
These results are discordant with the consensus that the activity of SST via 
SSTR 1,2 and 5 in mice and SSTR2 in humans is responsible for its inhibitory 
effect on insulin secretion (reviewed by Ludvigsen, 2007; Strowski et al., 2003; 
Strowski and Blake, 2007). It was therefore necessary to ascertain whether 
SSTR3 is involved in mediating the insulinostatic and pro-survival effects of 
SST in clonal beta cells. 
As described in 1.3.1.2, MK4256 is a recently identified SSTR3 competitive 
antagonist (He et al., 2012). In oral glucose tolerance tests (OGTT) performed 
 Chapter 3 - Introduction 
 94   
 
in mice increasing doses of MK4256 resulted in reduced blood glucose levels. 
This was confirmed in Sstr3-/- mice where the reduction in blood glucose 
following administration of MK4256 was not significant (He et al., 2012). 
Based on the studies outlined above, the aims of this chapter were to 
investigate whether the insulinostatic and pro-survival effects of SST were 
conveyed via SSTR3 with the use of SSTR3 antagonist MK4256. 
 
3.2 Aims and objectives  
3.2.1 To further evaluate the role of SST in beta cell survival. 
3.2.2 To confirm the expression of Sstr3 at mRNA level and detection of 
SSTR3 at protein level in MIN6 beta cells and pancreatic mouse islets. 
3.2.3 To determine whether SSTR3 mediates the inhibitory effect of SST on 
insulin secretion in MIN6 cells. 
3.2.4 To investigate whether SSTR3 is implicated in the effect of SST on MIN6 
beta cell survival. 
 




The somatostatin used in this study was somatostatin-14 (Bachem, 
Switzerland) and this will be referred to as somatostatin or SST in the 
subsequent sections. 
3.3.1 Static insulin secretion and radioimmunoassay 
Static incubation experiments with MIN6 cells were conducted as described in 
section 2.4.1 and insulin release was assessed in response to 20 mM glucose, 
forskolin (FSK, 10 µM) and 3-isobutyl-1-methylxanthine (IBMX, 100 µM) 
with or without SST and the SSTR3 antagonist, MK4256 (MedChemExpress, 
Sweden). Samples were diluted and insulin content was measured by RIA as 
described in 2.4.4.1. Since MIN6 cells are a clonal beta cell line that is grown 
in medium containing 25 mM glucose it has been reported that their glucose 
responsiveness is lost at later passages 35-40 (Kayo et al., 1996). Indeed it has 
been observed by us and others that MIN6 cell glucose responsiveness was not 
consistently reproducible despite using cells of passage number 35 or below. 
Therefore, FSK and IBMX were used to potentiate glucose-induced insulin 
secretion from MIN6 cells. In the presence of glucose FSK stimulates 
adenylate cyclase activity that in turn increases cAMP levels resulting in 
elevated insulin release (Wiedenkeller and Sharp, 1983). IBMX is a 
phosphodiesterase inhibitor that prevents breakdown of cAMP therefore 
causing increase in insulin secretion from beta cells (Rabinovitch et al., 1978). 
Since SST has been shown to exert its inhibitory activity via interference with 
adenylate cyclase and cAMP production (Hildebrandt and Kohnken, 1990; 
Tentler et al., 1997), FSK and IBMX were chosen as the appropriate 
potentiators of glucose-induced insulin secretion.  
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3.3.2 Beta cell apoptosis 
The effect of SST on MIN6 or INS-1 cell apoptosis was tested in the presence 
of a range of selected stressors linked to type 2 diabetes: 
Sodium palmitate (lipotoxicity) 
Fatty acid (FA)-free BSA was prepared as a 10% w/v solution in 2% FBS 
DMEM and filter sterilised. A 50 mM solution of sodium palmitate was 
prepared by adding 1 ml of 50:50 v/v ethanol/H2O to 13.9 mg of sodium 
palmitate and solubilised at 70 °C for 10 min. Palmitate and control solutions 
(50:50 v/v ethanol/H2O) were diluted 1:10 in FA-free BSA solution and both 
were incubated at 37 °C for 1 h to allow binding of palmitate to BSA.  At the 
end of the incubation both solutions were further diluted 1:10 in 2% FBS 
DMEM to obtain 0.5 mM palmitate and 0.5% ethanol in 0.95% BSA. 
Thapsigargin (ER stress) 
Thapsigargin was prepared as a 1 mM solution in DMSO and further diluted 
in 2% FBS DMEM to obtain a final concentration of 1 µM. 
Pro-inflammatory cytokines 
TNF-α (activity 1x107) and IL-1β (activity 5x108, Peprotech, UK) were re-
constituted in glucose-free RPMI containing 2% FBS at 1000 U/ml and 100 
U/ml respectively. The cytokines were used at final concentrations of 500 
U/ml (TNF-α) and 50 U/ml (IL-1β). 
20 mM glucose (glucotoxicity) 
RPMI media containing 11 mM glucose and 2% FBS was supplemented with 
9 mM glucose (45 % w/v stock solution) to prepare a 20 mM glucose solution. 
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20 mM glucose and 0.5 mM palmitate (glucolipotoxicity) 
A 0.5 mM palmitate solution was prepared as described above for lipotoxicity 
using RPMI medium that was supplemented with 9 mM glucose as described 
for glucotoxicity. 
Cell apoptosis experiments were performed as described in section 2.6. Briefly, 
MIN6 cells (15,000 cells/well) were pre-treated for 48 h with or without 0.1 or 
1 µM SST and exposed to the cellular stressors indicated above for 20 h. INS-
1 cells (5,000 cells/well) were cultured for two days and exposed to 
glucotoxicity, lipotoxicity or glucolipotoxicity for 20 h. Apoptosis was detected 
using the Promega Caspase-Glo assay as described in 2.6.1. Pertussis toxin 
(PTX) was prepared as a 100 µg/ml solution in dH2O and used at 100 ng/ml 
final concentration. 
For the assessment of the role of SSTR3 on MIN6 cell apoptosis, MIN6 cells 
were pre-incubated with or without 0.1 or 1 µM SST ± 1 or 5 µM MK4256 for 
48 h, followed by exposure to 0.5 mM palmitate for 20h. Apoptosis was 
detected using the Promega Caspase-Glo assay as described in 2.6.1. 
3.3.3 Gene expression analysis 
MIN6 cells were harvested at 70-80% confluency following normal tissue 
culture maintenance, islets were harvested following maintenance in complete 
medium for two days and hypothalamic tissue was lysed as described in 
2.7.1.1. RNA extraction, cDNA reverse transcription and qPCR were 
performed as described in section 2.7 with the use of primers for house-
keeping genes (section 2.7.3) and Sstr3 (Damsteegt et al., 2019, Table 3.1). 
Gene expression was determined relative to Ppia and Hprt. 
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Table 3.1 Sstr3 primers 
 
3.3.4 Protein expression 
In order to prepare the protein samples MIN6 cells were harvested at 70-80% 
confluency following normal tissue culture maintenance, islets were harvested 
following maintenance in complete medium for two days and hypothalamic 
tissue was prepared as described in 2.8.1.3. Protein concentration was 
quantified and expression of targets of interest was detected by Western blot 
as described in section 2.8. Rabbit polyclonal SSTR3 antibody (ThermoFisher 












Sstr3 FW: TGGTGATCTACGTGGTCCTG 
RV: AGACGGCACATGAGAGATCC 
163 59.9 




In this study MIN6 cells were used as a model to test whether the observed 
effects of SST in islets are mediated via the somatostatin receptor-3. The 
monotypic MIN6 cells differ from the composite structure of islets containing 
SST-secreting delta cells, therefore a number of experiments were conducted 
on MIN6 cells to test that somatostatin used in this study was active. 
3.4.1 The role of SST in MIN6 cells 
3.4.1.1 Insulinostatic effect of SST in MIN6 cells 
In order to assess the effect of SST on insulin secretion from MIN6 cells, a 
static insulin secretion experiment followed by radioimmunoassay was 
conducted. Exposure to 20 mM glucose alone did not significantly affect 
insulin secretion from MIN6 cells (p<0.05 vs 2 mM glucose; Fig. 3.4.1), but 
adjunct treatment with FSK and IBMX significantly increased insulin 
secretion from these cells (p<0.0001, n=8). Treatment with 1 µM SST 
significantly reduced both 20 mM glucose-induced (p<0.01, n=8) and 
FSK+IBMX-induced (p<0.001, n=8) insulin secretion (Fig. 3.4.1). 
3.4.1.2 Effect of SST on MIN6 beta cell survival in response to 
cellular stressors 
Lipotoxicity 
In order to confirm the protective effect of SST reported in Damsteegt et al. 
(2019) MIN6 cells pre-treated with or without SST were exposed to a number 
of cellular stressors typical of type 2 diabetes as described in 3.3.2. Treatment 
with both 0.1 and 1 µM SST resulted in significant reduction of 0.5 mM 
palmitate-induced apoptosis in MIN6 cells (p<0.05, Fig. 3.4.2). 
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Figure 3.4.1 The effect of SST on insulin secretion from MIN6 beta 
cells. MIN6 cells were seeded at 20,000 cells/well and incubated for 48 h. The 
cells were pre-incubated with 2 mM glucose for 2 h and treated as indicated for 1 
h. Supernatants were assayed for insulin concentration by an in-house 
radioimmunoassay. Data is presented as mean+SEM, n=8, one experiment. One-
Way ANOVA with posthoc test Bonferroni **p<0.01, ***p<0.001, ***p<0.0001. 
NS = not significant p>0.05. 
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Incubation with the ER-stress inducer, thapsigargin, caused a significant 
elevation in apoptosis in MIN6 cells (p<0.0001), however treatment with 0.1 
or 1 µM SST did not significantly reduce the increased caspase 3/7 activity 
(p>0.05 vs 1 µM Tg; Figure 3.4.3). 
 
 
Figure 3.4.2 The effect of SST on MIN6 beta cell apoptosis induced by 
sodium palmitate. MIN6 beta cells were plated at 15,000 cells/well and pre-
treated for 48 h with either 0.1 or 1 µM SST then exposed to 0.5 mM palmitate for 
20 h with or without SST. Cell apoptosis was detected by measuring caspase 3/7 
activity. Data is presented as mean+SEM, n=4-5, one independent experiment. 
One-Way ANOVA with posthoc test Bonferroni *p<0.05. 
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Exposure to a combination of cytokines (500 U/ml TNF-α and 50 U/ml IL-1β) 
significantly increased apoptosis in MIN6 cells (p<0.0001; Fig. 3.4.4). 
Treatment with 0.1 and 1 µM SST however could not significantly reduce 




Figure 3.4.3 The effect of SST on MIN6 beta cell apoptosis induced by 
thapsigargin. MIN6 beta cells were plated at 15,000 cells/well and pre-treated 
for 48h with either 0.1 or 1 µM SST then exposed to 1 µM thapsigargin for 20 h ± 
SST. Cell apoptosis was detected by measuring caspase 3/7 activity. Data is 
presented as mean+SEM, n=5, graph represents results of one experiment out of 
three independent experiments. One-Way ANOVA with posthoc test Bonferroni. 
NS = not significant p>0.05. 
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Glucotoxicity and glucolipotoxicity 
When testing cellular stressors typical of type 2 diabetes glucotoxicity and 
glucolipotoxicity should also be considered since hyperglycaemia and 
simultaneous presence of high circulating free fatty acid contribute to the 
pathogenesis of type 2 diabetes (reviewed by Hasnain et al., 2016). MIN6 cells 
are maintained in 25 mM glucose therefore do not constitute an ideal model 
for studying glucotoxicity. Hence INS-1 cells maintained in 11 mM glucose 
were tested. In our experimental model glucotoxicity with 20 mM glucose 
Figure 3.4.4 The effect of SST on MIN6 beta cell apoptosis induced by 
exposure to pro-inflammatory cytokines. MIN6 beta cells were plated at 
15,000 cells/well and pre-treated for 48 h with either 0.1 or 1 µM SST then 
exposed to a combination of cytokines (500 U/ml TNFα+ 50 U/ml IL-1β) for 20 h 
± SST. Cell apoptosis was detected by measuring caspase 3/7 activity. Data is 
presented as mean+SEM, n=5, graph represents results of one experiment out of 
two independent experiments. One-Way ANOVA with posthoc test Bonferroni. NS 
= not significant p>0.05. 
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alone was not sufficient to cause a significant increase in apoptosis in INS-1 
cells compared to 11 mM glucose (p>0.05, Fig. 3.4.5). Incubation with 0.5 mM 
palmitate and 0.5 mM palmitate + 20 mM glucose significantly increased 
apoptosis compared to control in MIN6 cells (both p<0.0001). However, 
addition of 20 mM glucose to 0.5 mM palmitate did not cause a significant 
synergistic increase in INS-1 cell apoptosis compared to 0.5 mM palmitate 
alone (p>0.05, Fig. 3.4.5). Therefore, the effect of SST on glucotoxicity or 
glucolipotoxicity was not tested in this research model. 
 
Figure 3.4.5 Comparison of the effect of glucotoxicity, lipotoxicity and 
glucolipotoxicity on INS-1 beta cell apoptosis. INS-1 beta cells were plated 
at 5,000 cells/well and incubated for 48 h then exposed to either 11 mM glucose 
20 mM glucose, 0.5 mM palmitate or 20mM glucose + 0.5 mM palmitate for 20 h 
as indicated. Cell apoptosis was detected by measuring caspase 3/7 activity. Data 
is presented as mean+SEM, n=5, graph represents results of one experiment out 
of four independent experiments. One-Way ANOVA with posthoc test Bonferroni. 
****p<0.0001. NS = not significant p>0.05. 
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3.4.2 Role of somatostatin receptor -3 in beta cell 
function  
Prior to testing whether the observed effects of SST in clonal beta cells were 
mediated by SST receptor-3, a number of experiments were conducted to 
detect the expression of SSTR3 at mRNA and protein levels in MIN6 cells and 
mouse islets. 
3.4.2.1 mRNA expression of Sstr3  
In order to detect mRNA expression, qPCR analysis was performed, and it 
revealed that Sstr3 was expressed in MIN6 cells, mouse islets and in murine 




Figure 3.4.6 mRNA expression of Sstr3. The mRNA expression of Sstr3 was 
detected in hypothalamus and isolated islets from mice and in MIN6 beta cells. 
Mean mRNA expression ± SEM relative to housekeeping genes Ppia (A) and Hprt 
(B) is shown (n=3-4, separate biological samples).  
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3.4.2.2 Protein expression of SSTR3  
Western blot analysis showed that SSTR3 was expressed in clonal beta cells 
(MIN6 and INS-1, Fig. 3.4.7 A and B) and in the murine hypothalamus (Fig. 
3.4.7 C). However, multiple unclear bands were observed for SSTR3 in 
primary mouse islets (Fig. 3.4.7 D). Expression levels relative to beta actin are 
indicated in Fig. 3.4.7 E, where expression of highest expression of SSTR3 was 










MIN6 Hypothalamus Islet 
Sstr3 21.73 ± 0.49 25.09 ± 0.23 21.79 ± 0.39 
Ppia 16.29 ± 0.33 16.08 ± 0.23 17.51 ± 0.34 
Hprt 19.46 ± 0.38 18.12 ± 0.49 20.74 ± 0.18 
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Figure 3.4.7 Protein expression of SSTR3. SSTR3 was detected in beta cells 
MIN6 (A), INS-1 (B) and in murine hypothalamus (C) but not in murine islets (D). 
Panel E shows mean + SEM relative expression levels of SSTR3 compared to 
loading control beta actin (n=3, separate biological samples). 20 µg protein was 
loaded per sample and resolved using a 12-15% polyacrylamide gel. Proteins were 
detected by Western blot. Primary antibodies used: SSTR3 1:5000 and beta actin 
as loading control 1:8000. Detected using Li-Cor fluorescent secondary antibodies 
and image studio software.  
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3.4.2.3 The role of SSTR3 in insulin secretion 
In order to test whether the insulinostatic effect of SST is mediated via SSTR3 
in MIN6 cells, static incubations were conducted as described in 2.4.1 with the 
SSTR3 antagonist, MK4256. Acute insulin secretion in the presence of FSK 
and IBMX was significantly reduced by exposure to 1 µM SST (p<0.001, Fig. 
3.4.8), whereas 1 and 5 µM MK4256 alone did not significantly affect insulin 
release from MIN6 cells (p>0.05 vs 20 mM glucose+ 10 µM FSK + 100 µM 
IBMX). However, co-treatment of 1 µM SST with 5 µM MK4256 resulted in 
significant reversal of the insulinostatic effect of SST (p<0.01; Fig. 3.4.8). 
Although an increase in insulin secretion was observed with co-treatment of 1 
µM SST with 1 µM MK4256 this was not statistically significant compared to 
the effect of 1 µM SST alone (p>0.05). 
Figure 3.4.8 The effect of SST and the SSTR3 antagonist, MK4256, on 
insulin secretion from MIN6 beta cells. MIN6 cells were plated at 20,000 
cells/well and incubated for 48 h. The cells were then pre-incubated with 2 mM 
glucose and treated as indicated for 1 h. Supernatants were assayed for insulin 
content by an in-house radioimmunoassay. N=8, Data is presented as mean+SEM, 
graph represents results of one experiment out of three independent experiments. 
One-Way ANOVA with posthoc test Bonferroni **p<0.01, ***p<0.001, ***p<0.0001. 
NS = not significant p>0.05. 
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3.4.2.4 The role of SSTR3 in mediating the pro-survival 
effects of SST 
Following confirmation that SSTR3 antagonist MK4256 could significantly 
reverse the insulinostatic effect of SST in MIN6 cells, it was investigated 
whether the observed pro-survival effect of SST could be reversed by the same 
compound. 
Exposure of MIN6 cells to 0.5 mM palmitate significantly increased apoptosis 
in MIN6 cells which was significantly reduced by treatment with 1 µM SST 
(p<0.05). Addition of 1 and 5 µM MK4256 did not reverse the protective effect 
of SST in MIN6 cells (p>0.05; Fig. 3.4.9) and instead resulted in a significant 
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Figure 3.4.9 The effect of SST and SSTR3 antagonist MK4256 on MIN6 
beta cell apoptosis. MIN6 beta cells were plated at 15,000 cells/well and pre-
treated for 48h with 1 µM SST ± 1 or 5 µM MK4256 then exposed to 0.5 mM 
palmitate for 20h with or without compounds of interest. Cell apoptosis was 
detected by measuring caspase 3/7 activity. Data is presented as mean+SEM, n=5, 
graph represents results of one experiment out of three independent experiments. 
One-Way ANOVA with posthoc test Bonferroni. *p<0.05, **p<0.01. NS = not 
significant p>0.05. 
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3.4.3 The anti-apoptotic effect of SST in MIN6 cells is Gαi 
signalling pathway dependent  
Since the protective effect of SST could not be reversed by MK4256, it was 
tested whether treatment with 100 ng/ml pertussis toxin (PTX) could reverse 
this effect. PTX is a bacterial adenine diphosphate (ADP)-rybosylating toxin 
that acts on Gαi signalling pathway to exert its inhibitory effects. ADP-
rybosylation holds the Gαi in an inactive state thereby preventing interaction 
with GPCRs and  hence preventing inhibition of adenylate cyclase (Mangmool 
and Kurose, 2011). Since SSTRs signal via both Gαi dependent and 
independent signalling pathways (reviewed by Ferjoux et al., 2000) PTX was 
used as an antagonist of SST. Exposure to 1 µM SST significantly reduced 
Figure 3.4.10 The effect of SST on MIN6 beta cell apoptosis. MIN6 beta 
cells were plated at 15,000 cells/well and pre-treated for 48 h with either 1 µM 
SST14 or 100 ng/ml PTX then exposed to 0.5 mM palmitate for 20 h. Cell 
apoptosis was detected by measuring caspase 3/7 activity. Data is presented as 
mean+SEM, n=6, graph represents results of one experiment out of three 
independent experiments. One-Way ANOVA with posthoc test Bonferroni 
*p<0.05, ****p<0.0001. NS = not significant p>0.05. 
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apoptosis induced by 0.5 mM palmitate (p<0.05; Fig. 3.4.10) which was 
significantly reversed in the presence of PTX (p<0.0001 vs 0.5 mM palmitate 
+1 µM SST).




Beta cell dysfunction and apoptosis are central in the development of type 2 
diabetes. Strategies to overcome detrimental effects of cellular stressors such 
as lipotoxicity and inflammation are fundamental for treatment of the 
condition (reviewed by Hasnain et al., 2016; Wajchenberg et al., 2007). The 
experiments described in this chapter aimed to affirm the effect of 
somatostatin on beta cell function and the identification of the receptor 
mediating its effects. 
3.5.1 The effects of somatostatin on MIN6 beta cell function 
As detailed in section 3.4.1 treatment with somatostatin significantly inhibited 
glucose and FSK+IBMX-induced stimulation of insulin secretion confirming 
that the compound used in this study is active and fulfils its function as an 
insulinostatic hormone (Hauge-Evans et al., 2009). Pre-treatment with SST 
for 48 h significantly decreased palmitate-induced apoptosis in MIN6 beta 
cells. These results are in corroboration with the previous work in our lab 
reported in Damsteegt et al. (2019) where the same effect was observed. 
Previously others have reported both pro and anti-apoptotic roles for SST. Jia 
et al. (2013) found that hepatic injury following 90% hepatectomy was 
alleviated by treatment with SST in combination with prostaglandin E1 
(PGE1). Here the percentage survival of hepatocytes was greater compared to 
hepatectomy control for the compounds individually and in combination. It 
was also found that expression of caspase-3, CHOP as well as of pro-
inflammatory cytokines TNF-α and interleukin 6 (IL6) was reduced by co-
treatment of SST with PGE1 (Jia et al., 2013). It was reported that SST is 
present in the neuroretina and retinal pigment epithelium of both diabetic and 
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non-diabetic patients. However, its levels were lower in the neuroretina of 
patients with diabetes where a higher level of apoptotic cells was observed. 
This elevation in apoptosis was inversely correlated with the level of SST 
suggesting that lower levels of SST are associated with higher level of retinal 
neurodegeneration (Carrasco et al., 2007). Others have shown that prolonged 
treatment with a high dose of SST analogue octreotide conveyed protection 
against incidence of severe acute pancreatitis (SAP) in patients with predicted 
SAP and reduced the number of patients diagnosed with SAP by elevating 
plasma SST that in turn decreased TNF-α and IL6 levels (Wang et al., 2013). 
Similarly, in rats fed a high fat diet causing high plasma TNF-α levels, injection 
of octreotide reduced elevation in plasma TNF-α (Liu et al., 2012). These 
studies suggest that similar to our observations SST plays a pro-survival role 
in a number of tissues. Others however have suggested that SST and its 
analogues caused apoptosis in cancer tissues including breast cancer where 
treatment with SST induced activation of caspase-8 and increased the number 
of apoptotic cells in clonal breast cancer cell line Michigan Cancer Foundation-
7 or MCF7 (Liu et al., 2000). It has also been reported that SST inhibits 
proliferation in a number of cancers including lung, brain and colorectal 
(reviewed by Ferjoux et al., 2000 and Pyronnet et al., 2008), and displayed 
anti-angiogenic activity in the highly vascularised Kaposi sarcoma tumour 
induced by subcutaneous injection in nude mice (Florio et al., 2003). Here 
treatment with SST inhibited tumour growth and the sarcomas were highly 
lacking in vascularisation. The effects were found to be mediated by SST 
receptor 3 (Florio et al., 2003). Taken together these data suggest that the 
effects of SST on apoptosis are divergent and tissue specific as evident by the 
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anti-apoptotic activity observed mainly in tumour cells (reviewed by Pyronnet 
et al., 2008). 
However, the anti-apoptotic effect of SST was not observed in MIN6 cells 
exposed to 500 U/ml TNF-α + 50 U/ml IL-1β in contrast to our previous 
observations (Damsteegt et al., 2019). It is possible that in the current 
experiments the detrimental effect of cytokines could not be overcome by the 
addition of SST. In addition, treatment of MIN6 cells with SST could not 
significantly reduce apoptosis caused by ER-stress inducer thapsigargin. This 
was interesting because both palmitate and thapsigargin have been shown to 
affect intercellular Ca2+ concentrations and activate unfolded protein response 
(UPR) (Cnop et al., 2010). Our previous findings reported in Damsteegt et al. 
(2019) indicated that exposure to palmitate upregulated downstream 
modulators of UPR in MIN6 cells including DNA damage-inducible transcript 
3 (Ddit3) that encodes pro-apoptotic transcription factor C/EBP-homologous 
protein (CHOP) that is also induced by the activity of thapsigargin (Yamaguchi 
and Wang, 2004). We have shown that treatment with SST significantly 
downregulated Ddit3 mRNA expression in MIN6 cells incubated with both 
control medium and medium containing 0.5 mM palmitate (Damsteegt et al., 
2019). Therefore, the ineffectiveness of SST in protecting MIN6 cells against 
apoptosis caused by thapsigargin may be due to its highly potent 
pharmacological activity (Garcĺa-Casas et al., 2018) that could not be 
overcome by exposure to SST in the current study. Indeed, thapsigargin 
induces ER-stress by inhibiting sarco-endoplasmic reticulum Ca2+-ATPase 
(SERCA) pumps that regulate intracellular calcium levels (Thastrup et al., 
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1990). Binding of thapsigargin to the ATPase was found to be irreversible 
despite further dilution of the compound (Sagara et al., 1992).  
Since the current study investigated the role of SST in overcoming the 
detrimental effects of stressors typical of type 2 diabetes it was important to 
include glucotoxicity and gluco-lipotoxicity as part of the study. With the use 
of the  INS-1 cell line it was observed that treatment with 0.5 mM palmitate 
(lipotoxicity) and 0.5 mM palmitate + 20 mM glucose (glucolipotoxicity) but 
not 20 mM glucose (glucotoxicity) significantly increased apoptosis in INS-1 
cells. Beta cell dysfunction as a result of glucotoxicity typically results 
following prolonged exposure to high glucose levels (Donath et al., 2005; 
Kaiser et al., 2003). It is therefore possibly that the 20 h incubation period 
used in the current study was not long enough to observe any increase in 
apoptosis due to elevated glucose levels. In addition, no synergistic effect was 
observed for glucolipotoxicity compared to lipotoxicity alone in increasing 
caspase 3/7 activity in INS-1 cells (Damsteegt et al., 2019). As reported in El-
Assaad et al. (2003) prolonged exposure to hyperglycaemic conditions 
resulted in a synergistic increase in beta cell apoptosis following exposure to 
0.4 mM palmitate (El-Assaad et al., 2003), again implying that prolonged 
exposure to high levels of glucose is necessary to observe a greater 
glucolipotoxic effect. In addition, it is possible that as a clonal beta cell line, 
INS-1 cells are more susceptible to the detrimental effects of 0.5 mM palmitate 
within the 20 h incubation period model used in this study compared to 20 
mM glucose. Indeed, it has been previously reported that greater cellular 
dysfunction in hepatocytes was caused by exposure to free fatty acid oleate 
than 30 mM glucose within the same incubation period (Pang et al., 2013) 
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suggesting that lipotoxicity is a faster and more potent inducer of cell apoptosis 
than glucotoxicity. 
One of the downstream signalling pathways activated upon binding of SST to 
its receptors is mediated via Gαi. Therefore, pertussis toxin, a known inhibitor 
of Gαi (Mangmool and Kurose, 2011), was used to test the hypothesis that the 
effects of SST on MIN6 cells were mediated by the activation of Gαi. As shown 
in section 3.4.3 and also in Damsteegt et al. (2019) treatment with PTX 
significantly reversed the anti-apoptotic effect of SST in response to 0.5 mM 
palmitate in MIN6 cells, indicating that the protective effect of SST is mediated 
via a Gαi dependent pathway in accordance with observations made by Sharma 
et al. (1996) for octreotide. It is therefore possible that by inhibiting insulin 
secretion, SST potentially lessens the metabolic burden of MIN6 cells 
improving their response to apoptosis induced by some cellular stressors 
typical of type 2 diabetes. However, the binding of SST to its receptors also 
activate downstream signalling pathways that are independent of Gαi. These 
include inhibition of Ca2+ and activation of K+ channels that result in the 
hyperpolarisation of cell membrane causing inhibition of insulin secretion 
(reviewed by Theodoropoulou and Stalla, 2013), further supporting the 
possibility that inhibition of insulin secretion in MIN6 cells may play a role in 
their survival. Acute exposure to free fatty acids promotes insulin secretion 
from beta cells (Turk et al., 1993; Cen et al., 2016) that can result in increased 
strain on MIN6 cell secretory function. Indeed, insulin secretion is a highly 
active process that lead to production of reactive oxygen species and oxidative 
stress (Fridlyand and Philipson, 2004).  Furthermore, it was reported that co-
treatment of PGE1with somatostatin resulted in the accumulation of anti-
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apoptotic protein Bcl-2 in hepatocytes (Jia et al., 2013) and over-expression 
of human Bcl-2 in mouse islet beta cells was found to inhibit apoptosis induced 
by a protein kinase inhibitor, staurosporine (Allison et al., 2000). Therefore, it 
is possible to suggest that SST performs its pro-survival activity in MIN6 cells 
via both reduction in apoptosis and upregulation of pro-survival Bcl-2.                                                                                                                                                                           
3.5.2 The role of SSTR3 in mediating the effects of SST in MIN6 cells 
As mentioned before SST acts via five GPCRs (SSTR1-5). Many studies have 
reported their expression in islets and beta cells (e.g. Ludvigsen et al., 2004; 
Strowski et al., 2000). However, in most studies SSTR3 expression was not 
prominent and based on pharmacological studies and in vivo studies with SST 
receptor knockout mice, other SST receptor subtypes have been thought to be 
functionally important in the beta cell (Kailey et al., 2012; reviewed by 
Strowski and Blake, 2007). We have detected SST receptor-3 mRNA to be 
expressed at the highest level in MIN6 beta cells compared to the other SSTR 
subtypes (Damsteegt et al., 2019). These results were in corroboration with 
recent single-cell transcriptomic studies where only Sstr3 expression was 
detected in primary beta cells (Adriaenssens et al., 2016; DiGruccio et al., 
2016). The results described in 3.4.2.1 also showed that Sstr3 was present in 
clonal beta cell lines and mouse islets. Next it was explored whether SSTR3 
was also expressed at protein level in MIN6 cells and in mouse islets in the 
current study. In addition, due to contrasting evidence about functional role 
of the SST receptor subtypes it was tested whether SST inhibited insulin 
secretion and promoted cell survival via its activation of SSTR3 in MIN6 cells. 
As described in 3.4.2.2 it was found that SSTR3 is expressed in both MIN6 and 
INS-1 clonal beta cell lines and in the mouse hypothalamus. Despite detecting 
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Sstr3 mRNA in mouse islets its protein expression could not be identified by 
Western blot suggesting that perhaps in the islet as a composite tissue the 
expression of SSTR3 may not be as high, consistent with previous literature 
describing SSTR1, 2 and 5 as SST receptors playing the most prominent roles 
in the mouse islets (Kailey et al., 2012; Ludvigsen et al., 2004). Nonetheless it 
appears that in clonal beta cell lines the high expression of SSTR3 (Damsteegt 
et al., 2019) may still have a functional role as also suggested by single-cell 
transcriptomic analyses for isolated primary beta cells (Adriaenssens et al., 
2016; DiGruccio et al., 2016). In the current study, the role of SSTR3 was 
further explored in functional studies investigating the effect of SST on insulin 
secretion in MIN6 cells.  
In corroboration with Pasternak et al. (2012) where a precursor of MK4256 
was used together with octreotide, it has been confirmed here that the 
insulinostatic effect of SST was reversed by SSTR3 antagonist MK4256 in 
MIN6 beta cells, however at the higher concentration of 5 µM. Therefore, it is 
not possible to disregard that the inhibitory effect of SST on insulin secretion 
in MIN6 cells has been mediated via SST receptors other than SSTR3. Indeed, 
it was reported that MK4256 displayed antagonistic activity of SSTR3 at IC50 
of 0.95 nM and showed 83% inhibition of human functional cAMP at 2 µM. It 
also exhibited 42% inhibitory activity at 20 µM for SSTR4 and 34% at 5 µM for 
SSTR5 (He et al., 2012).  These findings can be further evaluated by using 
small interfering RNA (siRNA) to knockdown SSTR3 in MIN6 beta cells and 
to test whether the insulinostatic effect of SST is similar to the reports of 
Pasternak et al., (2012), where a global Sstr3  knockout mouse model was 
used. Despite MK4256 antagonising the inhibitory activity of SST on insulin 
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secretion in MIN6 cells, my findings did not satisfy the hypothesis that the pro-
survival effect of SST is mediated via SSTR3. This might be because SST-
mediated activation of other SSTR subtypes may be involved in conveying its 
pro-survival effect in beta cells. However, even at 5 µM the antagonist MK4256 
did not significantly reverse the protective effect of SST. Instead a significant 
reduction in apoptosis was observed similar to that of SST alone. This could be 
due to agonistic effect of the compound at high concentration because 
according to He et al. (2012) at 5 µM, the compound showed 27% agonistic 
activity on SSTR4.  
As detailed in 3.5.1 previous studies have associated SST and its receptors with 
both an anti-proliferative role for SST in cancer (reviewed by Ferjoux et al., 
2000; reviewed by Pyronnet et al., 2008) and a pro-survival role in retinal 
neurodegeneration as well as neuronal inflammation (Hernández et al., 2013; 
reviewed by Pintér et al., 2006). The majority of these studies indicated 
SSTR2, 4 or 5 as the receptor(s) mediating the reported effects irrespective of 
the outcome, with only a few exploring the role of SSTR3. War et al. (2011) 
investigated the role of the C-terminal domain of SSTR3 in the anti-
proliferative action of SST in human kidney cells (HEK) transfected with wild 
type (wt) SSTR3 and a mutant SSTR3 with a deleted C-terminus and found 
that the anti-proliferative effect of SST was mediated via wt-SSTR3 (War et al., 
2011). Previously, Sharma et al. (1996) had shown that the pro-apoptotic 
signalling of octreotide was mediated exclusively via SSTR3 following 
induction of p53 and Bax in Chinese Hamster Ovary (CHO) cells expressing 
SSTR1-5. Since SSTRs are GPCRs that activate a number of downstream 
signalling proteins, it is possible that their activation is dependent on the type 
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of tissue hence its needs, resulting in tissue-specific variations in SST receptor 
expression and function. 
3.5.3 Summary  
The results reported in this thesis indicate that clonal beta cell apoptosis in 
response to lipotoxicity was reduced by treatment with SST and that SSTR3 is 
expressed at protein level in MIN6 beta cells and facilitates inhibition of 
insulin secretion by SST. However, the findings do not indicate that the anti-
apoptotic effect of SST is also mediated via SSTR3, although the findings 
confirm that it is Gi dependent. In conclusion, somatostatin protects beta cells 
against lipotoxicity and cytokine-induced (Damsteegt et al., 2019) apoptosis. 
Although SSTR3 may partly contribute to the mediation of the insulinostatic 
effect of SST in MIN6 beta cells it is unlikely that SST conveys its anti-
apoptotic effect via this receptor in MIN6 cells.  
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4.1 Introduction 
Ghrelin is an orexigenic hormone that is mainly produced in the stomach, but 
also expressed in the upper intestines, brain, heart and pancreas 
(Gnanapavan, 2002; Sato et al., 2011; Wierup et al., 2002; Weirup et al., 
2014). The two main forms of ghrelin are acyl-ghrelin and des-acyl-ghrelin. 
The acylation of des-acyl ghrelin is catalysed by the enzyme ghrelin-O-
acyltransferase (GOAT). This modification is essential for binding to its 
receptor (reviewed by Castañeda et al., 2010; reviewed by Sivertsen et al., 
2013). In this chapter the word ghrelin will refer to acyl-ghrelin unless 
otherwise specified.  
As described in section 1.3.2 ghrelin plays a role in the regulation of glucose 
homeostasis by interfering with glucose-induced insulin secretion in both 
rodents and humans (Reimer et al., 2003; Tong et al., 2010). Therefore, in the 
pancreas, ghrelin has been mainly characterised for its role in regulating 
insulin secretion from beta cells (reviewed by Dezaki, 2013; reviewed by 
Granata et al., 2010) with some studies reporting that ghrelin inhibits insulin 
secretion from clonal beta cells and rodent islets (Dezaki et al., 2004; Esler et 
al., 2007; Wierup et al., 2004). Others, however, have found that insulin 
secretion was increased or remained unchanged in the presence of ghrelin in 
clonal beta cells, rat and human islets (Adeghate and Ponery, 2002; Date et al., 
2002; Diaz-Ganete et al, 2015; Granata et al., 2007; Salehi et al., 2004).       
As stated before, most studies have focused primarily on the role of ghrelin in 
the regulation of insulin secretion and there is less information with regard to 
the potential impact of the peptide on beta cell and islet survival. With the use 
of a subclone of the beta cell line INS-1 (INS-1E) it was found that ghrelin 
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promoted clonal beta cell survival in response to a combination of cytokines 
typical of type 1 diabetes (Diaz-Ganete et al., 2015). Granata et al. (2007) have 
reported that serum starved clonal beta cell lines hamster islet transformed-
tioguanine resistant clone-15 (HIT-T15) and INS-1E showed elevated 
proliferation with increasing concentrations of both acyl and desacyl-ghrelin. 
In a research model of type 1 diabetes induced by TNF-α and interferon 
gamma (IFN-γ), apoptosis was partly prevented by treatment with ghrelin in 
HIT-T15 cells (Granata et al., 2007). In the same study, human islet apoptosis 
induced by serum starvation and/or exposure to a combination of TNF-α, INF-
γ and IL-1β was inhibited by exposure to ghrelin (Granata et al., 2007). 
However, the pro-survival function of ghrelin seems to be tissue specific and 
dependent on experimental conditions. In certain cancers such as 
aldosteronomas and in two human adrenocortical carcinoma cell lines 
treatment with ghrelin increased basal apoptosis whereas in non-cancerous 
tissues and cells such as human umbilical vein endothelial cells (HUVEC), rat 
osteoblasts and human normal adrenocortical cells ghrelin had no effect on 
basal apoptosis (Belloni et al., 2004). Taken together these studies imply that 
the investigations into the role of ghrelin in beta cell and islet survival is 
limited and its inhibitory role on insulin secretion remains controversial. 
Furthermore, only a very small number of studies have assessed the role of 
ghrelin on beta cell survival in response to cellular stress-inducing conditions 
typical of type 2 diabetes (Wang et al., 2010). These questions therefore 
remain to be further investigated. 
It was reported in chapter 3 of this thesis and in Damsteegt et al. (2019) that 
somatostatin (SST) promotes beta cell and islet survival under conditions of 
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cellular stress typical of type 2 diabetes. Both somatostatin and ghrelin act on 
the same tissues such as brain and gut (reviewed by Martinez, 2013; reviewed 
by Pradhan et al., 2013), suggesting a potential functional interaction between 
the two hormones. Exogenous ghrelin was found to stimulate circulating SST 
levels in humans (Arosio et al., 2003) and increased total (both acyl and des-
acyl) ghrelin levels were detected in SST knockout mice (Luque and Kineman, 
2007). Previous work in our laboratory has found that GHSR1a mRNA was 
upregulated in islets isolated from somatostatin-deficient mice (Hauge-Evans 
et al., unpublished) further suggesting the interaction between the two. 
Similarly, SST was shown to suppress plasma ghrelin levels and the SST 
mimetic octreotide was found to inhibit ghrelin secretion in a pre-perfused rat 
stomach (Shimada et al., 2003). Furthermore, centrally administered ghrelin 
reportedly enhanced growth hormone release by blocking the effect of SST in 
rats (Wargner et al., 2009). These studies suggest that the interaction between 
somatostatin and ghrelin is tissue-specific.  
Recently, it was shown that ghrelin can influence SST secretion in the pancreas 
as proposed in a study by DiGruccio et al. (2016) and confirmed by 
Adriaenssens et al. (2016), where ghrelin was suggested to act on islet delta 
cells and promote glucose-induced SST secretion, thus mediating an inhibitory 
effect of ghrelin on insulin secretion indirectly via release of SST from delta 
cells. We therefore hypothesized that the reported effect of ghrelin on beta cell 
and islet survival may similarly be mediated indirectly by SST. However, this 
is in contrast to studies described earlier proposing that ghrelin promoted 
clonal beta cell survival, which indicates a direct, delta-cell independent effect 
of ghrelin on the beta cells (Diaz-Ganete et al., 2015; Granata et al., 2007). 
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Hence, establishing the effect of ghrelin on beta cell and islet function 
constitutes an initial step in the process leading to the investigation of its 




4.2 Aims and objectives 
4.2.1 To investigate the effect of ghrelin on palmitate-induced apoptosis in 
MIN6 cells. 
4.2.2 To assess the effect of ghrelin on glucose and forskolin-induced insulin 
secretion from MIN6 cells. 
4.2.3 To investigate the effect of ghrelin on mouse islet apoptosis induced by 
pro-inflammatory cytokines typical of type 2 diabetes. 








4.3.1 Assessment of clonal beta cell viability and apoptosis 
Cell viability 
MIN6 cell viability was tested as described in section 2.5. Briefly, MIN6 cells 
were seeded at 25,000 cells/well and pre-incubated for 48 h in complete 
DMEM with or without 0-500 nM ghrelin (Tocris, UK) with replacement of 
treatment following 24 h of incubation. After the 48 h pre-incubation period 
the cells were exposed to 0.5 mM palmitate for 20 h and MTT assay was 
performed as described in section 2.5 to determine cell viability. 
Apoptosis 
Assessment of MIN6 cell apoptosis was performed by measurement of caspase 
3/7 activity as described in 2.6.1. Briefly, 15,000 cells/well were seeded in 
white-walled 96 well plates and pre-treated as indicated above for cell viability 
assay. Following exposure to 0.5 mM palmitate or 500 U/ml TNF-α and 50 
U/ml IL-1β, Caspase-Glo assay was performed as described in 2.6.1. 
4.3.2 Assessment of apoptosis in mouse islets 
Islets were pre-incubated in complete RPMI for 48 h as indicated above for 
MIN6 cells with or without 100 nM ghrelin. Next the islets were exposed to 
1000 U/ml TNF-α and 50 U/ml IL-1β ± 100 nM ghrelin and immediately 
handpicked into a white-walled 96 well plate (5 islets/well) in 40 µl of 
incubation media. Following 20 h incubation Caspase-Glo assay was 
performed as described in 2.6.2.  
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4.3.3 Static incubation experiments 
Insulin secretion from clonal beta cells 
Insulin secretion from MIN6 cells in response to 2 mM glucose, 20 mM 
glucose, 10 µM forskolin (FSK) + 100 µM 3-isobutyl-1-methylxanthine 
(IBMX) ± 100 nM ghrelin was determined as described in 2.4.1. 
Insulin secretion from mouse islets 
Islet insulin secretion was assessed in response to treatment with 2 mM 
glucose and 20 mM glucose with or without 100 nM ghrelin as described in 
2.4.2. 
All samples were diluted to concentrations detectable within the range of the 
standard curve and insulin contents were measured by radioimmunoassay as 
described in section 2.4.4.1.  
4.3.4 H&E staining 
Female mice used in this study were tested for oestrus cycle stage as described 
in 2.3. Briefly, vaginal smears were fixed, hydrated and stained with 
haematoxylin and eosin. The stained smears were dehydrated and mounted 
with a glass coverslip. The images of slides were taken with a bright field 
microscope and oestrus cycle stage determined as described in 2.3.  
 
 




4.4.1 The role of ghrelin in MIN6 cell secretory function and 
apoptosis 
Previous studies investigating the functional effects of ghrelin in clonal beta 
cells and islets have reported the peptide to be effective at 10-100 nM (Diaz-
Ganete et al., 2015; Granata et al., 2007; Wierup et al., 2004). For 
experimental purposes a concentration response test was conducted to 
identify the concentration of ghrelin to be used in the current research model. 
MIN6 cells were pre-treated for 48 h with 0-500 nM ghrelin with the medium 
being replaced after 24 h since the acylated form of the compound is unstable 
and the acyl group can be cleaved by esterases in the medium (reviewed by 
Delporte, 2013). Cell viability was significantly reduced in the presence of 
palmitate (p<0.0001), but incubation with ghrelin did not significantly 
prevent cell death at all concentrations tested (p>0.05) (Fig. 4.4.1). Further 
testing utilising the Promega CellTitre-Glo assay that detects cell viability by 
measurement of ATP content confirmed the above findings (data not shown). 
In accordance with the literature, 10 and 100 nM ghrelin were therefore 
chosen for further testing since these concentrations have been shown to be 
effective in other experimental in vitro settings.  
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The cell viability assays used were based on the measurement of cellular 
metabolic activity and provided only an indication of how many cells were 
viable rather than the specific modulators of cell survival such as proliferation 
and reduction in apoptosis. Therefore, measurement of caspase 3/7 activity 
was employed to detect cell apoptosis in order to elucidate whether ghrelin 
affects specific underlying regulators of cell survival. Similar to cell viability 
experiments, apoptosis induced by 0.5 mM palmitate (p<0.05; Fig. 4.4.2A) or 
500 U/ml TNF-α and 50 U/ml IL-1β (p<0.0001) was not significantly 
prevented following treatment of the cells with ghrelin (p>0.05) (Fig. 4.4.2B).  
Figure 4.4.1 The effect of ghrelin on MIN6 cell viability. MIN6 beta 
cells were plated at 25,000 cells/well and pre-treated for 48 h with or without 
a range of concentrations of ghrelin as indicated and exposed to 0.5 mM 
palmitate for 20 h ± ghrelin. Cell viability was detected by measurement of 
MTT incorporation. Data is presented as mean+SEM, n=6, graph represents 
results of one experiment out of two independent experiments. One-Way 
ANOVA with posthoc test Bonferroni ****p<0.0001.  
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Since ghrelin did not affect MIN6 beta cell apoptosis, the functional 
responsiveness of MIN6 cells to ghrelin in general was investigated by 
assessment of insulin secretion. Since MIN6 cells are grown in medium 
containing 25 mM glucose and do not consistently respond to stimulation with 
20 mM glucose, FSK and IBMX were used to potentiate glucose-induced 
insulin secretion from MIN6 cells. Incubation with 100 nM ghrelin did not 
significantly reduce insulin secretion stimulated by FSK and IBMX (p>0.05) 
nor did it affect insulin release at 20 mM glucose alone (p>0.05, Fig. 4.4.3). 
These results implied that ghrelin may not directly modulate beta cell function 
and survival. This is consistent with recent single-cell transcriptomic studies 
(Adriaenssens et al., 2016; DiGruccio et al., 2016), where ghrelin’s effect on 
insulin secretion from pancreatic beta cells was found to be mediated via 
release of SST from pancreatic delta cells. MIN6 cells are a monotypic, 
monolayer beta cell line therefore useful to study direct effects of any 
compounds on beta cells. However, to study interaction between different cell 
types, the islet research model is required. Hence mouse islets that are a 
composite organ containing both beta and delta cells were used in the 
subsequent experiments. For this purpose, islets from male CD-1 mice were 
used in initial experiments.  
 
 Chapter 4 - Results 
 132   
 
 
Figure 4.4.2 The effect of ghrelin on MIN6 cell apoptosis. MIN6 beta 
cells were plated at 15,000 cells/well and pre-treated for 48 h with or without 
10 or 100 nM ghrelin and exposed to 0.5 mM palmitate ± ghrelin (A) or 500 
U/ml TNF-α+ 50 U/ml IL-1β ±  ghrelin (B) for 20 h. Apoptosis was detected 
by measurement of caspase 3/7 activity. Data is presented as mean+SEM, n=5. 
Graph A represents results of one experiment out of three independent 
experiments and graph B of one experiment. One-Way ANOVA with posthoc 
test Bonferroni *p<0.05 and ****p<0.0001. NS = not significant p>0.05. 
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4.4.2 The role of ghrelin in islet survival and function 
First a concentration response study with 10 and 100 nM ghrelin was 
conducted, followed by a time course experiment, where the impact of 
treatment duration was assessed. A combination of pro-inflammatory 
cytokines (1000 U/ml TNF-α and 50 U/ml IL-1β) was used as a cellular stress 
inducing agent to ensure that an adequate apoptotic signal was obtained, as 
the detrimental effect of palmitate on survival in intact islets has been 
inconsistent in previous studies in our lab (Hauge-Evans et al., unpublished). 
 
 
Figure 4.4.3 The effect of ghrelin on MIN6 insulin secretion. MIN6 cells 
were plated at 20,000 cells/well and incubated for 48 h. The cells were then pre-
incubated with 2 mM glucose for 2 h and subsequently treated as indicated for 1 h. 
Supernatants were assayed for insulin content by radioimmunoassay. Data is 
presented as mean+SEM, n=6-8 and graph represents results of one experiment 
out of three independent experiments. One-Way ANOVA with posthoc test 
Bonferroni ****p<0.0001. NS = not significant, p>0.05. 
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Exposure to ghrelin for 24 h did not alter cytokine-induced apoptosis at 10 or 
100 nM of the peptide. Based on the literature (Diaz-Ganete et al., 2015; 
Granata et al., 2007) and MIN6 studies 48 h pre-treatment with 24 h 
replenishment and 10 and 100 nM concentrations were chosen for the 
subsequent experiments.   
 
Islets from male mice pre-treated with or without ghrelin and exposed to 
cytokines as described above were further assessed for apoptosis. As shown in 
figure 4.4.4 islet apoptosis was significantly increased in the presence of 
Figure 4.4.4 The effect of ghrelin on apoptosis in islets from male mice. 
Isolated mouse islets were pre-treated for 48 h with 10 or 100 nM ghrelin and 
exposed to 1000 U/ml TNF-α + 50 U/ml IL-1β for 20 h ± ghrelin. Cell apoptosis 
was detected by measurement of caspase 3/7 activity. Data is presented as 
mean+SEM, n=6. Graph represents results of one experiment out of 3-4 
independent experiments. One-Way ANOVA with posthoc test Bonferroni 
***p<0.001. NS = not significant p>0.05. 
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cytokines (p<0.001), however this was not significantly reversed by exposure 
to 10 or 100 nM ghrelin (p>0.05).  
These results implied that either ghrelin does not affect islet apoptosis or that 
the peptide used in the study was inactive. Therefore, it was tested whether 
ghrelin modified glucose-induced insulin secretion in mouse islets. Incubation 
with 20 mM glucose for 1 h significantly increased islet insulin secretory 
response compared to basal levels (p<0.001), however this was not affected by 
treatment with 100 nM ghrelin (p>0.05) (Fig. 4.4.5). 
 
 
Figure 4.4.5 The effect of ghrelin on insulin secretion from islets 
from male mice. Isolated islets were pre-treated with 2mM glucose for 1 
h followed by treatments as indicated for 1 h. Secreted insulin was detected 
by radioimmunoassay. Data is presented as mean+SEM, n=5-6, and graph 
represents results of one experiment out of three independent experiments. 
One-Way ANOVA with posthoc test Bonferroni **p<0.01, ***p<0.001. NS 
= not significant p>0.05. 
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Further to the results described above, a literature search was conducted to 
check for any reports of sex-dependent effects of ghrelin as these experiments 
were carried out with islets from male mice only. This revealed that ghrelin 
displays sexual dimorphism with regards to circulating levels and orexigenic 
effects in both rodents and humans (Choi et al., 2017; Clegg et al., 2007). It 
was therefore hypothesized that ghrelin’s effect in the pancreatic islets may 
depend on the biological sex of the animal from whom the islets were derived. 
Therefore, the role of ghrelin on survival and insulin secretory function was 
assessed in islets from age-matched female CD-1 mice. 
Prior to the assessment of the functional effects of ghrelin, female mice were 
assessed for their oestrus cycle stage at time of islet isolation as described in 
section 2.3. H&E staining revealed that approximately 60% of animals were at 
metestrus stage, 31% at oestrus and the remaining at pro-oestrus stage (Fig. 
4.4.6). This pattern was observed in mice used for all but two experiments 
where the distribution was 50:50 metestrus and oestrus stages. 
In order to test whether treatment with ghrelin could reverse apoptosis 
induced by cytokines in islets from female mice, isolated islets were pre-
treated for 48 h with or without ghrelin and exposed to cytokines for 20 h as 
indicated for islets from male mice. As shown in figure 4.4.7, incubation with 
10 and 100 nM ghrelin significantly reduced cytokine-induced apoptosis in 
islets from female mice (p<0.0001). 
Next, it was tested whether ghrelin modified glucose-induced insulin secretion 
in islets from female mice. Incubation with 20 mM glucose significantly 
increased islet insulin secretory response compared to basal level (p<0.001) 
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however this was not affected by treatment with 100 nM ghrelin (p>0.05, Fig. 






Figure 4.4.6 Determination of oestrus cycle stage of female mice. 
Vaginal smears were fixed in 3.7% formaldehyde and stained with H&E. Oestrus 
cycle stage was determined according to cell morphology. Images were taken with 
X20 objective and scale bar = 100 µm. Four representative images out of 48 are 
shown. 31% of female mice used were at oestrus stage (C) characterised by 
cornified squamous epithelial cells and high plasma oestrogen levels during the 
day. About 60% of female mice were at metestrus stage (A, B and D) characterised 
by leukocytes (dots) and a few nucleated or cornified squamous epithelial cells 
where plasma oestrogen levels are lowest during the mouse oestrus cycle. 
A B 
C D 
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Figure 4.4.7 The effect of ghrelin on apoptosis in islets from female 
mice. Isolated mouse islets were pre-treated for 48 h with 10 or 100 nM 
ghrelin and exposed to 1000 U/ml TNF-α + 50 U/ml IL-1β for 20 h ± ghrelin. 
Cell apoptosis was detected by measurement of caspase 3/7 activity. Data is 
presented as mean+SEM, n=6, and graph represents results of one experiment 
out of 2-3 independent experiments. One-Way ANOVA with posthoc test 
Bonferroni ****p<0.0001. 
 Chapter 4 - Results 









Figure 4.4.8 The effect of ghrelin on insulin secretion from islets from 
female mice. Isolated islets were pre-treated with 2 mM glucose for 1 h followed 
by treatments as indicated for 1 h. Secreted insulin was detected by 
radioimmunoassay. Data is presented as mean+SEM, n=5 and graph represents 
results of one experiment out of three independent experiments. One-Way 
ANOVA with posthoc test Bonferroni *p<0.05, ***p<0.001. 





Ghrelin, an orexigenic hormone, has been shown to inhibit insulin secretion 
in beta cells and to promote beta cell and islet survival (Dezaki et al., 2004; 
Diaz-Ganete et al., 2015; Granata et al., 2007). However, these actions remain 
contested due to reports that ghrelin either did not affect or it increased insulin 
secretion in rodent islets (Adeghate and Ponery, 2002; Salehi et al., 2004) and 
promoted apoptosis in other tissues (Belloni et al., 2004). In addition, the 
evidence supporting a pro-survival role for ghrelin in response to cellular 
stressors typical of type 2 diabetes remains limited. Furthermore, some have 
found that ghrelin interacts with somatostatin in a number of tissues such as 
brain and gastro-intestinal tract (Arosio et al., 2003; Shimada et al., 2003). 
Most recently it was reported that the insulinostatic action of ghrelin is due to 
an indirect and stimulatory action of ghrelin on pancreatic delta cells leading 
to the release of SST, which acts on the beta cell to inhibit insulin secretion 
(Adriaenssens et al., 2016; DiGruccio et al., 2016). It was therefore 
hypothesized that the effect of ghrelin on beta cell and islet survival may also 
be mediated by the action of SST. However, this is discordant with studies 
showing a pro-survival action of ghrelin in clonal beta cell lines exposed to 
stressors typical of type 1 diabetes (Diaz-Ganete et al., 2015; Granata et al., 
2007). Therefore, the experiments conducted in this chapter aimed to evaluate 
whether treatment with ghrelin could modify MIN6 cell and mouse islet 
survival and insulin secretory responses.  
4.5.1 The role of ghrelin in MIN6 cell function 
First of all it was necessary to establish whether the potential actions of ghrelin 
on pancreatic beta cell survival and insulin secretion are direct or indirect.  For 
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this the MIN6 cell line was used as a model. Since MIN6 are a monotypic beta 
cell line it was employed to investigate the direct effects of ghrelin without any 
paracrine regulation by islet hormones released from other islet cell types. 
Treatment with ghrelin did not significantly affect MIN6 cell apoptosis 
induced by 0.5 mM palmitate or a combination of cytokines as indicated in 
4.4.1 in contrast to results reported by some (Diaz-Ganete et al., 2015; 
Granata et al., 2007; Zhang et al., 2007). It is unlikely that this was due to 0.5 
mM palmitate and the concentration of cytokines used being too potent. For 
example, Wang et al. (2010) used 0.4 mM palmitate at similar conditions for 
a duration of 24 h with replacement of treatment every 8 h suggesting that the 
apoptosis induced by palmitate could in part be prevented by treatment with 
ghrelin in the same cell line. It is important to highlight that there are only a 
limited number of studies investigating the role of ghrelin on beta cell 
apoptosis, and any discrepancies in results may be due to different 
experimental models. Despite Wang et al. (2015) reporting an effect in MIN6 
cells, having conducted over three sets of repeats it is possible to confidently 
state that ghrelin did not significantly affect beta cell apoptosis induced by 
palmitate or a combination of cytokines in the current study as discussed next. 
When comparing the treatment with cytokines, although Diaz-Ganete et al. 
(2015) used a combination of three cytokines (100 ng/ml IFN-γ, 50 ng/ml 
TNF-α and 0.05 ng/ml IL-1β), the concentrations of those used in the current 
study did not differ much (50 ng/ml TNF-α and 0.1 ng/ml IL-1β) further 
suggesting that incubation with ghrelin could overcome the cytokine-induced 
apoptosis in clonal beta cells despite a more powerful combination of three 
cytokines than the two used in the current study. Importantly exposure to 
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ghrelin did not affect basal apoptosis levels in MIN6 cells in accordance with 
the observations by Diaz-Ganete et al. (2015) but not by Wang et al. (2010) 
where ghrelin also reduced basal apoptosis. It is therefore possible that the 
differences in experimental set up or absence of direct effect of ghrelin on 
MIN6 cells may have contributed to the discrepancy in results compared to the 
other studies.  
Following lack of effect being observed for ghrelin on MIN6 cell apoptosis it 
was tested whether it could affect insulin secretion in the clonal beta cells in 
order to ascertain the general responsiveness of MIN6 cells to exogenous 
ghrelin. Incubation with ghrelin did not modify insulin secretion from MIN6 
cells both in the presence of 20 mM glucose and 20 mM glucose with FSK and 
IBMX. These results are also discordant with a number of studies where acyl-
ghrelin significantly reduced glucose-induced and basal insulin secretion in 
rodents (Dezaki et al., 2004) or in clonal beta cells (Wierup et al., 2004).  
However our results conform with other reports where treatment with ghrelin 
did not alter insulin secretory function in rodent islets (Salehi et al., 2004).  
These results suggest that either the ghrelin peptide used in the current study 
was not active or that MIN6 cells do not respond to treatment with exogenous 
ghrelin. The latter may either be due to the presence of endogenous ghrelin or 
the absence of ghrelin receptors on MIN6 cells. It has been reported that beta 
cells displayed both ghrelin-like and ghrelin receptor-like immunoreactivity 
(Kageyama et al., 2005) and that ghrelin was detected at mRNA level in HIT-
T15 clonal beta cell line (Granata et al., 2007). The most plausible explanation, 
however, supports the findings in single-cell transcriptomic analyses, where 
the ghrelin receptor was only detected in the islet delta cells and it was revealed 
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that glucose-induced release of somatostatin was potentiated by the action of 
ghrelin on the islet delta cell (Adriaenssens et al., 2016; DiGruccio et al. 2016). 
Therefore, both studies suggested that the insulinostatic effect of ghrelin was 
due to the direct action of somatostatin and not ghrelin on beta cells. In 
accordance with these reports the findings of this chapter indicate that ghrelin 
may not directly influence clonal beta cell survival and insulin secretion. 
Hence mouse islets were used in the subsequent experiments. 
4.5.2 The role of ghrelin in mouse islet function 
Experiments conducted using islets from male mice as described in 4.4.2 
found that ghrelin did not significantly alter cytokine-induced apoptosis in 
islets in accordance with observations in MIN6 cells. However this result was 
divergent from the findings by Granata et al. (2007) where treatment with 
ghrelin reduced cytokine-induced apoptosis in human islets. Similar to the 
results in MIN6 cells ghrelin had no effect on basal apoptosis in mouse islets.   
It is well documented that both ghrelin and its receptor are present within the 
islets of Langerhans (Kageyama et al., 2005; Volante et al., 2002).  However, 
to my knowledge there is no report investigating involvement of the ghrelin 
receptor in mediating the action of ghrelin on islet survival, but instead many 
have characterised this for its effects on insulin secretion. Therefore, the role 
of ghrelin on islet insulin secretion was assessed and no significant outcome 
was observed. These results conform with the reports that exogenous ghrelin 
does not affect glucose-induced insulin secretion in islets from rodents 
(Adeghate and Ponery, 2002; Salehi et al., 2004).  Taken together these results 
reveal that the role of ghrelin in the regulation of islet function may be more 
complex than initially presumed.  
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The orexigenic effects and plasma levels of ghrelin have been reported to 
display sexually dimorphic characteristics in rodents and humans (Choi et al., 
2017; Clegg et al., 2007; Yamada et al., 2015). Based on the hypothesis that 
the action of ghrelin may be influenced by the sex of the mice from whom the 
islets were derived, it was tested whether ghrelin modified cytokine-induced 
apoptosis in islets from female mice. As reported in 4.4.2, treatment with 
ghrelin significantly reduced cytokine-induced apoptosis in islets from female 
mice suggesting a sex-dependent role for ghrelin in islet survival. This result 
confirmed that the peptide used in the current study was active and exposure 
to ghrelin only altered cytokine-induced but not basal apoptosis in accordance 
with observations in islets from male mice and MIN6 cells. Subsequent 
experiments investigating the effect of ghrelin on insulin secretion from islets 
from female mice found, however, no significant changes in glucose-induced 
insulin secretion in the presence of the peptide. It is important to highlight 
that the islets demonstrated good glucose-responsiveness therefore the lack of 
effect was not due to a substandard quality of islets. In addition, it is possible 
that research models used and differences in experimental set up may have 
contributed to observed effects. For example Dezaki et al. (2006) measured 
dynamic insulin secretion in a perfused isolated pancreas model where the 
effects of ghrelin on insulin secretion at different time points could be 
identified. In the current study a static insulin secretion model was used where 
overall insulin secretion at 1 h was detected. Furthermore by using the intact 
pancreas it is possible to better mimic physiological environment and input 
from non-endocrine tissues in this experimental setting cannot be discounted. 
As described in 1.3.2 a number of studies suggested that ghrelin regulates 
glucose homeostasis by altering islet responses to glucose (Broglio et al., 2003; 
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Tong et al., 2010). The results of the current study however suggest that the 
effect of ghrelin on glucose metabolism does not appear to be mediated via its 
effects on islet secretory responses as also suggested by Salehi et al. (2004). 
Others have reported that ghrelin also acts on liver and promotes hepatic 
gluconeogenesis (Barazzoni et al., 2007), suggesting that in vivo effects of 
ghrelin on glucose metabolism may be regulated by inputs from a number of 
organs. 
A study by Clegg et al., (2007) explored how ovariectomising and treatment 
with oestradiol affected ghrelin’s orexigenic action in rats. Here with the use 
of wild-type male, female and ovariectomised (OVX) female rats it was 
revealed that males and OVX females were more susceptible to orexigenic 
effects of ghrelin. Indeed, OVX female rats had increased ghrelin levels, food 
intake and weight gain compared to normal females. The ablation of the 
ghrelin receptor negated these effects (Clegg et al., 2007). In another 
investigation by Yamada et al. (2015), the effects of two weeks of social 
isolation resulting in physiological stress were studied in mice and their 
observations focused on changes in body weight, feeding behaviours and 
plasma ghrelin levels. Young male mice showed increased plasma ghrelin 
levels compared to females following one week of isolation. This was also the 
case for older male mice although to a lesser extent. Furthermore, it was 
reported that male patients affected by functional dyspepsia, a condition 
affecting the upper gastrointestinal tract, had lower plasma ghrelin levels 
compared to female patients (Choi et al., 2017). In another study involving 
male and female twins it was found that females had higher plasma ghrelin 
compared to males and that this level was higher in younger participants 
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(Makovey et al., 2007). Overall these findings indicate that there are 
differences between males and females with regards to plasma ghrelin levels 
and responsiveness.  
It is possible to argue that the presence of oestrogen in female individuals may 
have contributed to the divergent effects of ghrelin observed in mouse islets. 
It is well known that oestrogens protect against apoptosis; for example it was 
found that in a mouse model where oxidative stress was induced by 
streptozotocin (STZ), wild-type female mice showed normal islet architecture 
and beta cell number whereas male mice were more vulnerable to STZ 
treatment and had reduced beta cell mass and insulin content. In particular, 
male mice showed increased beta cell apoptosis and treatment with oestradiol 
suppressed this effect (Le May et al., 2006). In another study it was found that 
the expression of the oestrogen receptor alpha (ERα) naturally protected beta 
cells from oxidative stress in mice (Killic et al., 2014). Furthermore, in some 
mouse models such as those fed a high-fat diet, male mice were more prone to 
hypothalamic inflammation resulting in impaired glucose tolerance (Morselli 
et al., 2014). In spontaneously diabetic mice, glycaemia was worse in males 
compared to females with aging (Diaz et al., 2019). In both studies either the 
presence of oestrogen (Diaz et al., 2019) or ERα-dependent pathways 
(Morselli et al., 2014) were identified to be responsible for the differential 
outcomes. Sex-specific differences can arise not only due to the action of 
oestrogens but also androgens and it has been reported that the androgen 
receptor (AR) is expressed on islet beta cells (Mauvais-Jarvis, 2016). The 
studies investigating the role of androgens on beta cells have primarily focused 
on insulin secretory function. In males testosterone enhanced GSIS, whereas 
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in females excessive androgens resulted in hypersecretion of insulin and 
oxidative injury (Navarro et al., 2018; Xu et al., 2019). Indeed, female mice 
treated with dihydrotestosterone developed hyperinsulinaemia, insulin 
resistance and hyperglycaemia indicating beta cell failure, but this effect was 
not observed in beta cell-specific AR knockout mice (Navarro et al., 2018). 
Similarly, hyperinsulinaemia was detected in a female rat model of polycystic 
ovary syndrome which was found to be caused by elevated  Ins1  transcription 
(Mishra et al., 2018). Hence, it appears that only oestrogen conveys a 
protective effect on beta cell function in islets from both male and female mice. 
Therefore, it is possible that the protective effect of ghrelin in islets from 
female mice may be due to the presence of oestrogen rather than androgens, 
although isolated islets were used in the current investigation. Hence, at the 
time of the experiments islets from female mice were no longer exposed to 
elevated levels of E2 due to the ex-vivo experimentation. To my knowledge 
there are no reports on how long sex-related differences may last following 
islet isolation and as also discussed in section 7.2 it is possible that the 
observed sex-specific differences may be due to inherent differences between 
islets from male and female mice.  
A study examining variations in plasma ghrelin levels in pre and post-
menopausal women in response to oestradiol reported that there was no 
significant difference in ghrelin levels from start to end of treatment. However, 
post-menopausal women had significantly lower plasma ghrelin levels 
compared to pre-menopausal women (Dafopoulos et al., 2010). This result 
conflicts with the observations by Clegg et al. (2004) described earlier where 
ovariectomised females had greater plasma ghrelin levels despite circulating 
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oestrogen being lower in both conditions. A study assessing whether the stages 
of oestrus cycle influenced ghrelin levels in rats found no significant changes 
in plasma and stomach ghrelin levels between cycle stages. However, similar 
to the findings by Dafopoulos et al. (2010) rats over the age of 37 weeks 
showed significantly less plasma ghrelin levels (Johnson et al., 2016). 
Similarly, the female mice used in the current study presented different stages 
of the oestrus cycle and the studies by Dafopoulos et al. (2010) and Johnson 
et al. (2016) confirm the findings of H&E staining that the effect of ghrelin on 
islet survival is independent of the oestrus cycle stage of the animals used. 
Taken together these studies suggest that ovariectomy and menopause 
characterised by decreased circulating oestrogen affect plasma ghrelin levels, 
which, however, do not seem to be influenced by fluctuations in oestrogen 
levels during oestrus cycle.  
Since ghrelin displays sexual dimorphism in its levels and action in some 
tissues it implies that the expression of ghrelin receptor may also depend on 
the sex of the animal. A study conducted in yellow catfish found Ghsr1a mRNA 
expression to be elevated in stomach, gut and hypothalamus of males whereas 
it was less expressed in pituitary, heart and muscle compared to females 
(Zhang et al., 2016). Hence further elucidation of the expression of GHSR1a 
would aid to confirm whether the sex-specific effects of ghrelin depend on the 
expression of its receptor and this will be further investigated in chapter 5 of 
this thesis.  As discussed previously, single-cell transcriptomic analyses 
suggest that Ghsr1a expression is cell-type specific within the islets, with 
exclusive expression on the islet delta cells (Adriaenssens et al., 2016; 
DiGruccio et al., 2016). It is therefore possible that in islets from female mice 
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the pro-survival action of ghrelin may depend on altered expression of the 
ghrelin receptor thereby influencing somatostatin secretion and subsequent 
activation of SSTR-dependent intracellular pathways.  
4.5.3 Summary 
The results described in this chapter indicate that exogenous ghrelin does not 
play a role in apoptosis and insulin secretory function of MIN6 beta cells 
confirming the hypothesis that the effect of ghrelin on beta cell function may 
be indirect via its action on the delta cell and stimulation of secretion of 
somatostatin. However, experiments conducted in islets have revealed a sex-
specific role for ghrelin where a reduction in apoptosis by ghrelin was only 
detected in islets from female mice. This function may depend on differences 
in the expression of ghrelin receptor, endogenous ghrelin, prolonged exposure 
to oestrogen or crosstalk with somatostatin. Some of these potential mediators 
of ghrelin action are further characterised in chapter 5 and 6 of this thesis. 
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5.1 Introduction 
Ghrelin is known to act via the G-protein-coupled receptor (GPCR) GHSR1a 
and the acylation of the peptide has been found to be necessary for binding to 
this receptor (Kojima et al., 1999; Davenport et al., 2005). GHSR1a has been 
reported to be expressed almost ubiquitously in the body including in brain, 
stomach, pancreas, blood vessels, reproductive organs (testis and ovaries), 
intestines and heart (Gnanapavan et al., 2002; Katugampola et al., 2001; 
Uenberg et al., 2009). However, within the islet, the specific location of its 
expression remains disputed. GHSR1a-like staining was observed by 
Kageyama et al. (2005) in both beta and alpha cells in rat pancreatic islets and 
in pancreatic tumours by Volante et al. (2002). Chuang et al. (2011) have 
found GHSR1a to be expressed only in alpha cells, suggesting that the effect 
on islet function is due to ghrelin’s action on alpha-cells. But in 2016, single-
cell transcriptomic analyses identified the mRNA expression of Ghsr 
exclusively in another murine islet cell type, the pancreatic delta cell 
(DiGruccio et al., 2016); a finding that was confirmed by Adriaenssens et al. 
(2016). In both studies ghrelin’s effect on beta cells was found to be mediated 
via release of somatostatin from delta cells. A number of studies have shown 
that ghrelin modulates insulin secretion in beta cells using a clone of the INS-
1 cell line (Wierup et al., 2004) and beta cells isolated from rat islets (Date et 
al., 2002; Dezaki et al., 2004), indicating a direct action either via GHSR1a 
expressed at very low levels (Kageyama et al., 2005) or alternatively via 
another ghrelin-binding receptor being expressed on beta cells (Granata et al., 
2007). These studies highlight the controversy regarding the expression 
pattern of GHSR1a in the pancreatic islets that warrants further investigation. 
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In the process of elucidating the mechanisms conveying the findings reported 
in chapter 4, identification of the role of GHSR1a in islets therefore constitutes 
a fundamental step. 
As described in 1.3.2, a number of GHSR1a antagonists have been developed 
to date. In the present study the synthetic GHSR1a antagonist YIL781 and the 
endogenous antagonist LEAP2 were used to identify the role of GHSR1a in 
mediating the functional effects of ghrelin in clonal beta cells and islets 
reported in the previous chapter. Furthermore, based on the findings in 
chapter 4, the experiments of this chapter have also assessed whether a 
potential differential expression of GHSR1a in the islets from male and female 
mice may have contributed to the observed sex-specific response to cytokine-
induced apoptosis following exposure to ghrelin. 
 
5.2 Aims and objectives 
5.2.1 To explore whether the effect of ghrelin on islet apoptosis is mediated by 
GHSR1a in islets from female mice.  
5.2.2 To investigate additional roles of GHSR1a in apoptosis in islets from 
male mice and in MIN6 cells. 
5.2.3 To determine mRNA expression of Ghsr1a and protein expression of 
GHSR1a in islets and clonal beta cells. 
5.2.4 To assess the role of GHSR1a on glucose-induced insulin secretion in 
islets.





5.3.1 Clonal beta cell and islet apoptosis 
MIN6 cells 
Assessment of MIN6 cell apoptosis was performed by measurement of caspase 
3/7 activity as described in 2.6.1. Briefly, 15,000 cell/well were seeded in 
white-walled 96 well plates. Cells were pre-treated with or without 100 nM 
ghrelin ± GHSR1a antagonist (YIL781-Tocris, UK and LEAP2 – Peptides 
International, USA) in DMEM for 48 h with refreshment of treatment after 24 
h. Following exposure to 0.5 mM palmitate for 20 h with or without ghrelin ± 
GHSR1a antagonist Caspase-Glo assay was performed as described in 2.6.1. 
Islets 
Islets were pre-treated in complete RPMI for 48 h as indicated above for MIN6 
cells with or without 100 nM ghrelin ± GHSR1a antagonist. Islets were then 
exposed to 1000 U/ml TNF-α and 50 U/ml IL-1β ± 100 nM ghrelin ± GHSR1a 
antagonist and immediately handpicked into a white-walled 96 well plate (5 
islets/well) in 40 µl of supplemented media. Following 20 h incubation, 
Caspase-Glo assay was carried out as described in 2.6.2.  
5.3.2 Gene expression analysis 
RNA extraction, cDNA reverse transcription and qPCR were performed as 
described in section 2.7 with the use of primers for house-keeping genes 
(section 2.7.3); and Ghrelin receptor (Ghsr1a) made in-house (Table 5.1). 
Gene expression was determined relative to the house-keeping genes Ppia and 
Hprt. 
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Table 5.1 Details of Ghsr1a primers 
 
5.3.3 Static incubation experiments for assessment of insulin 
secretion from mouse islets 
Islet insulin secretion was assessed as described in 2.4.2 in response to 
treatment with 2 mM glucose and 20 mM glucose with or without 100 nM AG 
± 5 µM YIL781 or 100 nM LEAP2. All samples were diluted to concentrations 
detectable within the range of the standard curve and the concentration of 
insulin was measured by radioimmunoassay as described in section 2.4.4.1.  
5.3.4 Detection of protein  
Cell and tissue lysates were prepared using 1x RIPA buffer containing 1x 
protease inhibitor cocktail as described in 2.8.1. The lysates of leukaemia cell 
lines were kindly provided by Dr Yoana Arroyo. Following SDS-PAGE, 
proteins were transferred on to a nitrocellulose membrane by Western blot as 
described in 2.8.4. Rabbit polyclonal antibody to GHSR1a was purchased from 
Life Technologies (ThermoFisher Scientific, UK, cat no. 720278) and used at 
a final concentration of 1 µg/ml. GHSR1a expression was expressed relative to 
loading control beta-actin.  
  






Ghsr1a FW: GCACCACCACCAACCTCTAC 
RV:  GCAGCTCTCGCTGACAAACT 
155 60 





5.4.1 The effect of GHSR1a antagonists on islet and MIN6 apoptosis 
following co-treatment with ghrelin. 
Following the discovery in chapter 4 of ghrelin conveying a protective effect on 
pro-inflammatory cytokine-induced apoptosis only in islets from female mice, 
two GHSR1a antagonists were used to determine whether this effect of ghrelin 
could be reversed to identify whether ghrelin acts via the known receptor 
GHSR1a.  
YIL781 
First the competitive antagonist YIL781 was used. Treatment with 100 nM 
ghrelin significantly reduced cytokine-induced apoptosis in islets from female 
mice (p<0.0001; Fig. 5.4.1A), however exposure to 5 µM YIL781 did not 
significantly reverse this effect (p>0.05). Instead, incubation with 5 µM 
YIL781 alone resulted in a significantly reduction (p<0.0001) in islet apoptosis 
compared to cytokine-treated control.  
The finding led to the investigation whether YIL781 alone had a similar effect 
in islets from male mice and MIN6 cells to test the potential non-specific 
nature of the compound, and/or whether the observed effect was dependent 
on the presence of non-beta cells in islets. As reported in chapter 4, incubation 
with exogenous ghrelin did not significantly influence apoptosis induced by 
cytokines in islets from male mice (p>0.05; Figure 5.4.1B) and palmitate-
induced apoptosis in MIN6 cells (p>0.05; Figure 5.4.2). However, similar to 
the results observed for islets from female mice, treatment with 5 µM YIL781 
alone significantly reduced (p<0.01) apoptosis in MIN6 cells (Fig. 5.4.2). 
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Although a similar trend was observed in islets from male mice treated with 5 
µM YIL781, it was not significantly different compared to the cytokines only 
control (p>0.05) (Fig. 5.4.1B).  
Figure 5.4.1 The effect of ghrelin and YIL781 on apoptosis in islets 
from female (A) and male (B) mice. Isolated islets were pre-treated for 48h 
with or without 100 nM ghrelin ± 5 μM YIL781 and exposed to 1000 U/ml TNF-
α+50 U/ml IL-1β for 20 h ±100 nM ghrelin ± 5 μM YIL781. Cell apoptosis was 
detected by measuring caspase 3/7 activity. Data is presented as mean+SEM, n=6. 
Each graph represents results of one experiment out of three independent 
experiments. One-Way ANOVA with posthoc test Bonferroni ****p<0.0001. NS = 
not significant p>0.05. 
 
 Chapter 5 - Results 




These results implied that YIL781 may display non-specific effects. As the 
number of commercially available GHSR1a antagonists is limited the 
discovery of LEAP2 was of great interest for the current project. LEAP2 was 
then used to test if the effect of ghrelin in islets from female mice could be 
reversed. In addition, LEAP2 was also utilised to assess whether the observed 
change in apoptosis following YIL781 treatment was specific to YIL781, or was 
Figure 5.4.2 The effect of ghrelin and YIL781 on MIN6 beta cell 
apoptosis. MIN6 beta cells were plated at 15,000 cells/well and pre-treated for 
48 h with or without 100 nM ghrelin ± 5 μM YIL781 and exposed to 0.5 mM 
palmitate for 20 h ± 100 nM ghrelin ± 5 μM YIL781. Cell apoptosis was detected 
by measuring caspase 3/7 activity. Data is presented as mean+SEM, n=5. Graph 
represents results of one experiment out of three independent experiments. One-
Way ANOVA with posthoc test Bonferroni **p<0.01 and ****p<0.0001. NS = not 
significant p>0.05. 
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a general effect of GHSR1a antagonists, including the endogenous antagonist 
LEAP2.  
LEAP2 
Based on the results reported in Ge et al. (2018), where 100 nM LEAP2 exerted 
the greatest inhibition of ghrelin-mediated activation of GHSR1a, LEAP2 was 
used at 100 nM in the current study. Treatment with 100 nM ghrelin 
significantly reduced cytokine-induced apoptosis in islets from female mice 
Figure 5.4.3 The effect of ghrelin and LEAP2 on apoptosis in islets from 
female mice. Isolated islets were pre-treated for 48 h with or without 100 nM 
ghrelin ± 100 nM LEAP2 and exposed to 1000 U/ml TNF-α+50 U/ml IL-1β for 20 
h ± 100 nM ghrelin ± 100 nM LEAP2. Cell apoptosis was detected by measuring 
caspase 3/7 activity. Data is presented as mean+SEM, n=5-6. Graph represents 
results of one experiment out of three independent experiments. One-Way 
ANOVA with posthoc test Bonferroni **p<0.01 and ****p<0.0001. NS = not 
significant p>0.05. 
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(p<0.0001; Fig. 5.4.3), however incubation with 100 nM LEAP2 did not 
significantly reverse this (p>0.05).  
Next, the role of LEAP2 was tested in islets from male mice and MIN6 cells. 
Similar to previous experiments, 100 nM ghrelin did not significantly affect 
apoptosis induced by cellular stressors in these groups (p>0.05). In addition, 
incubation with 100 nM LEAP2 alone did not significantly affect palmitate-
induced apoptosis in both groups (p>0.05) (Fig. 5.4.4 and 5.4.5).  
  
Figure 5.4.4 The effect of ghrelin and LEAP2 on apoptosis in islets from 
male mice. Isolated islets were pre-treated for 48 h with or without 100 nM 
ghrelin ± 100 nM LEAP2 and exposed to 1000 U/ml TNF-α+50 U/ml IL-1β for 20 
h ±100 nM ghrelin ± 100 nM LEAP2. Cell apoptosis was detected by measuring 
caspase 3/7 activity. Data is presented as mean+SEM, n=5-6. Graph represents 
results of one experiment out of three independent experiments. One-Way 
ANOVA with posthoc test Bonferroni **p<0.01. NS = not significant p>0.05. 
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5.4.2 mRNA expression and protein expression of GHSR1a in islets 
and clonal beta cells. 
Following the observation that GHSR1a antagonists could not reverse the 
protective effect of ghrelin observed in islets from female mice, it was explored 
whether Ghsr1a and GHSR1a are present in the groups tested at mRNA and 
protein levels respectively. 
 
 
Figure 5.4.5 The effect of ghrelin and LEAP2 on MIN6 beta cell 
apoptosis. MIN6 beta cells were plated at 15,000 cells/well and pre-treated for 
48 h with or without 100 nM ghrelin ± 100 nM LEAP2 and exposed to 0.5 mM 
palmitate for 20 h ± 100 nM ghrelin ± 100 nM LEAP2. Cell apoptosis was detected 
by measuring caspase 3/7 activity. Data is presented as mean+SEM, n=5. Graph 
represents results of one experiment out of three independent experiments. One-
Way ANOVA with posthoc test Bonferroni ****p<0.0001. NS = not significant 
p>0.05. 
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mRNA expression analysis 
 
First, mRNA expression of Ghsr was assessed in control tissues, hypothalamus 
and fundus of male and female CD-1 mice. Ghsr1a was found to be expressed 
in the hypothalamic tissue in both male and female mice and the level of 
expression was not significantly different between the two groups (p>0.05; 
Fig. 5.4.6) (Table 5.2). However, Ghsr1a was not detected in the fundus of 
male and female mice and the expression of Ghsr1a was only traceable in 
MIN6 cells (Table 5.2). Next, the mRNA expression of Ghsr1a in islets from 
male and female mice was explored and it was also tested whether its 
expression was modified by 48 h exposure to 100 nM ghrelin, similar to the 
experimental conditions used when assessing apoptosis. The Ghsr1a 
expression was determined relative to house-keeping genes and fold change 
was calculated relative to male day 0 control.  The results showed that Ghsr1a 
was expressed at a significantly higher level in islets from female mice 
compared to those from males when compared to Ppia (p<0.05, Fig. 5.4.7A), 
but not Hprt (p>0.05, Fig. 5.4.7B) in control islets at day 3 of culture. Ghsr1a 
mRNA expression remained unchanged in the presence of 100 nM ghrelin 
relative to both house-keeping genes compared to control islets (p>0.05) (Fig. 
5.4.7 and Table 5.3).  
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Table 5.2 Mean Ct values ± SEM of Ghsr1a and housekeeping genes 
in hypothalamic and fundus tissues (n=5)  


















Ghsr1a 24.6±1.2 24.4±0.7 36.2±0.1 ND 29.0±1.4 
Ppia 16.1±0.2 16.2±0.2 18.3±0.6 18.3±0.6 16.2±0.3 
Hprt 19.3±0.3 19.6±0.2 21.8±0.7 22.2±0.7 19.7±0.3 
Figure 5.4.6 Expression of Ghsr1a mRNA in the murine hypothalamus. 
The data represent mean mRNA expression ± SEM of Ghsr1a relative to the 
housekeeping genes Ppia (A) and Hprt (B). Data is presented as mean±SEM, n=5.  
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Table 5.3 Mean Ct values ± SEM of Ghsr1a and housekeeping genes 































Ghsr1a 27.4±0.8 26.0±0.9 26.7±1.1 26.6±0.8 26.1±1.1 26.1±1.1 
Ppia 17.8±0.2 17.4±0.2 17.6±0.2 18.0±0.4 17.6±0.3 17.6±0.3 
Hprt 20.7±0.1 20.6±0.1 20.4±0.0 21.1±0.3 20.3±0.2 20.5±0.2 
Figure 5.4.7 Expression of Ghsr1a mRNA in islets from male and 
female mice. Isolated islets were treated for 48 h as indicated and the mRNA 
expression of Ghsr1a was detected by qPCR. mRNA expression relative to 
housekeeping genes Ppia (A) and Hprt (B) and male day 0 control is shown. Data 
is presented as mean+SEM, n=4. Paired student’s T-test *p=0.02. NS = not 
significant p>0.05. 
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Protein expression studies 
To evaluate more specifically whether the protein expression of GHSR1a was 
different between islets from male and female mice, Western blot analysis was 
performed. Prior to this a pilot study was conducted to assess the expression 
of GHSR1a in control tissues: hypothalamus and fundus of CD-1 mice. 
GHSR1a was expressed in hypothalamic tissue of male and female mice at a 
similar level (p>0.05) (Fig. 5.4.8 A, B and E), however it was not consistently 
detectable in the fundus of both groups (Fig. 5.4.8 C&D). Next it was tested 
whether GHSR1a was detectable in clonal beta cell lines MIN6 and INS-1. 
Both cell lines were found to express GHSR1a and its expression was not 
significantly different between the two cell lines (p>0.05) (Fig. 5.4.9 A-C). As 
shown in Fig. 5.4.7A, gene expression of Ghsr1a was higher in islets from 
female mice under control conditions, therefore the presence of GHSR1a was 
tested in untreated islets maintained in complete medium. GHSR1a was found 
to be present in both groups tested. Although in islets from female mice there 
was a trend towards a higher level of expression of the protein, this was not 
significantly different from the level in islets from male mice (p>0.05) (Fig. 
5.4.10 A-C). Since GHSR1a is almost omnipresent and not many studies have 
shown the detectability of GHSR1a at protein level in islets using Western blot 
due to limited availability of suitable antibodies, leukaemic cell lines THP-1 
(human monocytes), REH (lymphoblasts) and Kasumi-1 (myeloblasts) were 
used as negative controls. GHSR1a was not detected in these cells, however all 
three cell lines expressed beta-actin indicating that the observed expression 
levels of GHSR1a are not due to non-specific binding (Fig. 5.4.11). 
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Figure 5.4.8 Protein expression of GHSR1a in murine hypothalamus 
and fundus of male and female mice. GHSR1a expression was detected in 
hypothalamus of male (A) and female (B) mice but was not consistently detectable 
in the fundus of both groups (C and D). Each lane corresponds to one biological 
sample. Panel E shows mean relative expression levels + SEM of GHSR in 
hypothalamus compared to loading control beta actin (n=3). 20 µg protein was 
loaded per sample and resolved using a 12% polyacrylamide gel. Proteins were 
detected by Western blot. Primary antibodies used: GHSR1a (1 µg/ml) and beta 
actin as loading control (1:8000). Secondary antibodies: Li-Cor IRdye® donkey 
anti-rabbit 680RD and donkey anti-mouse 800CW. Membranes were imaged, and 
band intensities were quantified using Li-Cor Image Studio software. 
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Figure 5.4.9 Protein expression of GHSR1a in two clonal beta cell 
lines. GHSR1a expression was detected in MIN6 (A) and INS-1 (B) cells. Each 
lane corresponds to one biological sample. Panel C shows mean relative expression 
levels + SEM of GHSR compared to loading control beta actin (n=3). 20 µg protein 
was loaded per sample and resolved using a 12% polyacrylamide gel. Proteins were 
detected using Western blot. Primary antibodies used: GHSR1a (1 µg/ml) and 
beta actin as loading control 1:8000. Secondary antibodies: Li-Cor IRdye® donkey 
anti-rabbit 680RD and donkey anti-mouse 800CW. Membranes were imaged, and 
band intensities were quantified using Li-Cor Image Studio software. Unpaired 
Student’s T-test NS = not significant p>0.05. 
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Figure 5.4.10 Protein expression of GHSR1a in islets from male (A) 
and female mice (B). GHSR1a expression was detected in islets from both 
male and female CD-1 mice. Each lane corresponds to one biological sample. 
Panel C shows mean relative expression levels + SEM of GHSR compared to 
loading control beta actin (n=3). 20 µg protein was loaded per sample and 
resolved using a 12% polyacrylamide gel. Proteins were detected using Western 
blot. Primary antibodies used: GHSR1a (1 µg/ml) and beta actin as loading 
control 1:8000. Secondary antibodies: Li-Cor IRdye® donkey anti-rabbit 
680RD and donkey anti-mouse 800CW. Membranes were imaged, and band 
intensities were quantified using Li-Cor Image Studio software. Unpaired 
Student’s T-test NS = not significant p>0.05. 
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5.4.3 The role of GHSR1a on glucose-induced insulin secretion in 
islets. 
As reported above, the Ghsr1a was detected at both mRNA and protein levels 
in MIN6 cells and islets. Since the two GHSR1a antagonists used in this study 
have been characterised for their effects on insulin secretion (YIL781) and 
antagonising orexigenic effects of ghrelin (YIL781 and LEAP2), their effect on 
glucose-induced insulin secretion was assessed in islets from male and female 
mice to evaluate 1) whether ghrelin-independent effects of antagonists are 
seen with regards to insulin secretion and therefore whether potential action 
of endogenous ghrelin can be blocked by the antagonists; 2) whether the 
effects of antagonists vary between males and females with regards to 
secretory function.  
Figure 5.4.11 Protein expression of GHSR1a in three leukaemia cell 
lines. GHSR1a expression was not detected in any of the leukaemia cell lines 
tested as negative control, n=1. 20 µg protein was loaded per sample and resolved 
using a 12% polyacrylamide gel. Proteins were detected using Western blot. 
Primary antibodies used: GHSR1a (1 µg/ml) and beta actin as loading control 
1:8000. Secondary antibodies: Li-Cor IRdye® donkey anti-rabbit 680RD and 
donkey anti-mouse 800CW. Membranes were imaged using Li-Cor Image Studio 
software.  
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As shown in chapter 4, ghrelin did not significantly affect glucose-induced 
insulin secretion in both groups (p>0.05) (Fig. 5.4.12 and 5.4.13). Treatment 
with 5 µM YIL781 alone or in combination with ghrelin also did not 
significantly affect glucose-induced insulin secretion in islets (p>0.05) (Fig. 
5.4.12 A and B). Treatment with 100 nM LEAP2 however resulted in 
significantly greater glucose-induced insulin secretion in islets from male mice 
(p<0.01) (Fig. 5.4.13 B), but not females (p>0.05) (Fig. 5.4.13 A), and this 
effect was significantly reversed in the presence of 100 nM ghrelin in 2/3 
experiments (p<0.05; Fig. 5.4.13 B). In the third experiment the reversal did 
not reach statistical significance (p=0.06)  
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Figure 5.4.12 The effect of ghrelin and GHSR1a antagonist YIL781 on 
insulin secretion in islets from female (A) and male (B) mice. Isolated 
islets were pre-treated with 2 mM glucose for 1 h then treated as indicated for 1 h. 
Secreted insulin was detected by an in-house radioimmunoassay. Data is presented 
as mean+SEM, n=4-6. Each graph represents results of one experiment out of three 
independent experiments. One-Way ANOVA with posthoc test Bonferroni **p<0.01, 
****p<0.0001. NS = not significant p>0.05.  
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Figure 5.4.13 The effect of ghrelin and GHSR1a antagonist LEAP2 on 
insulin secretion in islets from female (A) and male (B) mice. Isolated 
islets were pre-treated with 2 mM glucose for 1h then treated as indicated for 1 
h. Secreted insulin was detected by an in-house radioimmunoassay. Data is 
presented as mean+SEM, n=6. Graph A represents results of one out of two 
independent experiments and graph B of one out of three experiments. One-Way 
ANOVA with posthoc test Bonferroni *p<0.05, **p<0.01. NS = not significant 
p>0.05. 




Based on the findings reported in chapter 4, where treatment with ghrelin 
significantly reduced cytokine-induced apoptosis only in islets from female 
mice as well as lack of effect of ghrelin in MIN6 cells and islets from male mice, 
the role of GHSR1a in mediating the functional effects of ghrelin in these 
tissues was tested. Particular interest was given to the role of GHSR1a in the 
context of sexual dimorphism in islets from male and female mice. 
A number of studies have reported that ghrelin acts via the known ghrelin 
receptor GHSR1a. Kojima et al. (1999) identified ghrelin as the target of the 
orphaned GHSR1a. Dezaki et al. (2004) have reported that simultaneous 
injection of ghrelin and glucose in oral glucose tolerance tests in mice resulted 
in reduced insulin response and increased glucose responses compared to a 
control without ghrelin. Also, the use of two GHSR1a antagonists reversed the 
effects of ghrelin (Dezaki et al., 2004). In addition, in dispersed rat islets 
reduction in glucose-induced insulin secretion by treatment with ghrelin was 
reversed by the addition of the GHSR1a antagonist YIL781 (Esler et al., 2007). 
Furthermore, in mice administered with ghrelin, stimulation of growth 
hormone release was significantly inhibited by the GHSR1a antagonist LEAP2 
(Ge et al., 2018). In the same study LEAP2 also significantly reversed the 
ghrelin-induced increase in food intake in mice. However, some studies have 
suggested that the function of ghrelin may be conveyed via another unknown 
receptor in beta cells (Granata et al., 2007) and in other tissues (Muccioli et 
al., 2007). Therefore, in this study it was assessed whether the protective effect 
of ghrelin observed in islets from female mice was conveyed via the known 
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receptor GHSR1a with the use of two GHSR1a antagonists, YIL781 and 
LEAP2.  
5.5.1 The role of GHSR1a in MIN6 cell and mouse islet apoptosis 
As described in section 5.4.1, both GHSR1a antagonists used in this study did 
not significantly reverse the observed protective effect of ghrelin on cytokine-
induced apoptosis in islets from female mice. Instead, cytokine-induced 
apoptosis was significantly reduced in the presence of YIL781 alone in islets 
from female mice and in MIN6 cells. However, in all groups treatment with 
LEAP2 alone or in combination with ghrelin did not significantly influence 
apoptosis induced by palmitate or cytokines.  
In the study by Ge et al. (2018) where LEAP2 was reported to be a non-
competitive inhibitor of GHSR1a, cells expressing GHSR1a were pre-treated 
with LEAP2 for 30 min prior to addition of ghrelin. Whereas in the current 
study, both compounds were added simultaneously. More recently others have 
reported that LEAP2 could acts as a competitive or non-competitive 
antagonist (Wang et al., 2019) or as an inverse agonist (M’Kadmi et al., 2018) 
depending on the experimental set up. Wang et al. (2019) have found that in 
ligand-receptor binding studies addition of LEAP2 before ghrelin resulted in a 
non-competitive effect of the antagonist whereas simultaneous addition of the 
two compounds resulted in a competitive-type antagonism. It was reported 
that these effects were potentially dependent on the slow dissociation of 
LEAP2 from GHSR1a (Wang et al., 2019) suggesting that subsequent addition 
of ghrelin may be unable to displace the antagonist.  
Furthermore, a recent study identified YIL781 as a partial agonist that only 
activated the G protein subunits Gq and G12 of GHSR1a, therefore resulted in 
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the stimulation of phospholipase C (PLC) (Mende et al., 2018). PLC activates 
PKC that is a regulator of cell survival (Cantley, 2013). Indeed it has been 
previously reported that activation of PLC subunits is fundamental for PKC-
dependent cell survival during oxidative stress (Bai et al., 2002b) and heat-
induced stress (Bai et al., 2002a). It is therefore possible that in the current 
study the reduction in apoptosis following exposure to YIL781 observed in all 
three groups, although not statistically significant in islets from male mice, 
may have been due to the biased activation of GHSR1a by YIL781.  
Taken together the results of section 5.4.1 and the above discussed studies 
suggested that the GHSR1a antagonists are not specific in testing ghrelin’s 
effects on apoptosis, that ghrelin does not act via GHSR1a to exert its action 
on survival, that it acts via an unknown receptor and/or that GHSR1a is not 
present in the tissues tested.  
5.5.2 The expression of GHSR1a in MIN6 cells and islets 
qPCR results confirmed that the Ghsr1a is present at mRNA level in islets as 
has been reported by others (Date et al., 2002), and to a lower extent in the 
clonal beta cell line MIN6. However, in a study by Granata et al. (2007) Ghsr1a 
expression was not detected in the beta cell line HIT-T15 as was also reported 
in single-cell transcriptomic analysis using primary beta cells (Adriaenssens et 
al., 2016; DiGruccio et al., 2016). Furthermore, in the current study it was also 
established that GHSR1a is present at protein level in both islets and the clonal 
beta cell lines tested. Previously, it was only demonstrated with the use of 
immunohistochemical staining and anti-sera that GHSR-like staining was 
detected in primary beta cells and alpha cells (Kageyama et al., 2005) and in 
alpha cells only (Date et al., 2002). Despite GHSR1a being expressed in clonal 
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beta cell lines, no effect of ghrelin was observed on MIN6 cell apoptosis or 
insulin secretion as reported in chapter 4. It is possible that endogenous 
ghrelin may be present in these cells as suggested by Granata et al. (2007) in 
HIT-T15 cells and in primary beta cells as reported by Kageyama et al. (2005), 
and potentially counteract the effect of exogenous ghrelin. Alternatively, it is 
possible that ghrelin does not act via the known receptor GHSR1a in MIN6 
cells. In addition, the expression level of GHSR1a was not significantly 
different between islets from male and female mice. At functional level 
however the pro-survival effect of ghrelin could not be reversed by GHSR1a 
antagonists suggesting ghrelin may exert its effects via an alternative receptor 
or that biological sex influences GHSR1a activity in a manner that is 
independent of its level of expression in the tissue as further explored in 
chapter 6 of this thesis. 
5.5.3 The role of GHSR1a in mouse islet insulin secretory 
responses 
Treatment with YIL781 alone or in combination with ghrelin had no effect on 
glucose-induced insulin secretion in islets from both male and female mice. 
However, based on the earlier described suggestion by Mende et al. (2018) 
that binding of YIL781 to GHSR1a activated PLC-dependent signalling, an 
increase in insulin secretion should have been observed. This is because 
activation of PKC promotes Ca2+ influx and exocytosis of insulin granules from 
beta cells (reviewed by Nesher et al., 2002). The lack of effect of YIL781 on 
insulin secretion in the current study implies either that endogenous ghrelin 
may have influenced its effect or that the antagonist is ineffective in the current 
experimental set up. 
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In contrast, treatment with the novel antagonist LEAP2 significantly increased 
glucose-induced insulin secretion sex-dependently in islets from male mice 
only. It is possible that in this group LEAP2 may have antagonised the action 
of endogenous ghrelin present in islets from male mice as observed in rat islets 
by Dezaki et al. (2004). Alternatively, LEAP2 may have antagonised the 
constitutive activity of the receptor. Indeed GHSR1a belongs to a small group 
of GPCRs that present constitutive activity (Holst et al., 2007) and GHSR1a 
has been shown to present about 50% intrinsic constitutive activity (Damian 
et al., 2011; Veldhuis and Bowers, 2010).  
A recent study by M’Kadmi et al. (2018) has found that LEAP2 displayed the 
characteristics of an inverse agonist and specifically caused reduction in the 
activation of Gq and G13 subunits of GHSR1a. Since LEAP2 antagonises 
GHSR1a, which recently has been found to be expressed exclusively on the 
islet delta cell, the reduction in Gq activation may imply a reduction in SST 
secretion. Consequently, this may have abolished the inhibition of SST on 
insulin secretion with concomitant increase in release resulting in the 
observed elevation in insulin secretion in the presence of LEAP2 in the current 
study. It is, however, unclear why the same effect of LEAP2 was not observed 
in islets from female mice. Since the measurable effect of LEAP2 in islets from 
male mice suggests that ghrelin may exert its action via GHSR1a as previously 
reported (Kojima et al., 1999), it is possible that sex-related differences in islet 
function (as reviewed by Gannon et al., 2018) may have contributed to 
divergent outcomes. Furthermore the insulinotropic effect of LEAP2 was 
significantly reduced in the presence of ghrelin in islets from male mice 
suggesting a competition between the two compounds. Therefore, sex-related 
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differences in the effect of LEAP2 on glucose-induced insulin secretion in islets 
further implies a role for endogenous ghrelin. Further experiments were 
conducted to assess whether potential differences in endogenous ghrelin 
between islets of male and female mice may have played a role in the observed 
differential effects of ghrelin and GHSR1a antagonists and the findings are 
reported in the next chapter of this thesis. 
5.5.5 Summary 
The results presented and discussed in this chapter aimed to elucidate the role 
of GHSR1a in mediating the functional effects of ghrelin in pancreatic islets 
and clonal beta cells. All experiments were conducted using islets from both 
male and female mice to identify the existence of any sex-related differences 
and are summarised in the Table 5.4. GHSR1a is present in mouse islets and 
MIN6 cells, and its expression level was comparable in islets from both sexes. 
GHSR1a antagonists however could not reverse the pro-survival effect of 
ghrelin in islets from female mice. Studies conducted in MIN6 cells indicated 
that a direct effect of ghrelin on beta cells was not evident despite GHSR1a 
being expressed in these cells. This may imply that endogenous ghrelin present 
within these cells may have influenced the activity of exogenous ghrelin. 
Indeed in islets from male mice the insulinotropic effect of GHSR1a antagonist 
LEAP2 indicated that the antagonist may have reversed the effect of 
endogenous ghrelin. Taken together these results indicate that the effect of 
ghrelin on islet function and survival are governed by sex related differences 
that may be both dependent and independent of GHSR1a. 
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Table 5.4 Sex-specific effects of GHSR1a-dependent factors tested 










Effect or feature Sex-specific differences 
The effect of YIL781 on islet apoptosis Reduced apoptosis in islets from female 
mice but no effect in islets from male 
mice. 
The effect of LEAP2 on islet apoptosis No overall difference in apoptosis in 
both groups 
Ghsr1a mRNA expression Increased level of expression in islets 
from female mice when expressed 
relative to Ppia, but not relative to Hprt. 
Treatment with ghrelin did not affect 
Ghsr1a expression in both groups. 
GHSR1a expression No overall difference in expression 
between both groups 
The effect of YIL781 on islet insulin 
secretory responses 
No difference in glucose-induced insulin 
secretion in both groups 
The effect of LEAP2 on islet insulin 
secretory responses 
Increased insulin secretion in islets 
from male mice that was reversed by 
exposure to ghrelin. No effect on islets 
from female mice. 
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6.1 Introduction 
6.1.1 Expression of ghrelin in the islet 
The 28 amino acid peptide ghrelin is expressed in the pancreatic islets of 
Langerhans (Volante et al., 2002). However its localisation within specific islet 
cell types remains controversial. In 2002 Wierup et al. identified a novel cell 
type, pancreatic epsilon cells, as the ghrelin producing cells in the islets. Others 
have reported that ghrelin-like immunoreactivity was detected in beta cells in 
rat islets (Kageyama et al., 2005), and strong ghrelin immunoreactivity was 
observed in beta cells in human islets (Volante et al., 2002). However, Date et 
al. (2002) have found ghrelin to be expressed in alpha cells of human and rat 
pancreatic islets as confirmed by Dezaki et al. (2004) using rat pancreatic 
islets. The number of ghrelin expressing cells has been found to be higher in 
the human foetal pancreatic islets compared to those in the adults, suggesting 
that islet-derived ghrelin may play a greater role during pancreatic 
development (Wierup et al., 2002). It is possible that the reported 
differentiation of epsilon cells, predominantly into alpha and PP cells in 
mature islets may have contributed to the reduced number of epsilon cells in 
adult pancreatic islets (Arnes et al., 2012). These studies suggest that ghrelin 
is expressed endogenously in a number of pancreatic islet cell types and that 
endogenous pancreatic ghrelin therefore may play a role in regulating islet 
function. Indeed, a study by Dezaki et al. (2004) revealed that in the presence 
of two GHSR1a antagonists, insulin secretion was significantly higher at 5.6 
mM glucose in isolated rat islets. The same effect was observed in the presence 
of anti-serum against ghrelin (Dezaki et al., 2004) suggesting that endogenous 
ghrelin negatively affects insulin secretion. The results reported in chapter 4 
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of this thesis have shown that islets from female mice respond differently to 
treatment with ghrelin compared to the ones from males. It is necessary to 
ascertain whether this sex difference in sensitivity to ghrelin is linked to a 
differential islet-specific production or release of the hormone between the 
two groups.  
6.1.2 Interaction between ghrelin, oestradiol and their receptors 
As discussed in chapter 4, ghrelin displays sexual dimorphism in its orexigenic 
activity and plasma levels in rodents and humans. However, whole-body 
observations cannot always be reproducible in vitro  where cell models are 
used as introduced in section 1.4. Nonetheless our findings indicate that 
ghrelin significantly reduced cytokine-induced apoptosis only in islets from 
female mice suggesting that the action of ghrelin may be modulated directly or 
indirectly by oestrogen, thus potentially rendering islets from female mice 
more sensitive to a protective effect of ghrelin. 
A number of studies point towards a potential mechanistic interaction 
between oestradiol (E2) and ghrelin (Sakata et al., 2006). In the stomachs of 
both male and female rats gastric oestrogen was found to increase production 
and expression of ghrelin (Sakata et al., 2006), whereas administration of E2 
suppressed orexigenic effects of ghrelin observed in male and OVX female rats 
(Clegg et al., 2007).  There are contrasting reports on the effect of E2 on 
circulating ghrelin levels in humans with one study reporting that E2 
replacement therapy in postmenopausal women resulted in increased levels of 
plasma ghrelin (Kellokoski et al., 2005), however another study by Dafopoulus 
et al. (2010) reported that the treatment with E2 in both pre- and 
postmenopausal women had no effect on plasma ghrelin levels. Taken together 
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these studies suggest that E2 modulates the expression and/or action of 
ghrelin in a tissue or species-specific manner. It has not, however, been 
explored whether this interaction exists in pancreatic islets and what 
implications this might have on beta cell function. 
 Oestrogen acts via three receptors: oestrogen receptor alpha (ERα or ESR1), 
beta (ERβ or ESR2) and a G-protein coupled receptor (GPER) (Geisler et al., 
2002; Nadal et al., 2000). In the hypothalamus of OVX mice both ghrelin 
receptor (GHSR1a) and ERs have been reported to be co-expressed and 
treatment with E2 resulted in significantly greater increase in expression of 
Ghsr1a mRNA in arcuate nucleus (Frazao et al., 2014).  
The results presented in chapter 5 however suggested that overall there was 
no significant difference in GHSR1a expression in islets of male and female 
mice. This implies that chronic exposure to E2 may not have resulted in a 
measurable change in GHSR1a expression in islets from female mice. It is 
however possible that differences in ER expression may have indirect effects 
on the action of ghrelin. Based on the above factors it was investigated whether 
there are underlying sex-specific differences in mRNA expression of ERs and 
if treatment with ghrelin modified their expression patterns. Secondly, it was 
assessed whether the presence of E2 could in the first instance modify the 
effect of ghrelin on clonal beta cell apoptosis. 
6.1.3 Interaction between somatostatin and ghrelin  
As reported in the previous chapters, several studies have suggested that 
somatostatin and ghrelin interact in the regulation of their plasma levels 
(Arosio et al., 2003; Luque and Kineman, 2007), actions on growth hormone 
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release (Wagner et al., 2009) and insulin secretion (Adriaenssens et al., 2016; 
DiGruccio et al., 2016).  
The lack of effect of ghrelin on MIN6 beta cell function, despite GHSR1a being 
expressed in these cells, confirmed this possibility. However, the pro-survival 
effect of ghrelin being limited to islets from female mice implied that ghrelin’s 
functional effects on beta cells may not only be indirect via the action of SST 
released by delta cells, but that it is also sex specific. Nevertheless, the 
expression of GHSR1a was not found to be different between islets from male 
and female mice. This suggests that should the effect of ghrelin be dependent 
on the action of SST, then sex-specific differences in islet SST receptor 
expression or SST levels may mediate its actions. Therefore, as part of this 
chapter it was explored whether Sstr3 mRNA expression displayed sex-
specific differences in mouse islets and whether it was modified by treatment 
with ghrelin. Next it was tested whether antagonising SSTR3 could modify the 
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6.2 Aims and objectives 
6.2.1 To assess mRNA expression and endogenous ghrelin content in mouse 
islets and MIN6 cells. 
6.2.2 To investigate the interaction between E2 and ghrelin in beta cells and 
islets with particular focus on: 
• The effect of ghrelin on sex-specific expression of oestrogen receptors 
in islets. 
•  The effect of oestradiol on the functional role of ghrelin in MIN6 cell 
apoptosis. 
6.2.3 To determine sex-specific expression of SSTR3, and whether the 
functional effects of ghrelin in murine islets are mediated by this receptor.




6.3.1 Gene expression analysis 
RNA extraction, cDNA reverse transcription and qPCR were performed as 
described in section 2.7 with the use of primers for house-keeping genes 
(section 2.7.3), Ghrelin (kindly provided by Dr Simone Nascimento, Table 
6.1), oestrogen receptor-1 (Esr1) and oestrogen receptor-2 (Esr2) purchased 
from Sigma (KiqStart primers), and Sstr3 (Table 3.1). Gene expression was 
determined relative to the house-keeping genes Ppia and Hprt 
Table 6.1 Ghrelin primers 
 
 
6.3.2 Static incubation experiments for assessment of ghrelin 
secretion 
Islet ghrelin secretion was assessed as described in 2.4.2 in response to 
treatment with 11 mM glucose and 2 mM glucose with or without 10 µM 
noradrenaline (NA) +100 µM ascorbic acid. Samples were diluted 1:4 for 
detection of total ghrelin and used neat for acyl-ghrelin, and their 
concentrations were measured by radioimmunoassay as described in section 
2.4.4.2.  
Gene Primer sequence (5’-3’) PCR 
product 
(bp) 
T annealing  
(°C) 
Ghrelin FW: GCTGTCTTCAGGCACCATCT 
RV: TTCTCTGCTGGGCTTTCTGG 
113 60 
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6.3.3 Detection of endogenous ghrelin content in MIN6 cells and 
tissue 
Cell pellets and tissue samples were prepared as described in 2.4.3 and 
incubated in 0.5 M acetic acid for 15 min at 100 °C. Following cooling down, 
the samples were stored at -80 °C and assayed as described in 2.4.4.2. 
6.3.4 Clonal beta cell apoptosis 
Prior to experiments MIN6 cells grown in T75 flasks were washed once with 
PBS and incubated for three days in phenol red-free DMEM supplemented 
with 10% charcoal-stripped FBS, 6 mM L-glutamine and penicillin (100 
U/ml)/ streptomycin (0.1 mg/ml). FBS contains other hormones including 
oestrogens (Cao et al., 2009). Therefore, to investigate the effect of 
exogenously added oestradiol (E2) it is necessary to use a serum that does not 
contain any additional amounts of the hormone. Charcoal stripping uses 
activated charcoal that removes lipophilic substances such as viruses and 
hormones by binding to them (De Faria et al., 2016). In addition, phenol red 
has a similar structure to oestrogens, therefore can bind oestrogen receptors 
(De Faria et al., 2016). This can be prevented by using a phenol red-free 
medium. Hence in the current study phenol red-free medium supplemented 
with charcoal-stripped FBS was used. Furthermore, to ensure that any effect 
of oestrogens present in normal culture medium is neutralised, the cells were 
pre-incubated for three days with the modified medium as reported by others 
(Weinstein-Oppenheimer et al., 2002).  
Assessment of MIN6 cell apoptosis was performed by measurement of caspase 
3/7 activity as described in 2.6.1. Briefly, 15,000 cell/well were seeded in 
white-walled 96 well plates. Cells were pre-treated with or without 10 or 100 
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nM ghrelin ± 100 nM E2 in DMEM for 48 h with refreshment of treatment 
after 24 h. Following exposure to 0.5 mM palmitate for 20 h with or without 
10 or 100 nM ghrelin ± 100 nM E2, Caspase-Glo assay was performed as 
described in 2.6.1. 
6.3.5 Static incubation experiments for assessment of insulin 
secretion from mouse islets  
Islet insulin secretion was assessed as described in 2.4.2 in response to 
treatment with 2 mM glucose and 20 mM glucose with or without 100 nM 
ghrelin or 1 µM SST ± 1 µM MK4256. All samples were diluted to 
concentrations detectable within the range of the standard curve and the 
concentration of insulin was measured by radioimmunoassay as described in 


















6.4.1 Determination of ghrelin content in islets and MIN6 cells 
Based on the reports that ghrelin in addition to epsilon cells is present in other 
islet cells including beta and alpha cells, and endogenous ghrelin influenced 
insulin secretion in rat islets (Dezaki et al., 2004), it was hypothesised that 
endogenous ghrelin may play a role in the differential effect of exogenous 
ghrelin in islets from male and female mice as well as MIN6 cells. mRNA 
expression of Ghrelin was detected by qPCR. An in-house radioimmunoassay 
to detect both acylated and total ghrelin in the tissues of interest was set up by 
Dr M. Patterson. 
6.4.1.1 mRNA expression studies 
First the mRNA expression levels of Ghrelin were detected in MIN6 cells as 
well as in fundus, hypothalamus and islets from male and female mice. Ghrelin 
mRNA was traceable in MIN6 cells (Table 6.2). Its expression was highest in 
the fundus of both male and female mice (Fig. 6.4.1; Table 6.2). The mRNA 
levels of Ghrelin however did not significantly differ between fundus, 
hypothalamus (Fig. 6.4.1) and islets (Fig. 6.4.2; Table 6.3) from both sexes 
(p>0.05). 
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Table 6.2 Mean Ct values ± SEM of Ghrelin and housekeeping genes 












Ghrelin 22.9±1.4 20.6±1.7 26.6±0.7 26.8±0.2 29.5±0.6 
Ppia 18.3±0.6 18.3±0.6 16.1±0.2 16.2±0.2 16.2±0.3 
Hprt 21.8±0.7 22.2±0.7 19.3±0.3 19.6±0.2 19.7±0.3 
Figure 6.4.1 Expression of Ghrelin mRNA in the murine hypothalamus 
and fundus. The data represent mean mRNA expression of Ghrelin relative to the 
housekeeping genes Ppia (A, C) and Hprt (B, D) in hypothalamus (A and B) and 
fundus (C and D) of male and female CD-1 mice. Data is presented as mean+SEM, 
n=5. 
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Table 6.3 Mean Ct values ± SEM of Ghrelin and housekeeping genes 








6.4.1.2 Detection of secreted and endogenous ghrelin 
Static incubation experiments where islets were treated with 11 mM, 2 mM 
glucose and 2 mM glucose + 10 µM NA + 100 µM ascorbic acid for 1 h were 
first conducted and supernatants were analysed by radioimmunoassay. It was 
not possible to detect basal (11 mM glucose) or stimulated (2 mM glucose ± 
NA) release of either acyl-ghrelin or total ghrelin in the islet supernatants. 
These results were confirmed by enzyme-linked immunosorbent assay 
(ELISA, assessed by Dr M. Patterson, data not shown). In contrast, both total 
 
Islets males Islets females 
Ghrelin 28.8±0.3 29.0±0.9 
Ppia 17.4±0.2 17.6±0.3 
Hprt 20.6±0.1 20.3±0.2 
Figure 6.4.2 Expression of Ghrelin mRNA in islets from male and 
female mice. The data represent mRNA expression of Ghrelin relative to the 
housekeeping genes Ppia (A) and Hprt (B) in islets of male and female CD-1 mice. 
Data is presented as mean+SEM, n=4. 
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and acyl-ghrelin were detected in stomach samples, which were used as 
positive controls (data not shown). 
Next, it was tested whether the islet content of ghrelin differed between male 
and female mice. In islets from female mice a significantly higher level of total 
ghrelin was detected compared to islets from male mice (p<0.01; Fig. 6.4.3A). 
The concentration of acyl-ghrelin did not differ significantly between the two 
groups (Fig. 6.4.3B). Since Ghrelin mRNA was detected in MIN6 cells it was 
tested whether ghrelin was detectable in these cells using RIA. Both total and 
acyl-ghrelin were detected in MIN6 cells confirming findings of qPCR 
experiments (acyl-ghrelin: 130±12 pmol/4x106 cells and total ghrelin: 






Figure 6.4.3 Endogenous total ghrelin (A) and acyl-ghrelin (B) content in 
mouse islets. Following the ghrelin secretion experiment, islets were pelleted, 
washed and lysed in 0.5 M acetic acid. Ghrelin content was assayed by an in-house 
radioimmunoassay. Data is presented as mean+SEM, n=3, one experiment. 
Unpaired Student’s T-test **p<0.01. NS = not significant p>0.05. 
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6.4.2 The sex-specific expression of islet ERs, and the effect of 
interaction between E2 and ghrelin on clonal beta cell survival 
6.4.2.1 Sex-specific expression of Esr1 and Esr2 in the mouse islet 
The expression of Esr1 and Esr2 was detected by qPCR. Hypothalamic 
expression was tested as positive control and it was found that the expression 
of both receptor subtypes in the hypothalamus was not significantly different 
between the two groups (p>0.05; Fig. 6.4.4; Table 6.4).  
 
Figure 6.4.4 mRNA expression of oestrogen receptors in 
hypothalamus of male and female mice. The data represent mRNA 
expression of Esr1 (A and B) and Esr2 (C and D) relative to the housekeeping 
genes Ppia (A, C) and Hprt (B, D) in hypothalamus of male and female CD-1 mice. 
Data is presented as mean+SEM, n=4-5.  
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Table 6.4 Mean Ct values ± SEM of Esr1 and Esr2 and housekeeping 
genes in mouse hypothalamic tissue (n=4-5) 
 
 
Next, the expression of Esr1 and Esr2 was assessed in islets from male and 
female mice in the presence and absence of 100 nM ghrelin. Only Esr1 and not 
Esr2 was detectable in islets from both groups and its expression was not 
different between male and female mice (p>0.05). Esr1 mRNA expression was 
not significantly influenced by 48 h exposure to 100 nM ghrelin (p>0.05) (Fig. 







Hypothalamus males Hypothalamus 
females 
Esr1 25.7±0.5 27.4±0.9 
Esr2 26.2±1.3 25.3±0.3 
Ppia 15.9±0.1 16.2±0.2 
Hprt 19.1±0.2 19.6±0.2 
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Table 6.5 Mean Ct values ± SEM of Esr1 and Esr2 and housekeeping 





























Esr1 30.2±1.0 30.1±0.6 30.0±0.5 29.4±0.5 30.0±0.3 29.8±0.4 
Esr2 33.1±0.2 32.8±0.6 32.5±0.6 33.9±0.2 33.5±0.4 32.7±0.7 
Ppia 17.9±0.3 17.6±0.3 17.6±0.3 18.0±0.5 17.6±0.4 17.6±0.4 
Hprt 20.7±0.3 20.6±0.2 20.4±0.1 21.1±0.4 20.2±0.1 20.3±0.4 
Figure 6.4.5 mRNA expression of Esr1 in islets from male and 
female mice. Isolated islets were treated for 48 h as indicated and the mRNA 
expression of Esr1 and Esr2 was detected by qPCR. Esr1 mRNA expression 
relative to housekeeping genes Ppia (A) and Hprt (B) and male day 0 control 
is shown. Data is presented as mean+SEM, n=3. Esr2 was not detected in 
islets. 
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6.4.2.2 Effect of E2 and ghrelin on MIN6 cell apoptosis 
 In order to test whether treatment with oestrogen could modify the MIN6 cell 
survival responses to treatment with ghrelin, preliminary cell apoptosis 
experiments were conducted as described in 6.3.4. Treatment with 10 or 100 
nM ghrelin or 100 nM E2 alone did not significantly affect palmitate-induced 
apoptosis in MIN6 cells (p>0.05, Fig. 6.4.6). Prolonged exposure of MIN6 cells 
to 100 nM E2 did not modify the lack of effect of ghrelin on MIN6 cell survival 
(p>0.05, Fig. 6.4.6). 
 
Taken together these results suggest that the expression of Esr1 in islets is 
neither influenced by biological sex in mice nor is it modified by treatment 
Figure 6.4.6 The effect of ghrelin and E2 on MIN6 cell apoptosis. MIN6 
beta cells were plated at 15,000 cells/well and pre-treated for 48 h with or without 
10 or 100 nM ghrelin ± 100 nM E2, and exposed to 0.5 mM palmitate ± ghrelin ± 
100 nM E2 for 20 h. Apoptosis was detected by measurement of caspase 3/7 activity. 
Data is presented as mean+SEM, n=5. Graph represents results of one experiment 
out of two independent experiments.  
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with ghrelin in MIN6 cells. Furthermore, prolonged incubation with E2 alone 
does not affect beta cell apoptosis induced by palmitate, and E2 does not 
directly modify the effect of ghrelin on clonal beta cell apoptosis under these 
conditions.  
 
6.4.3 SSTR3 as mediator of functional effects of ghrelin in murine 
islets 
6.4.3.1 Sex-specific expression of Sstr3 in mouse islets 
The mRNA expression of SStr3 in islets from male and female mice was 
detected by qPCR at day 0 and following incubation with or without ghrelin 
for 48 h. Prior to the experiments using islets, mRNA expression of Sstr3 was 
detected in the hypothalamus of male and female mice as a positive control, 
where SSTR3 was reported to be moderately distributed (Kumar, 2007; 
Kumar, 2012). Sstr3 expression in the hypothalamic tissue was not 
significantly different between males and females (p>0.05; Fig. 6.4.7; Table 
6.6). Likewise, Sstr3 mRNA expression was similar in islets from male and 
female mice after 48 h in culture, and no significant change was observed 
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Table 6.6 Mean Ct values ± SEM of Sstr3 and housekeeping genes 












Sstr3 25.1±0.4 25.5±0.4 
Ppia 16.1±0.2 16.2±0.2 
Hprt 19.2±0.4 19.4±0.1 
Figure 6.4.7 mRNA expression of Sstr3 in hypothalamus of male and 
female mice. The data represent mRNA expression of Sstr3 relative to the 
housekeeping genes Ppia (A) and Hprt (B) in hypothalamus of male and female 
CD-1 mice. Data is presented as mean ±SEM, n=4.  
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Table 6.7 Mean Ct values of ± SEM Sstr3 and housekeeping genes 
in mouse islets (n=3) 
 


























Sstr3 21.8±0.4 21.9±0.5 21.8±0.4 22.1±0.5 21.9±0.3 22.2±0.4 
Ppia 17.9±0.3 17.5±0.3 17.7±0.2 18.1±0.5 17.6±0.4 17.7±0.4 
Hprt 20.8±0.0 20.7±0.1 20.4±0.0 21.3±0.2 20.4±0.2 20.7±0.2 
Figure 6.4.8 mRNA expression of Sstr3 in islets from male and female 
mice. Isolated islets were treated for 48 h as indicated and the mRNA expression 
of Sstr3 was detected by qPCR. Sstr3 mRNA expression relative to housekeeping 
genes Ppia (A) and Hprt (B) and male Day 0 control is shown. Data is presented 
as mean+SEM, n=3. 
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6.4.3.2 The effect of ghrelin and SSTR3 antagonist MK4256 on islet secretory 
responses 
Treatment with 1 µM MK4256 on its own significantly increased glucose-
induced insulin secretion in islets from male (p<0.05 vs 20 mM; Fig. 6.4.9B; 
p<0.001 vs 20 mM Fig. 6.4.11B), but not female mice (p>0.05 vs 20 mM; Fig. 
6.4.9A). As also reported in chapter 4, incubation with ghrelin did not 
significantly reduce glucose-induced insulin secretion in both groups 
(p>0.05). This effect was not significantly altered in the presence of 1 µM 
MK4256 in islets from male mice in 2/3 experiments (p>0.05; Fig. 6.4.9B), 
but a significant increase in insulin secretion was observed in islets from 
female mice co-treated with 100 nM ghrelin + 1 µM MK4256 (p<0.05; Fig. 
6.4.9A). However, the effect of antagonist alone was not significantly altered 
in the presence of ghrelin in both groups (p>0.05). Since MK4256 was 
developed against SST, it was also tested whether the action of SST on glucose-
induced insulin secretion from islets could be modified in the presence of 
MK4256. As previously reported (Hauge-Evans et al., 2009; Hauge-Evans et 
al., 2015) addition of 1 µM SST did not significantly affect insulin secretion 
from isolated islets. However, co-treatment of SST with 1 µM MK4256 caused 
a significant increase in glucose-induced insulin secretion in islets from female 
mice compared to SST alone (p<0.01; Fig. 6.4.10). Similarly, in 2/3 
experiments conducted utilising islets from male mice, incubation with 1 µM 
MK4256 + 1 µM SST significantly increased glucose induced-insulin secretion 
compared to SST alone (p<0.01; Fig. 6.4.11B). However, overall the effect of 
antagonist alone was not significantly altered in the presence of SST in islets 
from both sexes (p>0.05). 
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Taken together these results suggest that islets from male and female mice 
express Sstr3 mRNA at a similar level, and that treatment with ghrelin does 
not alter its expression at transcriptional level. However, results from insulin-
secretion experiments imply that SSTR3 is involved at least in part in 
mediating an insulinostatic effect of SST as also observed with MIN6 cells in 
chapter 3.  
  
 Chapter 6 - Results 
 201   
 
 
Figure 6.4.9 The effect of ghrelin and SSTR3 antagonist MK4256 on 
insulin secretion in islets from female (A) and male (B) mice. Isolated 
islets were pre-treated with 2 mM glucose for 1 h then treated as indicated for 1 h. 
Secreted insulin was detected by an in-house radioimmunoassay. Data is 
presented as mean+SEM, n=3-6. Graph A represents results of one out of two 
independent experiments and graph B of one out of three experiments. One-Way 
ANOVA with Bonferroni posthoc test *p<0.05. NS = not significant p>0.05. 
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Figure 6.4.10 The effect of SST and SSTR3 antagonist MK4256 on 
insulin secretion in islets from female mice. Isolated islets were pre-
treated with 2 mM glucose for 1 h then treated as indicated for 1 h. Secreted 
insulin was detected by an in-house radioimmunoassay. Data is presented as 
mean+SEM, n=4-6. Graph represents results of one experiment out of two 
independent experiments. One-Way ANOVA with posthoc test Bonferroni 
**p<0.01.  NS = not significant p>0.05. 
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Figure 6.4.11 The effect of SST and SSTR3 antagonist MK4256 on 
insulin secretion in islets from male mice (A and B). Isolated islets were 
pre-treated with 2 mM glucose for 1 h then treated as indicated for 1 h. Secreted 
insulin was detected by an in-house radioimmunoassay. Data is presented as 
mean+SEM, n=3-6. Graph A represents results of one out of two independent 
experiments and graph B of one out of three experiments. One-Way ANOVA 
with posthoc test Bonferroni **p<0.05, **p<0.01, ***p<0.001.  NS = not 
significant p>0.05. 
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6.5 Discussion 
Following on from the findings in chapter 5 where it was established that sex-
specific expression of GHSR1a did not appear to mediate the effect of ghrelin 
on islet apoptosis, other potential factors influencing ghrelin’s functional 
effects on beta cells and islets were explored. These included the presence of 
endogenous ghrelin, interaction between ghrelin, oestradiol and oestrogen 
receptors, and sex-specific modulation of SST receptor 3 and its role in 
mediating the functional effects of ghrelin in mouse islets. 
6.5.1 Detection of endogenous ghrelin in MIN6 cells and mouse 
islets 
Molecular biology analysis showed that Ghrelin mRNA was present in all 
tissues tested with the level being traceable in MIN6 cells. Ghrelin was 
reported to be present also in the clonal beta cell line HIT-T15 (Granata et al., 
2007). The expression of Ghrelin did not differ between male and female mice 
in all tissues tested. Since when studying functional effects of a protein it is 
important to detect its expression at protein level, an in-house 
radioimmunoassay was set up.  
As described in 6.4.1.2 secreted ghrelin could not be detected using this assay 
or a commercially available ELISA. Very few have reported the detectability of 
secreted ghrelin from the pancreas, instead most studies reported the presence 
of endogenous ghrelin content in the pancreas (Date et al., 2002) and in 
isolated rat islets (Dezaki et al., 2004). Similarly, in the current study 
endogenous ghrelin was detected in islets and MIN6 cells. Acyl-ghrelin levels 
did not differ between islets from male and female mice, whereas surprisingly 
total ghrelin was significantly higher in islets from female mice. This result was 
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unexpected, because it was hypothesised that a higher level of endogenous 
ghrelin would be present in islets from male mice where exogenous ghrelin 
had no significant effect, but the GHSR1a antagonist LEAP2 did, as reported 
in 5.4.3. However, it is important to highlight that the ghrelin 
radioimmunoassay data is preliminary and further experiments are required 
to ascertain whether a true difference exists in endogenous ghrelin content 
between the islets from male and female mice.  
The detectability of ghrelin at protein level in the islets, albeit at a lower level 
than in circulation (Erdmann et al., 2004), implies that pancreatic ghrelin may 
play a role locally within the islet. Indeed it was previously reported that 
glucose-induced insulin secretion was enhanced by pharmacologically 
blocking GHSR1a activity, and by neutralising endogenous ghrelin using anti-
ghrelin antiserum in perfused rat pancreata (Dezaki et al., 2006). However, as 
described in 6.1.1, in foetal islets the number of ghrelin producing cells was 
found to be higher compared to those in the adult islets, suggesting that the 
islet-derived ghrelin may play a greater role during pancreatic development 
(Wierup et al., 2002). In contrast, others have reported that normal pancreatic 
development progressed in Ghrelin-/- mice, implying that ghrelin was not 
required for this process (Hill et al., 2009). However, it has been reported that 
the presence of ghrelin is necessary for the embryonic development of the 
whole animal (Luque et al., 2014). A recent publication showed that glucose-
induced insulin secretion did not differ in islets from both global ghrelin null 
and Ghrelin+/+ male and female mice (Gray et al., 2019). In both genotypes 
insulin secretion was equally increased in response to other stimuli such as 
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glucagon-like peptide 1 (GLP-1) and alanine (Gray et al., 2019), suggesting 
that endogenous ghrelin may not play a role in glucose homeostasis.  
Nevertheless, as reported in the previous chapter, we observed an 
insulinotropic effect of LEAP2 in islets from male mice, which suggests the 
presence of some underlying activity of endogenous ghrelin. However, it 
cannot be dismissed that the observed effect of LEAP2 may have been related 
to the inhibition of the constitutive activity of the GHSR1a as mentioned in 
5.5.3. 
6.5.2 The sex-specific expression of islet ERs, and the effect of 
interaction between E2 and ghrelin on clonal beta cell survival 
As reported in chapter 4, a sex-specific difference in response to cytokine-
induced apoptosis was observed in islets from female mice. It was therefore 
hypothesized that prolonged exposure to oestrogen may have resulted in the 
sex-specific outcome. The subsequent experiments described in chapter 5 and 
in section 6.4.1 showed that chronic exposure to E2 in females did not have a 
measurable impact on GHSR1a expression and islet ghrelin content. However, 
it is possible that differences in islet ER expression levels between the two 
sexes may have indirectly affected the action of ghrelin. 
It has been shown that ER receptor expression differs in male and female rats 
in a number of tissues such as kidney and gonads (Hutson et al., 2019), and 
that the presence of E2 regulates islet cell secretory function and survival in a 
sex-dependent manner (as reviewed by Gannon et al., 2018). However, to my 
knowledge there have been no reports of sex differences in the expression of 
ERs in islets. Furthermore, a potential modulation of ERs by ghrelin itself 
cannot be overlooked. Hence the mRNA expression of ERs was tested in islets 
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from male and female mice, including whether islet ER expression was 
modified by the presence of ghrelin. As illustrated in 6.4.2.1, Esr1 mRNA 
expression did not differ between islets from male and female mice and it 
remained unchanged following treatment with ghrelin. In contrast to studies 
by Alonso-Magdalena et al. (2008) and Nadal et al. (2000) it was not possible 
to detect Esr2 mRNA in the pancreatic islets, however it was detected in the 
hypothalamic tissues.  
Previously, E2 has been shown to promote beta cell survival (Kooptiwut et al., 
2018; Le May et al., 2006), and a number of studies have reported the 
influence of E2 on ghrelin levels (Choi et al., 2017; Clegg et al., 2007). 
Therefore, preliminary studies were performed to test whether incubation 
with E2 could modify the effect of ghrelin on MIN6 cell apoptosis. Unlike the 
findings in the literature, treatment with E2 did not significantly affect 
palmitate-induced apoptosis in MIN6 cells. Furthermore, co-treatment with 
E2 did not alter the lack of effect of ghrelin on palmitate-induced apoptosis in 
MIN6 cells, implying a lack of interaction between the two hormones in 
regulating clonal beta cell apoptosis. Alternatively, longer incubation with E2 
may be needed. However, the overall incubation time of the current study with 
E2 of three days is in accordance with the duration of treatment used by others 
(Kooptiwut et al., 2018; Le May et al., 2006). 
Therefore, these results suggest that ghrelin does not modify the gene 
expression of Esr1 in islets; and the preliminary results on MIN6 cell apoptosis 
suggest that E2 does not modify the functional effects of ghrelin in clonal beta 
cells. However, further experiments are required to ascertain the functional 
effect of interaction between ghrelin, E2 and ERs. One approach would be to 
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use islets from OVX female mice where any influence of oestradiol would have 
been abolished, to assess the effects of ghrelin on cytokine-induced apoptosis 
and Esr1 expression. Another method would be to administer ER antagonists 
such as ESR1-selective antagonist methyl-piperidino-pyrazole (MPP) in vivo 
to female mice and to test whether action of ghrelin is modified in isolated 
islets. Alternatively, the antagonist could be added to islets from female mice 
in vitro to assess whether any effect of ghrelin is blocked.  It is also possible to 
expose islets isolated from male mice to E2 for a prolonged period prior to 
incubation with ghrelin. However, since islets can be kept in culture for a 
limited time only, this will need to be considered during experimental set-up. 
These experiments were beyond the scope of the current project therefore are 
considered part of future work.  
6.5.3 SSTR3 as mediator of functional effects of ghrelin in murine 
islets 
Numerous studies have reported that somatostatin and ghrelin interact in a 
number of tissues including in the regulation of pancreatic insulin release as 
described throughout this thesis. In chapter 3 it was elucidated that the 
insulinostatic effect of SST is mediated in part via SSTR3, which recent reports 
have indicated to be the only SST receptor subtype expressed in beta cells 
(Adriaenssens et al., 2016; DiGruccio et al., 2016). However, it was not 
possible to clearly detect SSTR3 expression in islets at protein level by Western 
blot as reported in 3.4.2.2.  The findings of investigations into the effect of 
ghrelin on MIN6 cells and mouse islet function have suggested that ghrelin 
may act in an indirect and sex-dependent manner to modulate beta cell 
function. However, it was established that this was independent of sex-specific 
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differences in GHSR1a or Esr1 expression. In addition, a significant effect of 
ghrelin was observed on cytokine-induced apoptosis in islets from female mice 
only. However, if the effect of ghrelin were to be indirect via its action on the 
delta cell then it would be expected that the same effect would have been 
detected in islets from male mice, since GHSR1a expression was not different 
between the two groups. Thus, it was hypothesized that there may be sex-
specific differences in the expression of SSTR3 that could be modulated by the 
presence of ghrelin. In islets from both male and female mice the levels of 
Sstr3 expression were not different and they remained unchanged following 
treatment with ghrelin, further confirming the lack of interaction between 
ghrelin and SSTR3 at a transcriptional level in the current experimental 
setting. This however does not discount that sex-dependent differences in 
expression of SSTR3 may exist at protein level. However as mentioned above 
it was not possible to clearly detect its expression by Western blot. Therefore, 
further experiments using immunohistochemical staining of islet tissues may 
not only facilitate in identifying sex-specific differences in SSTR3 expression, 
but also its localisation within specific islet cell types. Although others have 
shown the detection of SSTR3 expression by immunohistochemistry in islets, 
no sex-specific comparison of SSTR3 expression in islets from male and female 
mice has been reported (Ludvigsen et al., 2004; Somvanshi et al., 2018). 
The above results therefore indicate that Sstr3 expression is neither sex-
dependent nor modified by ghrelin. In addition, the findings in 3.5.2 suggested 
that SSTR3 appeared to be partially involved in mediating insulin secretion 
but not apoptosis in MIN6 beta cells. Furthermore, a sex-dependent difference 
in insulin-secretory responses was observed for male mice following 
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incubation with GHSR1a antagonist LEAP2 in 5.4.3. Based on these findings, 
and the fact that MK4256 has previously been reported to alter blood glucose 
levels during OGTT (He et al., 2012), it was tested whether antagonism of 
SSTR3 would modify potential effects of ghrelin on islet insulin secretory 
responses.  
Results described in 6.4.3.2 indicated that treatment with 1 µM MK4256 alone 
increased secretion in islets from male but not from female mice. However, co-
treatment with ghrelin and 1 µM MK4256 did not modify the lack of effect of 
ghrelin on islet insulin secretion in islets from males, but significantly 
increased insulin secretion in islets from females. When co-incubated with 
SST, MK4256 significantly increased glucose-induced insulin secretion in 
islets from both groups. However, overall the increase in glucose-induced 
insulin secretion observed when MK4256 was co-incubated with SST or 
ghrelin (islets from female mice only), was not different compared to the effect 
seen with the antagonist alone. This implies that the insulinotropic effect was 
specific to the antagonist rather than counteraction of exogenous ghrelin or 
SST. Specifically it can be proposed that MK4256 acts via blocking endogenous 
SST. Indeed addition of ghrelin or SST alone did not significantly modify 
insulin secretory response in islets from both groups. It has previously been 
found that addition of exogenous SST did not alter or further decrease glucose-
induced insulin secretion in islets from male mice, and it was suggested that a 
lack of effect was potentially due to a tonic inhibitory action of endogenous 
SST produced by islet delta cells (Hauge-Evans et al., 2009; Hauge-Evans et 
al., 2015). These results suggest that SSTR3 mediates insulin secretory 
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responses in mouse islets in a sex-dependent manner as also observed for 
LEAP2 in 5.4.3. 
Despite ghrelin having no significant effect on glucose-induced insulin 
secretion in islets, it is possible that it may modulate SST release from delta 
cells, which may be responsible for the increase in insulin secretion observed 
in islets from female mice co-treated with SST + MK4256. Therefore, the effect 
of ghrelin on islet SST release could be investigated.  Furthermore SST 
secretion in the presence of the GHSR1a antagonist LEAP2 could also be 
tested to determine whether the insulinotropic action of LEAP2 was 
dependent on reduction of somatostatin secretion from islet delta cells. 
Nevertheless, the indirect activity of ghrelin may also depend on sexually 
dimorphic action or level of somatostatin itself. For example, negation of 
somatostatin by SST anti-serum significantly increased plasma growth 
hormone levels in male rats, but decreased in female rats suggesting a sex 
difference in hypothalamic somatostatin secretion (Painson and Tannenbaum, 
1991). In another study female mice lacking Sst had higher expression of 
growth hormone and Ghsr1a in the pituitary compared to control animals, but 
this difference was not observed in males (Luque and Kineman, 2007). 
Furthermore, SST has been found to influence growth hormone-releasing 
hormone (GHRH) electrical activity in a sexually dimorphic manner by 
causing faster, more frequent and varied action potential firing in male mice 
compared to females (Osterstock et al., 2016). Hence exploring whether islet 
somatostatin levels are sexually dimorphic is of interest in studying the 
indirect activity of ghrelin, however these experiments were beyond the scope 
of the current study. 
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6.5.4 Summary 
The results presented and discussed in this chapter aimed to elucidate the role 
of GHSR1a-independent factors in mediating the effects of ghrelin in beta cells 
and islets, with particular focus on sex-specific differences that have been 
summarised in table 6.8. Ghrelin was detected both at mRNA level and protein 
level in MIN6 beta cells and mouse islets suggesting the presence of 
endogenous ghrelin, which may have influenced the effectiveness of 
exogenous ghrelin. However, no overall sex-specific difference in endogenous 
ghrelin was found in islets from male and female mice.  Due to a sex-specific 
difference in the action of ghrelin on islet survival it was tested whether the 
expression of ERs or the presence of E2 may have influenced this outcome. 
Expression of Esr1 was similar in islets from both sexes, and its expression 
was not modified at transcriptional level by treatment with ghrelin. 
Preliminary findings in MIN6 cells showed that E2 did not modify the effect of 
ghrelin on palmitate-induced apoptosis in MIN6 cells in our experimental 
settings, therefore implying that the two hormones do not interact in 
mediating clonal beta cell survival. Finally, investigations into whether sex-
dependent differences in expression of Sstr3 were responsible for divergent 
functional outcomes in islets from male and female mice were conducted. 
Sstr3 mRNA expression was neither different in islets from male and female 
mice nor was its expression modified by ghrelin. Assessment of the role of 
SSTR3 in insulin secretion in islets from male and female mice revealed that 
SSTR3 is involved to some extent in mediating mouse islet insulin secretory 
responses in a sex-dependent manner. However, it is unlikely that any effect 
of ghrelin on insulin secretion is mediated by this receptor. Nevertheless, it 
cannot be disregarded that ghrelin may affect insulin secretion in a sex-specific 
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manner to modulate beta cell and islet function highlighting the need for 
further investigations. 
Table 6.8 Sex-specific effects of GHSR1a-independent factors 
tested in the current study 
 
 
Effect or feature Sex-specific effects 
Expression of Ghrelin mRNA in mouse 
islets 
Not different between males and 
females 
Endogenous acyl-ghrelin content in 
islets 
Not different between both groups 
Expression of Esr1 mRNA in mouse 
islets 
Not different between both groups and 
not modified by ghrelin 
Expression of Esr2 mRNA in mouse 
islets 
Not detected in both groups 
Expression of Sstr3 mRNA in mouse 
islets 
Not different between both groups and 
not modified by ghrelin 
Treatment of islets with 1 µM MK4256 Increased glucose-induced insulin 
secretion in islets from male mice only 
compared to 20 mM glucose 
Co-treatment of islets with ghrelin and 1 
µM MK4256 
Increased glucose-induced insulin 
secretion in islets from female mice only 
compared to ghrelin alone, but not 
compared to antagonist alone. 
Co-treatment of islets with SST and 1 
µM MK4256 
Increased glucose-induced insulin 
secretion in islets from both groups 
compared to SST alone, but not 
compared to antagonist alone. 
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The dysfunction and loss of beta cells contribute to the pathogenesis of 
diabetes (reviewed by Hasnain et al., 2016), however the mechanism of beta 
cell loss is not very well understood in type 2 diabetes. One possible 
explanation is cellular stress caused by numerous environmental stressors 
such as glucotoxicity, lipotoxicity or gluco-lipotoxicity as well as increased 
levels of circulating cytokines resulting in an inflammatory response. These 
factors cause beta cell oxidative stress and ER stress that in turn can result in 
beta cell dysfunction leading to beta cell death (reviewed by Hasnain et al., 
2016). In the early stages of type 2 diabetes beta cell dysfunction plays a major 
role which can be considered the main driver of this condition (reviewed by 
Hasnain et al., 2016). This may potentially be reversed and identifying target 
candidates that can modify the progression to beta cell apoptosis is therefore 
of outmost relevance (reviewed by Hasnain et al., 2016, reviewed by 
Wajchenberg, 2007).  
Somatostatin and ghrelin are two hormones that are expressed both 
systemically and in the pancreatic islets of Langerhans (Gnanapavan et al., 
2002; reviewed by Martinez, 2013). Both hormones have been associated with 
the regulation of islet function and glucose homeostasis by influencing insulin 
and glucagon secretion (Cheng-Xue et al., 2013; Dezaki et al., 2006; Hauge-
Evans et al., 2009). In addition, both SST and ghrelin have been found to 
promote beta cell and islet survival in response to cellular stressors typical of 
type 2 and type 1 diabetes, respectively (Damsteegt et al., 2019; Granata et al., 
2007). However, the evidence supporting a pro-survival role for ghrelin in 
response to cellular stressors typical of type 2 diabetes remains limited. 
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Most recently it was reported that the insulinostatic action of ghrelin is due to 
an indirect and stimulatory action of ghrelin on pancreatic delta cells leading 
to the release of SST, which acts on the beta cell to inhibit insulin secretion 
(Adriaenssens et al., 2016; DiGruccio et al., 2016). It was therefore 
hypothesized that the effect of ghrelin on beta cell and islet survival may also 
potentially be mediated via the action of SST. 
The focus of the current study was therefore to explore the roles of SST and 
ghrelin in beta cell and/or islet function with particular focus on apoptosis 
induced by cellular stressors typical of type 2 diabetes, and in acute insulin 
secretory responses. In addition, potential underlying molecular mechanisms 
that mediate their actions in beta cells and islets were explored. 
7.1 The roles of SST/SSTR3 and ghrelin/GHSR1a in clonal beta cell 
function 
The findings described in chapter 3 indicate that treatment with SST reduces 
clonal beta cell apoptosis induced by lipotoxicity in accordance with 
Damsteegt et al. (2019).  The evaluation whether SSTR3 is involved in this 
process found, however, that it is unlikely for the anti-apoptotic effect of SST 
in MIN6 cells to be mediated by this receptor. Nevertheless, it was found that 
SSTR3 may partly contribute to the insulinostatic effect of SST in these cells. 
It is important to highlight that MIN6 cell line is a transformed cell line with 
limitations. Indeed, a greater responsiveness to the SSTR3 antagonist 
MK4256 was observed in islets from male and female mice compared to MIN6 
cells, despite the inability to clearly detect the receptor in islets by Western 
blot. In this study the effect of SST on islet apoptosis was not assessed, however 
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our previous work in islet cells from male mice showed that apoptosis induced 
by lipotoxicity was reduced by treatment with SST (Damsteegt et al., 2019).  
It is important to highlight that beta cell regenerative capacity is limited and 
is lost with age in both rodents and humans (Perl et al., 2010; Rankin and 
Kushner, 2009). In addition, beta cell dysfunction and loss are strongly 
associated, and not only do these factors contribute to the onset of diabetes, 
but also progress with the disease (reviewed by Saisho et al., 2015). Impaired 
beta cell function is associated with impaired glycaemic control (Ritzel et al., 
2006) and treatment failure (reviewed by Saisho et al., 2015). Therefore, it has 
been suggested that preservation and recovery of dysfunctional beta cells 
constitute a valuable approach for the treatment of type 2 diabetes. Hence, 
strategies to reduce beta cell workload and improve function are suggested to 
be effective. Indeed, use of insulin secretagogues in type 2 diabetes therapy is 
limited especially due to elevated beta cell workload, with the exception of 
incretins, which in rodents have been found to elicit beneficial effects on beta 
cell mass (reviewed by Saisho et al., 2015; reviewed by van Raalte and 
Verchere, 2017). A recent study reported that the use of an adipokine, adipsin, 
was shown to improve hyperglycaemia and increase tissue area of islets 
transplanted in the anterior chamber of the eyes of db/db mice (Gómez-
Bannoy et al., 2019), suggesting that improvement in beta cell mass aids in 
improved responsiveness to hyperglycaemia. 
The observation in the current study that the insulinostatic hormone SST 
protected clonal beta cells from lipotoxicity-induced apoptosis highlights the 
potential beneficial effect of beta cell rest. A study conducted by Laedtke et al. 
(2000) found that overnight infusion of SST resulted in more regular insulin 
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secretion patterns in patients with type 2 diabetes where it is deregulated, and 
better insulin secretory capacity, further highlighting the importance of 
reducing beta cell workload. Furthermore, in type 2 diabetes patients SST 
release is impaired, potentially contributing to beta cell dysfunction (Strowski 
and Blake, 2007). Therefore, adjunct therapy of SST with insulin or novel 
SGLT2 antagonists may be of benefit to provide beta cell recovery. However, 
since SST is present physiologically and may influence growth it is important 
to consider development of islet-specific targeted therapy. Nevertheless, the 
findings in this thesis are preliminary, therefore in vivo studies in rodents as a 
next step would aid in further understanding the usefulness of this approach 
in the prevention of beta cell dysfunction and loss. 
The results illustrated in chapter 4 showed that exogenous ghrelin did not play 
a role in apoptosis and insulin secretory function in MIN6 beta cells despite 
GHSR1a being present in these cells. Ghrelin was detected both at mRNA level 
and protein level in MIN6 beta cells suggesting the presence of endogenous 
ghrelin, which may have influenced the effectiveness of exogenous ghrelin. 
However, the function of endogenous ghrelin is disputed. Alternatively, this 
result confirms the hypothesis that the effect of ghrelin on beta cell function 
may be mediated indirectly via its action on the delta cell with stimulation of 
somatostatin secretion as suggested by Adriaenssens et al. and DiGruccio et 
al. in 2016, although this effect was not investigated with regards to cell 
survival. However, since we have shown that SST protects islet cells from 
stressors typical of type 2 diabetes (Damsteegt et al., 2019), it is, therefore, 
likely that any potential effect of ghrelin on islet apoptosis may be mediated by 
SST.  
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Work conducted in islets aimed to assess this, however it was first necessary 
to explore if ghrelin itself had any effect on rodent islet apoptosis. 
7.2 Sex-dependent role of ghrelin in islet function 
Experiments conducted in islets revealed a sex-specific role for ghrelin where 
a reduction in apoptosis by ghrelin was only detected in islets from female 
mice. As indicated in chapters 5 and 6, ghrelin and GHSR1a are present in 
mouse islets and their expression levels were comparable between islets from 
both sexes, suggesting that the differences in expression level of the receptor 
and/or influence from endogenous ghrelin were not responsible for the 
observed effects on islet apoptosis. GHSR1a antagonists, however, could not 
reverse the pro-survival effect of ghrelin in islets from female mice. Here the 
use of animal models with islet-specific knockout of Ghrelin or Ghsr1a may be 
helpful in further understanding the molecular mechanisms of actions of 
ghrelin.  
Another interesting observation in this study was the sex-related differences 
in response to glucose-induced insulin secretion following treatment with 
GHSR1a and SSTR3 receptor antagonists, LEAP-2 and MK4256, respectively. 
In islets from male mice the endogenous GHSR1a antagonist LEAP2 increased 
insulin secretion as shown in section 5.4.3, indicating that the antagonist may 
have reversed the effect of endogenous ghrelin or alternatively modulated the 
constitutive activity of the receptor. The assessment of constitutive activity of 
a GPCR can be detected by measurement of cAMP levels in cells. The high 
constitutive activity is proportional to the level of cAMP that remains 
increased in the presence of a phosphodiesterase inhibitor (Prasad, 2010). 
However, in islets and any cell type expressing a variety of GPCRs the accurate 
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detection of constitutive activity of one specific receptor is hindered due to 
interference from the activity of other GPCRs (Damien et al., 2012). Hence 
most studies investigating the constitutive activity of GHSR1a have relied on 
either overexpression of GHSR1a in a cell line that does not naturally express 
it (Holst et al., 2003) or using lipid discs expressing the purified receptor 
(Damien et al., 2012). However, these methods cannot provide information on 
sex-specific differences in the constitutive activity of GHSR1a. Nevertheless, 
inverse agonists have been shown to reduce the constitutive activity of a 
receptor (Khilnani and Khilnani, 2011) and, therefore, may potentially be 
useful in testing receptor constitutive activity. Hence the results on sex-
specific differences in insulin secretion observed for LEAP2, recently 
identified as an inverse agonist (M’Kadmi et al., 2018), may be indicative of 
inverse agonism of constitutive activity of GHSR1a. The increase in insulin 
secretion in islets from male mice following treatment with LEAP2 perhaps 
reflect the higher constitutive activity of GHSR1a in these islets compared to 
the ones from female mice. However, at the moment this remains speculative, 
and is hindered by current methods available being non-ideal for the detection 
of sex-specific differences in GHSR1a constitutive activity in islets. 
Despite the levels of Sstr3 mRNA expression being comparable in islets from 
both sexes, treatment with MK4256 modified glucose-induced insulin 
secretion in a sex-specific manner. It is possible to suggest that perhaps sex-
specific differences in SST release may have contributed to the divergent 
outcomes. This may be a result of both ghrelin-dependent and independent 
mechanisms, since the levels and roles of SST itself have been reported to be 
sex-dependent in other tissues (Painson and Tannenbaum, 1991; Van Vugt et 
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al., 2008) as discussed in 6.5.3. In the present study, although exogenous 
ghrelin itself had no effect on insulin secretion, it may have influenced insulin 
release in a sex-dependent manner resulting in observed sex-specific 
differences in insulin secretion following incubation with MK4256. Further 
experiments are, however, needed to confirm this.  
In general, the effects of ghrelin on glucose homeostasis are mainly negatively 
associated due to increase in blood glucose observed when ghrelin is 
administered in vivo, due to inhibition of insulin secretion (Broglio et al., 
2001; Tong et al., 2010). However, others have suggested that the 
hyperglycaemia in vivo could also be related to increased hepatic 
gluconeogenesis by ghrelin and increased glucagon secretion (reviewed by 
Alamri et al., 2016). Taken together these results suggest that the effect of 
ghrelin on islet function and survival are governed by sex related differences 
that may be modulated by complex systemic mechanisms. 
The discovery of sex-specific differences in islets constitute an important 
finding in the study of diabetes where sex-dependent differences are 
commonly reported (Gannon et al., 2018; Tramunt et al., 2019), and most 
studies relating ghrelin to islet function have investigated islets from male 
rodents and sex-unspecified human islets. Epidemiological studies indicate 
that the prevalence of type 2 diabetes is reported to be higher in males between 
the ages 20-79 with greater incidence with age, and the biological reasons for 
the higher incidence in men are still being explored (IDF, 2019; Nordström et 
al., 2016). Men have impaired fasting blood glucose levels reportedly due to 
inherent differences in systemic glucose metabolism (reviewed by Kautzky-
Willer et al., 2016). Although in both sexes increase in insulin secretion is 
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observed, males had a greater rate of insulin secretion with increasing body 
mass index (reviewed by Kautzky-Willer et al., 2016). Nordström et al. (2016) 
suggested that the higher content of visceral fat in males was responsible for 
the greater incidence of the condition in males. It has been reported that 
female patients display better glycaemic control due to higher beta cell 
function and glucose responsiveness (reviewed by Gannon et al., 2018). For 
example, in a study comparing healthy male and female participants of 
comparable BMIs, females had lower blood glucose during OGTT compared to 
males, and higher disposition and insulinogenic indices suggesting a better 
beta cell function in female participants (Kautzky-Willer et al., 2012). The sex 
differences in risk and predisposition to type 2 diabetes were suggested to be 
associated with the greater presence of oestrogen in females, epigenetic 
modifications, glucagon secretion and embryonic beta cell development 
(reviewed by Gannon et al., 2018; reviewed by Tramunt et al., 2019).  For 
example, as also discussed in chapter 4, oestrogen has been reported to protect 
beta cells and islets from apoptosis both in vivo and in vitro (Kooptiwut et al., 
2018; Le May et al., 2006), and it has been suggested that Esr1 may in part 
mediate this effect (Le May et al., 2006). 
The present results show that differences in Esr1 expression levels did not 
mediate the protective effect of ghrelin on apoptosis in islets from female mice 
in vitro, however this does not discount the fact that oestrogen itself may 
modulate the pro-survival effect of ghrelin in islets from female mice. 
Preliminary data in MIN6 cell line showed that treatment with E2 did not 
modify the effect of ghrelin on apoptosis in these cells. However, since ghrelin 
had no effect on MIN6 cell apoptosis to begin with, exploring the role of E2 in 
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islets would be ideal as suggested in chapter 6, where a range of potential 
future experiments were suggested. A study comparing sex-differences in 
glucose responses found that male participants displayed more impaired 
insulin secretion compared to females. The mean age of female participants 
was 60 and therefore thought to be post-menopausal. Interestingly, in this 
study it was suggested that the beneficial effects of prolonged exposure to E2 
were extended beyond menopause, however no information was available on 
the use of HRT or indication of level of beta cell mass/survival due to logical 
limitations (Russo et al., 2014). 
Although others have reported sex-specific differences in ghrelin levels and its 
orexigenic properties, this has not been reported in pancreatic islets. 
Investigations into the role of ghrelin on islet apoptosis was only reported in 
one study that utilised sex-unspecified human islets and in the conditions 
typical of type 1 diabetes. Therefore, the findings of the current study highlight 
that ghrelin displays sex-specific differences in modulating islet responses to 
apoptosis induced by pro-inflammatory cytokines.  
Based on the findings of this thesis, the assessment of mechanisms underlying 
the sex-specific effect of ghrelin in mouse islets indicate that the differences in 
the levels of expression of GHSR1a, endogenous ghrelin, Esr1 and Sstr3 do 
not mediate the observed effect. It is therefore possible that inherent 
differences in islets between males and females may exist and influence islet 
function. So far, reports suggest that maternal obesity and nutrition can 
influence embryonic islet development in a sex-dependent manner (reviewed 
by Gannon et al., 2018; reviewed by Tramunt et al., 2019). For example, 
female offspring of obese female mice displayed reduced blood glucose and 
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increase insulin levels following glucose challenge. These offspring had greater 
mitochondrial density and respiration compared to controls from non-obese 
mothers (Nicholas et al., 2019). In the same study male offspring had impaired 
mitochondrial function and unchanged insulin secretion compared to those 
from non-obese mothers, suggesting that female progeny from obese mothers 
are more adapted to confront high nutrient levels after birth (Nicholas et al., 
2019). However, in the present study wild-type CD-1® mice specifically bred 
for laboratory testing were used. It is believed that the mice are born from 
healthy females, although no information is available on the status of maternal 
characteristics of these mice.  
Alternatively, as mentioned before, ghrelin may modulate SST secretion in a 
sex-specific manner or via an as-yet-unknown mechanism that is specific to 
the islets from female mice to protect islets from female mice from apoptosis 
induced by pro-inflammatory cytokines. This suggests the potential usefulness 
of ghrelin in personalised medicine.  
7.3 Potential use of ghrelin in precision medicine to prevent beta 
cell apoptosis in females 
Precision medicine, also known as personalised medicine, refers to the use of 
strategies to manage or treat a condition based on an individual’s or a group’s 
needs and/or genetic predisposition (Fitipaldi et al., 2018). The heterogeneity 
in diabetes is precisely the prerequisite for considering personalised 
approaches in its management and treatment, since both rodents and humans 
display divergence in the pathogenesis of this condition (reviewed by Bowman 
et al., 2018; Keller et al., 2019). In a recent study, non-diabetic male mice fed 
a high fat/high sucrose diet were more insulin resistant than female mice, 
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therefore were found to secrete more insulin than females to compensate for 
hyperglycaemia (Keller et al., 2019), further highlighting the sex-dimorphic 
responses to hyperglycaemia and importance of personalised approaches for 
its regulation. 
So far, some progress has been made in employing precision medicine for 
monogenic types of diabetes such as neonatal diabetes and monogenic 
diabetes of the young (MODY) with clear advantages in disease management 
(Mohan and Radha, 2019). However, precision medicine extends beyond 
genetics since heterogeneity of diabetes is also influenced by environmental 
factors such as lifestyle and availability of infrastructure (Dendup et al., 2018; 
Groop, 2016), but approaches addressing these factors are still preliminary 
(Merino and Florez, 2019). 
Furthermore, the differences in diabetes risk and islet function between male 
and female individuals also suggest that biological sex-based therapies may be 
advantageous in the development of treatment strategies for diabetes mellitus 
(Mauvais-Jarvis, 2017). 
The sex-specific role of ghrelin in the prevention of beta cell apoptosis 
observed in the present study, therefore, constitutes an interesting therapeutic 
approach for women affected by prediabetes or type 2 diabetes. This is 
important since the majority of academic and preclinical studies in the 
pharmaceutical industry are performed in male rodents, which may lead to 
potential therapeutics that would be effective in women being overlooked. 
However, it is important to highlight that the results in the current study are 
limited by the use of ex vivo islets, and it has been reported that studies in 
rodents do not always translate into humans (reviewed by Bowman et al., 
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2018). Nevertheless, the novel sex-specific role of ghrelin in islet apoptosis 
identified in the current study constitutes a promising approach for a 
personalised treatment approach in women, and therefore warrants further 
investigation. However, prior to its use in human studies, it is necessary to test 
whether in vivo ghrelin administration improves beta cell function in islets 
from female mice. For this mouse models of beta cell dysfunction could be 
used (King, 2012). Since prolonged exposure to ghrelin induces adiposity 
(Tschöp et al., 2000), which in turn has been linked to beta cell dysfunction 
(reviewed by Hasnain et al., 2016), a non-obese model of beta cell dysfunction 
such as AKITA mouse may be utilised (King, 2012). AKITA mice have a 
dysfunctional beta cell mass due to ER stress (Chen et al., 2011), therefore 
could be employed to test whether administration of ghrelin improves the 
disease phenotype in these animals. An ideal mode of treatment would be islet 
specific targeted therapy with ghrelin to prevent other effects of ghrelin that 
may be unwanted in patients with type 2 diabetes. For example, islet-specific 
nanoparticles (Ghosh et al., 2011), a model developed for treating islet 
autoimmunity in type 1 diabetes, may be a useful approach. 
 
Concluding remarks 
This study aimed to investigate the roles of SST and ghrelin in modulating beta 
cell and/or islet function in response to cellular stressors typical of type 2 
diabetes. It was found that SST promotes beta cell survival against lipotoxicity 
and cytokines (Damsteegt et al., 2019). This constitutes an interesting 
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mechanism to be targeted in the prevention of beta cell dysfunction and loss, 
that are characteristic of type 2 diabetes pathogenesis. 
Investigations into the role of ghrelin suggested that it does not directly 
modulate clonal beta cell function, however the interaction between ghrelin 
and SST in modulating islet function remains unclear. Nevertheless, any 
potential effects of ghrelin do not appear to be mediated via SSTR3.  
Experiments conducted utilising islets uncovered a sex-specific role for ghrelin 
in islet apoptosis induced by proinflammatory cytokines. This potentially has 
implications for diabetes as a heterogenous disease that also displays sexual 
dimorphism in its manifestation. The novel role of ghrelin in islets from female 
mice may therefore be useful in precision medicine approaches to prevent beta 
cell loss in women. However, these results remain preliminary for human use 
and warrants further investigations. 
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Diabetes UK, 2018 
Characterising the role of ghrelin and the growth hormone 
secretagogue receptor type 1a (GHSR1a) antagonist, YIL781, in the 
regulation of beta cell survival. 
Hewawasam NV1, Patterson M1, Reeves S1 and Hauge-Evans AC1 
Aims: Ghrelin reportedly acts via GHSR1a to influence beta cell function. 
However, the receptor expression in beta cells remains controversial. The aims 
of this study were to evaluate the effect of the acyl-ghrelin (AG) on beta cell 
survival and to determine the expression of ghrelin and GHSR1a in MIN6 beta 
cells and islets.  
Methods: Islet and MIN6 cells were pre-treated with AG or the GHSR1a 
antagonist, YIL781 (5μM), for 48h prior to 20h exposure to palmitate (0.5mM) 
or TNF-α (1000U/ml) and IL-1β (50U/ml). Apoptosis was assessed by 
measurement of caspase 3/7 activity. mRNA expression was determined using 
qPCR. 
Results: Ten or 100nM AG did not affect palmitate-induced caspase activity 
in MIN6 cells (20h, n=6, P>0.2 vs. control) nor cytokine-induced apoptosis in 
islets (20h, n=6; P>0.1 vs. control). However, YIL781±AG significantly 
reduced apoptosis in palmitate-treated MIN6 cells compared to control (n=6; 
p<0.05 YIL781 only; p<0.01 YIL781+10nM AG; p<0.01 YIL781+100nM AG) 
and in cytokine-treated islets compared to 100nM AG only (n=6; p<0.05, 
YIL781+100nM AG). GHSR1a mRNA was expressed in islets and traceable in 
MIN6 cells. Ghrelin mRNA was detected in both tissues. GHSR1a and ghrelin 
mRNA expression was down-regulated in islets following 48h treatment with 
100nM AG (GHSR1a:53% reduction compared to controls, ghrelin: 95%), 
whereas GHSR1a (61% compared to control) but not ghrelin mRNA 
expression (108%) was down-regulated by 5µM YIL781. 
Conclusion: Although GHSR1a is expressed in the islet, exogenous AG does 
not affect beta cell survival. The effect of the GHSR1a antagonist suggests a 
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A Novel Role for Somatostatin in the Survival of Mouse Pancreatic 
Beta Cells. 
Damsteegt EL1, Hassan Z2, Hewawasam NV1, Sarnsamak K1, Jones PM2  and 
Hauge-Evans AC.1 
Background/Aims: Cross-talk between different pancreatic islet cell types 
regulates islet function and somatostatin (SST) released from pancreatic delta 
cells inhibits insulin secretion from pancreatic beta cells. In other tissues SST 
exhibits both protective and pro-apoptotic properties in a tissue-specific 
manner, but little is known about the impact of the peptide on beta cell 
survival. Here we investigate the specific role of SST in the regulation of beta 
cell survival in response to physiologically relevant inducers of cellular stress 
including palmitate, cytokines and glucose.  
Methods: Pancreatic MIN6 beta cells and primary mouse islet cells were pre-
treated with SST with or without the Gi/o signalling inhibitor, pertussis toxin, 
and exposed to different cellular stress factors. Apoptosis and proliferation 
were assessed by measurement of caspase 3/7 activity, TUNEL and BrdU 
incorporation, respectively, and expression of target genes was measured by 
qPCR.  
Results: SST partly alleviated upregulation of cellular stress markers 
(Hspa1a and Ddit3) and beta cell apoptosis in response to factors such as 
lipotoxicity (palmitate), pro-inflammatory cytokines (IL1β and TNFα) and low 
glucose levels. This effect was mediated via a Gi/o protein-dependent pathway, 
but did not modify transcriptional upregulation of the specific NFκB-
dependent genes, Nos2 and Ccl2, nor was it associated with transcriptional 
changes in SST receptor expression. 
Conclusion: Our results suggest an underlying protective effect of SST which 
modulates the beta cell response to ER stress and apoptosis induced by a range 
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Diabetes UK, 2019 
Exploring gender differences in islet survival in response to ghrelin 
treatment. 
Hewawasam NV1, Austin AL2, King A2, Patterson M1, Reeves S1 and Hauge-
Evans AC1 
Aims: Ghrelin is expressed in a number of tissues including stomach and 
islets. It inhibits insulin secretion and promotes islet survival, however, most 
studies relating ghrelin to islet function have investigated islets from male 
rodents. The aim of this study was to explore whether treatment with acyl-
ghrelin (AG) affects gene expression and apoptosis in islets from male and 
female mice.  
Methods: Oestrus cycle stage was determined by haematoxylin and eosin 
(H&E) staining of vaginal smears. Islets from male and female CD-1 mice were 
incubated with 10 or 100nmol/l AG for 48h and exposed to TNF-α 
(1000U/ml) and IL-1β (50U/ml) for 20h. Gene expression was determined by 
qPCR and apoptosis by measurement of caspase 3/7 activity.  
Results: H&E staining showed that all female mice except one were 
synchronised at metestrus stage (n=10). Ghrelin mRNA expression was 2-fold 
higher in stomach tissue from females compared to males, but was equal in 
islets from both groups. Ghrelin receptor (Ghsr) expression was 2-fold greater 
in islets from female mice. Following incubation with 100nmol/l AG, Ghsr 
expression remained unchanged, however Ghrelin expression was 
downregulated by 90% in islets from female mice only. Treatment with 10 and 
100nmol/l AG reduced cytokine-induced apoptosis compared to control in 
islets from female (30%±0.1 (10nmol/l), p<0.01 and 29%±0.0 (100nmol/l) 
p<0.01, n=3) but not male mice (0.5%±0.1 (10nmol/l) p>0.9 and 6%±0.1 
(100nmol/l), p> 0.8, n=4).  
Conclusion: Our results suggest a differential effect of ghrelin on islet 
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EASD, 2019 
Gender differences in the effect of ghrelin on pancreatic islet 
survival  
Hewawasam NV1, Austin AL2, King A2, Patterson M1, Reeves S1 and Hauge-
Evans AC1 
Background and aims: Ghrelin is expressed in a number of tissues 
including stomach, hypothalamus and islets of Langerhans. It inhibits insulin 
secretion and promotes islet survival. In addition, ghrelin displays gender 
dimorphism with regards to plasma levels in humans and rodents, and 
orexigenic responses in rodents. However, most studies relating ghrelin to islet 
function have investigated islets from male rodents and gender unspecified 
human islets. The aim of this study was to explore whether there are any 
gender specific differences in mRNA expression of Ghrelin, ghrelin receptor 
(Ghsr) and oestrogen receptor 1 (Esr1) in murine islets, and whether 
treatment with acyl-ghrelin (AG) affects their expression levels as well as 
apoptosis in islets from both groups. It was also tested whether any effect 
observed is conveyed via the Growth Hormone Secretagougue Receptor type 
1a (GHSR1a). 
Materials and methods: Oestrus cycle stage was determined by 
haematoxylin and eosin (H&E) staining of vaginal smears. Islets from male 
and female CD-1 mice were incubated with 10 or 100 nmol/l AG +/- 5 µmol/l 
GHSR1a antagonist YIL781 for 48h and exposed to TNF-α (1000 U/ml) and 
IL-1β (50 U/ml) for 20h. Gene expression was determined by quantitative 
PCR and apoptosis by measurement of caspase 3/7 activity. 
 
Results: H&E staining showed that the majority (67%) of female mice used 
were synchronised at metestrus stage with the remaining at oestrus stage 
(33%), (n=24). Expression of Ghrelin was not significantly different in 
stomach (p>0.5, n=3) and hypothalamus of male and female mice. Ghrelin 
receptor (Ghsr) expression was 2-fold greater in islets from female mice 
(p<0.05), however Ghrelin (p>0.2, n=3) and oestrogen receptor 1 (n=2) 
mRNA expression was not significantly different between the two groups. 
Following incubation with 100 nmol/l AG, mRNA expression 
of Ghrelin (p>0.9, n=3), Ghsr (p>0.09, n=3) and Esr1 (n=2) remained 
unchanged in both groups. Treatment with 10 and 100 nmol/l AG reduced 
cytokine-induced apoptosis compared to control in islets from female (45%±4 
(10 nmol/l), p<0.0001 and 35%±4 (100 nmol/l) p<0.001, n=6, experiment 
representative of four repeats), but not male mice (113%±8 (10 nmol/l) p>0.6 
and 113%±10 (100 nmol/l), p> 0.6, n=6, experiment representative of three 
repeats). Treatment with 5 µmol/l YIL781 did not reverse the observed 
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protective effect of ghrelin in islets from female mice. However, it resulted in 
significant reduction in apoptosis (47%±6 (5 µmol/l YIL781), p<0.0001 and 
35%±.4 (5 µmol/l YIL781 + 100 nmol/l AG), p<0.001, n=6, experiment 
representative of three repeats). 
 
Conclusion: Our results suggest a differential effect of ghrelin on islet 
survival in male and female mice which may involve regulation of an 
endogenous islet ghrelin receptor, and suggest a potential agonistic effect of 
GHSR1a antagonist YIL781.  
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Future Physiology, 2019 
 
Gender differences in the effect of ghrelin on pancreatic islet 
survival. 
Hewawasam NV1, Austin AL2, King A2, Patterson M1, Reeves S1 and Hauge-
Evans AC1 
 
Background and aims: Ghrelin is expressed in a number of tissues 
including stomach, hypothalamus and islets of Langerhans. It inhibits insulin 
secretion and promotes islet survival. In addition, ghrelin displays sexual 
dimorphism with regards to plasma levels in humans and rodents, and 
orexigenic responses in rodents. However, most studies relating ghrelin to islet 
function have investigated islets from male rodents and sex unspecified 
human islets. The aim of this study was to explore whether there are any sex-
specific differences in mRNA expression of Ghrelin, ghrelin receptor (Ghsr) 
and oestrogen receptor 1 (Esr1) in murine islets, and whether treatment with 
acyl-ghrelin (AG) affects their expression levels as well as apoptosis in islets 
from both groups. It was also tested whether any effect observed is conveyed 
via the Growth Hormone Secretagougue Receptor type 1a (GHSR1a). 
 
Materials and methods: Oestrus cycle stage was determined by 
haematoxylin and eosin (H&E) staining of vaginal smears. Islets from male 
and female CD-1 mice were incubated with 10 or 100 nmol/l AG +/- 5 μmol/l 
GHSR1a antagonists YIL781 or +/-100 nM Liver expressed antimicrobial 
peptide-2 for 48h and exposed to TNF-α (1000 U/ml) and IL-1β (50 U/ml) for 
20h.  
Apoptosis was determined by measurement of caspase 3/7 activity, gene 
expression by quantitative PCR and protein expression by Western blot. 
 
Results: H&E staining showed that the majority (60%) of female mice used 
were synchronised at metestrus stage with the remaining at oestrus stage 
(31%), (n=48). Treatment with 10 and 100 nmol/l AG reduced cytokine-
induced apoptosis compared to control in islets from female (45±4% (10 
nmol/l), p<0.0001 and 35±4% (100 nmol/l) p<0.001, n=6, One-Way 
ANOVA), but not male mice (113±8% (10 nmol/l) p>0.6 and 113±10% (100 
nmol/l), p>0.6, n=6). Expression of Ghrelin was not significantly different in 
stomach and hypothalamus of male and female mice (both p>0.05, n=5, 
Student’s T-test). Ghsr mRNA expression was 2-fold greater in islets from 
female mice (p<0.05, n=4, T-test), however Ghrelin and Esr1 (p>0.5,n=3-4) 
mRNA expression levels were not significantly different between the two 
groups. Following incubation with 100 nmol/l 
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AG, mRNA expression of Ghrelin, Ghsr and Esr1 (p>0.1, n=3-4, T-test) 
remained unchanged in both groups. GHSR expression was not significantly 
different in the islets from male and female mice at protein level (p=0.09, n=3, 
T-test). Treatment with either GHSR antagonists did not reverse the observed 
protective effect of ghrelin in islets from female mice. However treatment with 
YIL781 resulted in significant reduction in apoptosis (47±6% (5 μmol/l 
YIL781), p<0.0001 and 35±4% (5 μmol/l YIL781+100 nmol/l AG), p<0.001, 
n=6, One-Way ANOVA). 
 
Conclusion: Our results suggest a differential effect of ghrelin on islet 
survival in male and female mice which may be independent of endogenous 
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Diabetes UK, 2020 
Pancreatic islets display sexual dimorphism in insulin secretion in 
response to liver-expressed antimicrobial peptide-2 
Hewawasam NV1, King A2, Patterson M1, Reeves S1 and Hauge-Evans AC1 
Introduction: Prevalence of type 2 diabetes, beta cell function as well as 
dysfunction are influenced by sex. We have found that treatment with 
exogenous ghrelin significantly reduced cytokine-induced apoptosis in islets 
from female, but not male mice. Reportedly, ghrelin acts via the G-protein 
coupled receptor growth hormone secretagogue receptor type 1A (GHSR1a). 
Liver-expressed antimicrobial peptide-2, LEAP-2, has recently been 
characterised as a GHSR1a antagonist. The aim of this study was to investigate 
whether the action of ghrelin on islet function is modified by LEAP-2 and 
whether the response to ghrelin and LEAP-2 is subject to sex-related 
differences. 
Methods: Apoptosis was detected by measurement of caspase 3/7 activity. 
Static insulin secretion experiments were conducted and insulin content was 
measured by radioimmunoassay.  
Results: Treatment with 100nM LEAP-2 did not significantly affect cytokine-
induced apoptosis in islets from both male and female mice and it did not 
significantly reverse the protective effect of ghrelin observed in islets from 
females (p=0.27, n=6). In our study we did not observe an insulinostatic effect 
of ghrelin in islets from both groups (p=0.99 males and p=0.76 females, n=5). 
However, in islets from male mice treatment with 100nM LEAP-2 resulted in 
significantly higher glucose-induced insulin secretion compared to 20mM 
glucose (p=0.001, n=5-6) but not in female (p=0.49, n=5) and this was 
significantly reduced in the presence of ghrelin (p=0.0016, n=5-6). 
Conclusion: Treatment with LEAP-2 did not significantly reverse the 
protective effect of ghrelin in islets from female mice. However, it significantly 
increased glucose-induced insulin secretion in islets from male, but not from 
female mice, suggesting a sexually dimorphic effect of LEAP-2 in islet function. 
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